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CHAPTER 1: GENERAL INTRODUCTION 
 
Statement of the Problem 
 Influenza A viruses (IAV) have been recognized as a component of the porcine 
respiratory disease complex since its identification as a filterable agent by Shope in 1930.138 
The virus isolated by Shope and later characterized as an H1N1 is believed to have been 
introduced to swine in 1918 coinciding with the human influenza pandemic.90 The ecology of 
IAV in United States (US) swine remained stable until the introduction of the human triple 
reassortant H3N2 virus in 1998.187 Influenza viruses with an H1 hemagglutinin similar to 
human seasonal influenza viruses circulating at that time were introduced into North 
American swine in 2003 adding additional diversity to the IAV ecology.72,162 Contemporary 
IAVs currently circulating in US swine are triple reassortants consisting of multiple subtypes 
including H1N1, H1N2 and H3N2. Influenza viruses remain in a continual state of evolution 
through antigenic drift and antigenic shift. Currently, four distinct H1 phylogenetic clusters 
are recognized in swine exemplifying their immense genetic variability that has been 
influenced primarily by the introduction of variant IAVs since 1998, continual reassortment 
and antigenic drift.163 
 Vaccines have been used since 1994 to control influenza infections in swine with 
variable success. As IAVs in swine have become more diverse, it has been increasingly 
difficult to prevent infection and clinical disease with inactivated influenza vaccines, which 
are currently the only approved formulation for swine in the US.152,160 In addition, serological 
cross-reactivity between viruses in different phylogenetic clusters has become more variable 
and correlates with the lack of cross-protection demonstrated with vaccines.89  Current 
2 
 
 
knowledge would predict continued genetic evolution and antigenic diversity in 
contemporary influenza viruses in swine, suggesting novel vaccine platforms are needed to 
cross-protect against these emergent, heterologous viruses. 
 Inactivated influenza vaccines have also been correlated with exacerbated clinical 
signs and enhanced respiratory disease in swine.58,78,160 When challenged with a heterologous 
H1 influenza virus, pigs that had received inactivated vaccine demonstrated severe clinical 
disease compared to non-vaccinated pigs challenged with the same virus. These studies 
suggested the vaccine was integral to disease enhancement. Respiratory or systemic disease 
syndromes have been implicated with other inactivated RNA viral vaccines and these models 
are well accepted in the human health and virus research communities.61,119 However, a 
consistent model that reproduces vaccine-associated enhancement of disease in swine with 
influenza virus has not been established. In addition, the lung pathology and immune 
responses that may be associated with this phenomenon have not been thoroughly described. 
 
Specific aims 
 The overall objective of the studies described herein was to characterize the clinical 
disease, pathology and immune response of vaccine-associated enhanced respiratory disease 
in influenza vaccinated and challenged swine. The central hypothesis of this dissertation is 
that swine administered an inactivated, adjuvanted influenza vaccine may demonstrate 
vaccine-associated enhanced respiratory disease (VAERD) when challenged with a 
heterologous, homosubtypic virus. The following are specific aims based on the central 
hypothesis: 1) establish a reproducible model for vaccine-associated enhanced respiratory 
disease in swine administered an inactivated, adjuvanted influenza vaccine followed by 
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challenge with heterologous virus (Chapter 2); 2) characterize the immune response to 
inactivated influenza vaccines prior to challenge and the serological cross-reactivity with 
heterologous virus used in the VAERD model (Chapter 2); 3) describe the kinetics of lung 
lesion development and pro-inflammatory cytokine response in swine demonstrating vaccine 
associated enhanced respiratory disease (Chapter 3); 4) characterize the adaptive immune 
response after challenge in pigs demonstrating vaccine-associated enhanced respiratory 
disease (Chapter 4). 
 
Dissertation organization 
 This dissertation is organized in the journal publication format that includes 
manuscripts previously published, accepted for publication, or in preparation for submission 
with five chapters. The first chapter (Chapter 1) consists of a general introduction and 
literature review. The three chapters that follow (Chapters 2-4) consist of three individual 
manuscripts related to the specific aims of the research project and the final chapter (Chapter 
5) contains general conclusions and suggestions for future research. References are included 
at the end of each chapter. One manuscript has been published in Vaccine (Chapter 2) and a 
second manuscript has been accepted for publication in Veterinary Pathology (Chapter 3). 
Dr. Phillip Gauger is the principal author of the manuscripts presented in this thesis; Dr. Amy 
Vincent is the corresponding author of each individual manuscript; Drs. Crystal Loving, 
Jamie Henningson, Kelly Lager, Bruce Janke, Marcus Kehrli, Jr. and James Roth were 
involved in the experimental design, execution, data analysis and critical review of the 
manuscripts.  
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Literature review 
Influenza A virus: General overview 
Influenza A virus (IAV) is a primary cause of respiratory disease in swine worldwide 
84,110,173
 and a component of the porcine respiratory disease complex (PRDC).14 Influenza 
infection in swine manifests as an acute onset of respiratory disease characterized by fever, 
lethargy, anorexia, respiratory distress, coughing, conjunctivitis and nasal discharge.2,97,132,111 
Reproductive failure associated with SIV-induced fever has also been documented, which 
may include infertility, abortions and weak-born piglets.73,166,177 Swine operations may be 
affected by seasonal infections or endemic circulation of IAV’s resulting in high morbidity 
(approaching 100%) but typically low mortality (less than 1%).  Influenza is a zoonotic viral 
disease that represents a health and economic threat to both humans and animals worldwide 
with occasional transmission from one species to another.104,165,174 
Influenza A virus is a member of the Orthomyxoviridae family which contains 
additional genera including Influenza B, Influenza C, Thogotovirus and Isavirus.83 Influenza 
A viruses are segmented, single-stranded, negative-sense viruses with RNA genomes. The 
surface glycoproteins hemagglutinin (HA) and neuraminidase (NA) are important to the 
pathogenesis, transmission and life cycle of influenza viruses, are highly variable and 
targeted by the host immune system.24 Only the H1, H3, N1 and N2 subtypes are endemic 
and currently circulate in North American swine. The HA and NA genes may vary due to 
two types of processes known as antigenic drift and antigenic shift. Antigenic drift results 
from minor changes in the genome due to polymerase errors during replication and occurs 
more commonly in RNA viruses in general. Antigenic shift occur when two or more viruses 
infect the same cell and exchange the HA or NA gene segments resulting in a reassortant 
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virus, although any of the eight gene segments are subject to reassortment. Prior human 
influenza pandemics may have been the result of antigenic shift, such as the Asian Flu 
pandemic of 1957 and the Hong Kong Flu pandemic of 1968, or may have been the result of 
a complete species jump of avian IAV to humans in the Spanish Flu Pandemic in 1918.74,172 
In addition, the human pandemic A H1N1 (pH1N1) virus also resulted from reassortment of 
North American and Eurasian swine lineage influenza viruses.37 
Influenza was first recognized in swine in the Mid-western US in 191881 and 
coincided with the human pandemic known as the Spanish Flu.172 The virus was isolated 
from pigs in 1930 and belonged to the H1N1 lineage.138 Influenza A viruses in swine that 
evolved from the 1930 virus are currently designated as classical H1N1 viruses (cH1N1). For 
over 70 years, the cH1N1 virus remained relatively stable at the genetic and antigenic level 
and was the only subtype responsible for acute influenza outbreaks of respiratory disease in 
swine in the US. It is unknown why additional subtypes did not become established in pigs 
during this extended period. Some reassortant influenza viruses may not efficiently transmit 
among pigs to allow endemic infections to occur. One could also speculate that earlier 
production practices based on smaller groups of pigs, limited movement of swine and 
restricted exposure to humans may have contributed to this lack of antigenic variability as 
well. 
In 1998, emergence of an H3N2 subtype with human lineage HA and NA genes into 
North American swine altered the future epidemiology of porcine IAV’s. A severe influenza-
like disease was observed in swine in North Carolina as well as Texas, Minnesota and Iowa. 
Genetic analysis of these H3N2 viruses isolated from multiple cases demonstrated the 
presence of two genotypes. A North Carolina isolate was a double reassortant with gene 
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segments from the cH1N1 swine lineage polymerase acidic (PA), polymerase basic 2 (PB2), 
matrix (M), nucleoprotein (NP) and nonstructural (NS) genes but also included human 
lineage HA, NA and polymerase basic 1 (PB1) genes. Influenza viruses isolated from swine 
in Iowa, Minnesota and Texas were triple reassortants containing gene segments from the 
cH1N1 swine lineage (NS, NP, M), and also included segments from avian lineage (PB2, 
PA) and the same human lineage gene segments (HA, NA, PB1) as the double reassortant 
H3N2 viruses.187 Within one year, the triple reassortant influenza viruses became widespread 
in the US swine population and with time replaced the cH1N1, suggesting the unique 
combination of swine, avian and human gene segments may have provided a selective 
advantage over other influenza viruses in swine.171 The double reassortants detected at that 
time never became endemic in swine, also suggesting the fitness of the triple reassortant gene 
combination. 
The six internal gene segments of the triple reassortant influenza viruses that includes 
the PB1 of human lineage, PA and PB2 of avian lineage and NP, M and NS of swine lineage 
is known as the triple reassortant internal gene constellation or ‘TRIG’ cassette.163 The vast 
majority of contemporary influenza viruses isolated from swine in the US and Canada now 
contain the TRIG regardless of subtype. Shortly after the introduction of H3N2 viruses in 
1998, reassortant viruses began to emerge in swine. The cH1N1 and H3N2 reassortant 
viruses contained the HA and NA genes from the cH1N1 and TRIG from H3N2 viruses. 
These viruses are referred to as the reassortant H1N1 (rH1N1) subtype.73,170 Reassortant 
swine influenza viruses with the HA from the cH1N1 and NA and TRIG from the H3N2 
virus are the contemporary H1N2 viruses.21,73 All of these subtypes co-circulate in the North 
American swine population. 
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Further adding to the diversity of H1 influenza viruses in swine was the detection of 
HA genes derived from human seasonal viruses in 2005 that have spread throughout the US 
pig population.72,162 The HA genes of the human-like swine viruses were similar to the 
human seasonal H1N1 and H1N2 viruses that were circulating just prior to that time. The 
human-like swine virus HA is genetically and antigenically distinct from cH1N1-lineage HA, 
although the TRIG genes of the human-like swine viruses are similar to the TRIG of the 
contemporary triple-reassortant swine viruses. Epidemiological data suggests the number of 
influenza outbreaks associated with the human-like HA reassortant viruses in swine has 
increased in recent years and are becoming a dominant genotype in the US (Iowa State 
University Veterinary Diagnostic Laboratory data, 2011). 
The H1 viruses currently circulating in swine have been classified into individual 
clusters based on branches in a phylogenetic tree and represent the evolutionary diversity 
demonstrated by the HA genes from each of these groups.162 The HA from cH1N1 influenza 
viruses consist of α-, β-, and γ-clusters. The δ-cluster consists of H1 swine viruses with the 
human-like HA. Phylogenetic analysis has demonstrated the δ-cluster contains two 
subclusters designated δ1 and δ2 and likely represents two separate introductions of H1N2 
and H1N1 human seasonal influenza viruses into the swine population, respectively.89 The δ-
cluster viruses have a preference for NA genes of human lineage rather than the N1 of 
cH1N1 swine lineage. The diversity of clusters within H1 viruses circulating in swine and the 
divergence noted in the δ-cluster group further emphasizes the rapidity with which influenza 
A viruses are drifting and/or reassorting within the swine population. 
Divergence of H3 influenza viruses has led to the development of a different cluster 
system. Since 1998, three introductions of human H3 subtype viruses have been detected in 
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swine 132,170 and could be classified as clusters I, II and III. The cluster III viruses became 
dominant in North America and have now evolved into cluster IV which is the most common 
H3 cluster virus isolated from North American swine.43  
In early spring of 2009, a novel H1N1 influenza virus caused severe outbreaks of 
respiratory disease in humans that quickly spread across the globe at a rate prompting the 
WHO to declare a pandemic five months from the first reported case. This novel pandemic 
H1N1 demonstrated a combination of genes from influenza A viruses of North American and 
Eurasian swine lineages. The pH1N1 virus is a triple reassortant with a unique set of six gene 
segments closely related to the North American triple-reassortant influenza viruses (PB2, 
PB1, PA, HA, NP and NA) and Eurasian lineage M and NA genes.26 Prior to the 2009 human 
pandemic, no closely related influenza A viruses with this gene combination had been 
identified in swine in North America or elsewhere in the world as an immediate precursor to 
the pH1N1.32,140,147 The closest related HA gene to the pH1N1 virus is the North American γ-
cluster H1 lineage. Importantly, the pH1N1 forms its own phylogenetic node within the H1 γ-
cluster viruses confirming its uniqueness among other influenza A viruses in North American 
swine.  However, the pH1N1 spread around the world in humans and was quickly transmitted 
to pigs in the US where it now remains an additional endemic virus co-circulating with the 
previous H1 and H3 variants.  
Influenza A Virus Vaccines in Swine  
Influenza vaccines were introduced for use in swine in 1994 as inactivated, 
multivalent, whole virus preparations administered with oil in water adjuvant.163 Since the 
introduction of the H3N2 triple reassortant virus, vaccines have been manufactured with an 
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H3N2 antigen and a combination of H1 viruses that may or may not be currently circulating 
in swine.  Over the past ten years, influenza vaccine usage in swine has increased 
epitomizing the need to control this economically important swine pathogen.163 The National 
Animal Health Monitoring System (NAHMS) reported 40% of large producers vaccinating 
breeding females in 2000 that increased to 70% in 2006.105 Consistent with the NAHMS 
report, a recent study evaluating management and production practices on 153 swine farms in 
Minnesota and Iowa between 2007 and 2009 reported vaccination usage in 71% of breeding 
females.9 In contrast, vaccine use in growing pigs constituted less than 10% of the swine 
farms surveyed.9 However, it is reasonable to expect vaccine use in swine to continue and 
perhaps increase in an effort to control infection, transmission, reassortment and the potential 
derivation of zoonotic pandemic influenza viruses. 
Increasing genetic and antigenic diversity recognized among contemporary influenza 
viruses circulating in swine has created a challenge to produce efficacious vaccines. 
Inactivated vaccines effectively reduce clinical disease and lung lesions and provide partial 
protection when priming antigen and challenge viruses demonstrate similar HA proteins. 
13,79,82,92,152,161,160,158
 However, unlike natural infection, inactivated vaccines have 
demonstrated limited efficacy or inconsistent cross-protective immunity against heterologous 
homosubtypic or heterosubtypic viruses.13,92,79,154,152,161,160,158 In a previous study, pigs that 
were naturally exposed to European H1N1 and H3N2 viruses demonstrated complete 
protection against a novel, heterologous H1N2 virus infection with an unrelated HA 
protein.153 In contrast, inactivated vaccines containing H1N1 and H3N2 viruses did not 
confer protection against a heterologous H1N2 virus.154 These data suggest live exposure, or 
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vaccination that mimics natural infection, may provide optimal protection or reduction in 
clinical signs associated with IAV infection in swine. 
There are no commercially available modified live attenuated vaccines currently 
licensed for swine influenza. However, research using genetically altered, live attenuated 
influenza vaccines have demonstrated increased efficacy against heterologous infection. A 
process was utilized to alter the HA cleavage site of a swine H1N1 influenza virus from a 
trypsin-sensitive to an elastase-sensitive motif that attenuated the virus in vivo.95 Intratracheal 
administration of the elastase-dependent attenuated virus in pigs protected against challenge 
with heterologous virus.6 Live attenuated influenza viruses with modifications in the 
polymerase genes that attenuate viral replication at normal body temperatures115 or 
modifications in the NS1 protein have proven efficacious as mucosally delivered vaccines in 
swine as well.164 Modified live, attenuated vaccines have the advantage of enhancing cell-
mediated immune responses typically directed against conserved internal proteins182 and 
increasing heterologous cross-protection that may be lacking in inactivated vaccines.180 
Due to the lack of cross-protection experienced through the use of commercial 
vaccines, producers now rely on inactivated autogenous vaccines incorporating influenza 
viruses isolated from the farm of origin. In 2006, the NAHMS survey reported 20% of farms 
used autogenous vaccines in breeding females.105 A current study in Minnesota and Iowa 
swine farms reported 72% of influenza vaccines used in breeding females on 153 swine 
farms surveyed were autogenous whereas only 24% were commercial vaccines.9 Major 
challenges will continue to affect the ability of inactivated influenza vaccines to adequately 
protect swine. Influenza viruses change their antigenic composition more rapidly than 
vaccines can be manufactured and receive government approval. Inactivated vaccines may 
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continue to lack cross-protection against the multitude of emerging, variant influenza viruses 
and passively acquired, maternally-derived immunity will likely interfere with vaccine 
immunity. Research with human and avian IAV has focused on identifying a universal 
epitope that would provide broad cross-protection against all influenza viruses. However, this 
approach has not demonstrated consistent results. Future vaccines may require innovative 
approaches utilizing novel preparations or non-traditional methods of delivery. These may 
include subunit, vectored, virus-like particle or plasmid DNA-based vaccines.91  
Vaccine associated enhanced respiratory disease 
 The immune response elicited by a vaccine may vary from failure to partial or 
complete protection against infection and/or clinical disease. However, vaccines unable to 
prevent infection may also exacerbate the clinical signs and increase the severity of disease. 
The concept of vaccine-associated enhancement of influenza respiratory disease in swine was 
originally reported with a DNA construct expressing a fusion protein consisting of the 
extracellular domain of the M2 protein (M2e) and nucleoprotein (NP).58 The M2eNP DNA 
vaccine induced an antibody and lymphoproliferative immune response to the virus although 
subsequent challenge with an H1N1 resulted in severe clinical respiratory disease in all 
M2eNP immunized pigs compared to non-vaccinated and challenged pigs and death of three 
pigs. Pigs administered only the M2e protein developed an antibody response and 
demonstrated clinical signs that were more severe than challenged pigs that did not receive 
vaccine but less severe than the M2eNP DNA group. The results of this study suggested both 
non-neutralizing antibodies to M2e and T helper (Th) cells directed against the NP were 
necessary for disease enhancement. However, lung lesions were not assessed in this report 
and the mechanism of enhancement was not further characterized. 
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 A 2008 report of vaccine-associated enhancement of influenza respiratory disease 
supported the results of the previous M2eNP vaccine study.  Two intramuscular doses of a 
UV-inactivated H1N1 α-cluster adjuvanted vaccine followed three weeks later by 
intratracheal challenge with an H1N2 γ-cluster virus resulted in enhanced macroscopic lung 
lesions in three of nine pigs compared to the non-vaccinated, challenged group.160 Pigs with 
enhanced lung consolidation also demonstrated more severe microscopic lung lesions that 
included a broader distribution of influenza virus antigen beyond intrapulmonary airways, a 
local cross-reactive IgG antibody response but no detectable heterologous IgA antibodies. 
The unexpected results of this study suggested a correlation between the immune response to 
inactivated influenza vaccine and enhanced disease when vaccine antigen and challenge 
viruses do not cross-react serologically in the HI assay. Few reports have documented an 
association between enhanced respiratory disease and non-replicating influenza vaccines. 
However, several reasons support the further characterization of enhanced respiratory disease 
and understanding the potential immune-mediated mechanisms that may be responsible for 
this phenomenon in the studies reported herein. These include: the use of inactivated or non-
replicating influenza vaccines in swine is increasing;9 commercial influenza vaccines 
(including autogenous products) are inactivated, adjuvanted products similar to vaccines used 
in studies recognizing enhanced disease in swine;163 and the increasing diversity within H1 
influenza viruses circulating in swine heightens a potential vaccine-challenge mismatch in 
field infections and subsequent disease enhancement.89 
 Vaccine associated enhanced respiratory disease (VAERD) in swine manifests as 
severe respiratory disease that may include a combination of anorexia, lethargy, coughing 
and dyspnea of prolonged duration in pigs that received two doses of an inactivated, 
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adjuvanted influenza vaccine approximately three and six weeks prior to inoculation with a 
heterologous, homosubtypic influenza virus.38 Clinical signs in VAERD-affected swine, 
including a febrile response that may persist from 48 to 96 h post infection, are enhanced 
compared to influenza-naïve, non-vaccinated swine challenged with the same virus. Kitikoon 
et al. 2009, described a clinical presentation similar to VAERD using the same vaccine, 
heterologous challenge model from an earlier study in pigs160 that further suggested the 
vaccine is a necessary component of VAERD in swine.78 An additional necessary component 
of VAERD includes challenge with an influenza virus sufficiently heterologous to lack 
serological cross-reactivity in the HI assay.160 The current VAERD model uses a δ1 cluster 
H1N2 virus as vaccine antigen that shares only 76% HA nucleotide homology with the 
pH1N1 challenge virus, a distinct clade in the γ-cluster H1 viruses. The HA and NA are 
highly variable surface glycoproteins targeted by the host humoral immune response that 
may influence mutations in the genome and subsequent antigenic drift.163 The percent 
nucleotide variability between vaccine and challenge virus HA proteins necessary to cause 
VAERD is unknown and perhaps the amino acid variation between proteins may be more 
indicative of potential VAERD. Regardless, the increasing genetic and antigenic diversity 
demonstrated in H1 IAVs circulating in swine combined with the increased use of inactivated 
vaccines creates optimal conditions for vaccine-virus mismatch and potential VAERD in the 
swine population. 
Enhanced viral diseases of mammals 
 Enhanced disease in influenza-vaccinated and challenged swine comprises only one 
of many viruses that have been associated with vaccine- or immune-mediated aggravated 
disease in mammals. The clinical presentation varies considerably among these viruses when 
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infection occurs in the presence of subneutralizing antibody and may manifest as increased 
viral replication in vitro to severe systemic infection in vivo.148 Antibody-enhanced viral 
infections were initially recognized when Murray valley encephalitis virus (MVEV) was 
incubated in vitro with diluted antisera that was later determined to have subneutralizing  
antibodies.55 The infectivity of the virus increased when incubated with high dilutions of 
antisera demonstrated by an elevated number of plaques in cell culture compared to virus 
incubated in control serum. Immune-mediated enhanced disease attracted further attention in 
early clinical trials where children administered a formalin-inactivated respiratory syncytial 
virus (FI-RSV) vaccine experienced severe illness and enhanced respiratory disease after 
natural exposure to respiratory syncytial virus (RSV) compared to children that received a 
placebo vaccine.75 In addition, two FI-RSV vaccinated children experienced severe illness 
and died following natural infection in the same study.75 Additional viruses, such as Dengue 
(DENV) and Measles virus (MV), have been associated with enhanced replication or disease 
in humans after sequential infection with different serotypes of DENV22,48 or several years 
post-vaccination with a formalin-inactivated measles (FI-MV) vaccine.34 Due to these early 
vaccine failures, the production of safe and effective RSV and DENV vaccines has yet to be 
realized. 
 Mammalian viruses other than RSV, MV or DENV have been linked to enhanced 
infection or disease either in vitro or in vivo and in many cases manifest as an immune-
mediated enhancement of infection. In addition to MVEV, the following viruses have been 
associated with increased replication, prolonged viremia or enhanced clinical disease 
following vaccination, previous exposure or treatment with immune sera: Ross River virus 
(RRV),88 human Metapneumovirus (hMPV),183 Feline Coronavirus (FCoV),175 Human 
15 
 
 
Immunodeficiency virus (HIV),133 Simian Immunodeficiency virus (SIdefV),85 Feline 
Immunodeficiency virus (FIV),60 Equine Infectious Anemia virus (EIAV),65 West Nile 
(WNV) and Japanese Encephalitis virus (JEV),55,56 Lactate Dehydrogenase Elevating virus 
(LDEV),64 Rabies virus (RV),77 Aleutian Disease virus (ADV),70 Simian Hemorrhagic Fever 
virus (SHFV),117 Porcine Reproductive and Respiratory Syndrome virus (PRRSV),184 and 
African Swine Fever virus (ASFV)40 among others (Table 1). Although not extensively 
studied, some bacteria and protozoa have used pathogenic immune complexes to aid their 
survival in macrophages. These include Mycobacterium spp., Listeria monocytogenes, 
Coxiella burnetii and Salmonella spp. as well as Leishmania spp.50 Chronic or prolonged 
infections of these organisms may be attributed to increased intracellular infections 
secondary to antibody mediated reactions that represent a form of enhanced disease in a 
particular host species.50 
 Viruses associated with enhanced replication or disease share some genetic or 
pathogenic features that may suggest one or more characteristics necessary to manifest 
enhanced, heightened or prolonged disease. Nearly all of these pathogens are single-stranded, 
enveloped RNA viruses that represent significant human and animal health concerns 
excluding ADV (Parvoviridae DNA virus) and ASFV (Asfarviridae DNA virus). These 
viruses may induce subneutralizing antibodies that lack the ability to prevent subsequent 
infection and indirectly facilitate uptake of the virus, increase replication, promote prolonged 
viremia or cause persistent infection.47,145,185  
Antigenic diversity among different serotypes or subtypes within a particular genus is 
another common feature of some disease enhancing viruses, including IAVs in swine, where 
cross-neutralizing antibodies are not shared between heterologous viruses. Interestingly, 
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VAERD in swine is a recently recognized phenomenon that may be correlated with the 
increasing antigenic diversity prevalent in H1 influenza viruses circulating in North 
American swine.89 Similar to other viruses, such as DENV, where antigenic differences 
between serotypes resulted in enhanced disease when serial infection occurred in the 
presence of preexisting antibodies,52,51 the lack of serological cross-reactivity and cross-
protective vaccine immunity between different H1 phylogenetic clusters may result in 
vaccine/challenge virus mismatch and VAERD.89,159 
 Immune-mediated enhanced disease requires an initial priming event to induce a 
subneutralizing immune response that may consist of low affinity antibody.148 Ubol, et al. 
2010 described three situations where prior immunological sensitization may occur: A) 
infection with viruses that demonstrate naturally occurring heterologous variants within the 
same genera; B) infection with rapidly evolving, heterovariant viruses during the course of a 
chronic infection or in the presence of pre-existing, non-protective immunity; C) vaccination 
with poorly immunogenic antigen resulting in incomplete protective or transient immune 
responses. Dengue virus consists of four different, naturally occurring serotypes and 
represents scenario A immune stimulation described above. Viruses such as FCoV and RSV 
may represent scenario B and C, respectively. However, it is difficult to classify some 
disease enhancing viruses into one specific group. Swine influenza viruses in particular may 
be classified in more than one group considering multiple antigenic variants naturally occur 
in the environment, influenza viruses are continually evolving into additional antigenic 
variants89,106,162 and inactivated influenza vaccines approved for use in swine may prime an 
immune response that does not provide adequate cross-protection against heterologous 
viruses within the same subtype.161,159 RNA viruses in general demonstrate a high rate of 
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genetic mutation that may be a predisposing factor for enhanced disease in their respective 
host in the presence of sub-neutralizing antibody. Further studies may help elucidate inherent 
viral characteristics that promote enhanced disease. 
Immunopathology associated with enhanced viral diseases 
 Pathology associated with exacerbated disease is often secondary to non-protective 
antibodies or antigen-antibody mediated reactions that may increase viral uptake, enhance 
replication, prolong viremia and/or induce marked inflammation.47 Acronyms have been used 
to describe the clinical manifestation of different disease-enhancing viruses. These include: 
enhanced pulmonary disease (EPD) of HMPV, enhanced respiratory disease (ERD) of RSV, 
atypical measles (ATM) of MV, Dengue hemorrhagic fever (DHF) or Dengue shock 
syndrome (DSS) of DENV and VAERD associated with heterologous influenza infection in 
vaccinated swine (Table 1). 
  Multiple Flaviviruses, such as MVEV, West Nile virus and Japanese Encephalitis 
virus, have demonstrated enhanced replication in vitro in the presence of antisera at high 
dilutions.55,56 However, more attention has focused on the enhanced immunopathology 
associated with DENV infection. Dengue fever (DF) manifests as an acute, flu-like illness of 
approximately 7-10 days where affected individuals may experience fever, headache, 
myalgia or nausea but usually recover.87 A severe form of DF, known as DHF, may manifest 
as an acute febrile illness with hemorrhage, thrombocytopenia and increased vascular 
permeability accompanied by loss of plasma and serous effusions. Hypotension, circulatory 
failure and death accompanied by DHF is known as DSS.22,25,134 An elevated viremia is often 
associated with severe DENV disease as well.44  
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 Measles virus is responsible for illness and death in many developing countries 
primarily affecting infants and young children less than nine months of age.119 In spite of 
vaccine availability, seroconversion rates are lower at this young age due to the presence of 
interfering maternal antibody and an immature immune system incapable of a robust 
antibody response against the virus.1,36 Children experiencing ATM present with elevated 
body temperature, an urticarial, vesicular or petechial rash on the extremities and severe 
pneumonitis.34,93,129,186 In addition, eosinophilia, pleural effusions, lymphadenopathy and 
edema are features of ATM-affected children. No histopathology characterizing lung 
inflammatory infiltrates is available from early cases of ATM as there were no fatalities. 
However, roentgenograms demonstrated diffuse lung infiltrates and hilar 
lymphadenopathy.93,186 This is in contrast to “typical” measles lung lesions that include 
peribronchiolar inflammation and mild parenchymal infiltrates with pneumonia less common 
compared to ATM.186 In addition, residual nodular pulmonary lesions were reported in 
recovered ATM-affected children that were not observed in typical measles infection.93 A 
morbiliform or maculopapular petechial rash typically starts on the distal extremities 
including the palms, wrists and ankles progressing to vesicles that may become pruritic. 
Atypical measles has been reproduced in rhesus macaques that resulted in an atypical rash 
and pneumonitis in vaccinated and challenged subjects similar to ATM in human infants.120 
Inactivated measles vaccines were removed shortly after adverse reactions were correlated 
with immunization. 
 Feline Coronavirus chronic infection in cats manifests as a severe, immune-mediated 
disease known as Feline Infectious Peritonitis (FIP) that results in enhanced infection of 
multiple organs including the central nervous system.54 Experimental infection of 
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seropositive kittens with FCoV reported detection of viral antigen in macrophages as well as 
tracheobronchial lymph nodes, lungs, trachea, liver, spleen, kidneys, omentum and 
brain.114,176 Perivascular necrotizing pyogranulomatous inflammation, thrombosis, fibrinous 
serositis and lymphoid necrosis followed an early onset of viremia compared to seronegative 
kittens challenged with FCoV.176 The authors concluded the early onset of viremia and the 
acute, severe form of FIP in seropositive cats supports an immunologically mediated, 
enhanced form of FCoV known as the effusive form of FIP.114,176 
 Lentiviruses infect multiple mammalian species and many have been associated with 
enhanced disease reported in vaccinated and challenged subjects including EIAV, FIV and 
SIdefV. 131,142,167 Lentivirus enhanced disease has been described as increased susceptibility 
to infection and replication as well as prolonged viremia.60,142,167 However, specific 
pathological changes have not been consistently described in these cases. In one study, 
macaques immunized with an attenuated recombinant SIdefV vaccine experienced enhanced 
disease described as rapid depletion of CD4+ target cells and progression towards acquired 
immunodeficiency syndrome (AIDS) compared to controls.142 Another study evaluating 
inactivated EIA subunit-vaccines in ponies demonstrated complete protection to homologous 
challenge and enhanced disease to a heterologous strain of EIA.65 The enhanced disease in 
this report was described as fever, marked depression, anorexia and weight loss compared to 
non-immunized controls. In addition, all severely affected vaccinates in the study survived 
the enhanced clinical disease which may have precluded evaluation of specific 
immunopathology by post-mortem examination. Enhanced expression of disease 
demonstrated with different Lentivirus vaccines is of particular concern in humans. Serum 
from HIV-infected individuals has demonstrated enhanced HIV infection in some types of 
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human cells in vitro.94 There is concern similar disease enhancement may occur with the use 
of HIV vaccines in humans. However, some clinical trials conducted in humans thus far have 
not indicated enhanced forms of infection with HIV vaccines in vivo. 
  One of the more thoroughly described enhanced diseases, and its associated 
immunopathology, is a virus belonging to the Paramyxoviridae family. Respiratory syncytial 
virus is the most common cause of lower respiratory disease in infants and young children 
worldwide generating the need for efficacious vaccines. Over forty years ago, a formalin-
inactivated RSV vaccine administered to children was correlated with approximately 80% of 
hospitalizations after exposure to natural infection.35,75 In addition, two vaccinated children 
experiencing ERD secondary to RSV infection died after exposure to the virus. Subsequent 
investigations of the mechanism of ERD involved extensive evaluation of the 
immunopathology and how it contributed to the enhanced disease. Autopsies conducted at 
that time revealed a bronchopneumonia with emphysema and pneumothorax.75 
Microscopically, lesions consisted of excessive numbers of neutrophils, macrophages and 
giant cells in large bronchi. The bronchial epithelium was infiltrated with neutrophils and 
mononuclear cells. Smaller bronchioles and bronchi contained neutrophils, lymphocytes and 
in some areas increased numbers of eosinophils. In addition, the bronchiolar epithelium was 
infiltrated with neutrophils and mononuclear cells with aggregates of neutrophils within 
vacuoles of the bronchial epithelium forming microabscesses. Alveoli also contained a 
similar inflammatory infiltrate of neutrophils and macrophages and peribronchiolar 
inflammation was primarily lymphocytic with few neutrophils and macrophages.75,126 
Additional studies confirmed a peripheral eosinophilia in hospitalized children with ERD that 
appeared to be consistent with the eosinophils described in the lung.20 Similar pulmonary 
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pathology has been described in cotton rats vaccinated and challenged with hMPV, another 
virus of the Paramyxoviridae family.183 Accentuated peribronchiolitis, interstitial pneumonia 
and alveolitis were consistent pathological features in the lung although eosinophils were not 
described. Interestingly, the histopathology associated with ERD is remarkably similar to 
what has been described for influenza challenged, VAERD-affected swine excluding the 
eosinophil infiltrates noted in ERD.38 Similar respiratory pathology may be due to the 
propensity of each virus to infect and replicate in bronchiolar epithelium, but may also point 
to a common pathway in the underlying mechanism of the two diseases. 
The presence of eosinophils in the lungs of humans with ERD provoked much 
interest among researchers and suggested a pathognomonic lesion of enhanced 
disease.10,27,68,141 Conversely, the validity of eosinophils and their involvement with ERD has 
been the subject of much debate and may depend on the animal model.112 Prince et al. 2001, 
reviewed the histopathology from the first human ERD cases75 and noticed a predominance 
of neutrophils, macrophages and lymphocytes in the bronchial exudate that consisted of only 
1-2% eosinophils. Peribronchiolar inflammation contained over 80% lymphocytes without an 
exuberant eosinophil population.126 Another report using FI-RSV vaccinated macaques with 
ERD described elevated eosinophils in bronchoalveolar lavage fluid (BALF) compared to 
mock-vaccinated and challenged control animals.27 Interestingly, this report did not compare 
the relative percentage of all granulocytes and mononuclear cells with eosinophils in BALF 
and specifically mention the FI-RSV vaccinated and challenged animals had a locally-
extensive bronchointerstitial pneumonia with macrophages and neutrophils in alveolar 
lumina.27 Additional studies have also described vaccine-enhanced RSV disease with 
neutrophilic alveolitis without eosinophils using African green monkeys,69 cotton 
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rats127,126and calves.39 Neutrophilic alveolitis, atypical of a primary viral pneumonia, and 
lymphocytic peribronchiolitis are repeatable among different models and considered by some 
the key features of vaccine-enhanced respiratory disease.126  
Immune-mediated mechanisms of enhanced viral diseases 
 The pathogenesis of enhanced disease in any species is a complex, multifactorial 
network of immune functions that may include humoral and cell-mediated immune 
responses, immune complexes, hypersensitivity reactions, cytokines and viral mediated 
factors. It is erroneous to presume one component is sufficient to induce an exacerbated 
response to viral infection. Rather, multiple factors combine to convert the physiological 
response from an antiviral mode to a viral facilitating process that may result in elevated viral 
replication, prolonged viremia, excessive inflammation, hypotension, shock or death 
depending on the species and virus involved. However, immune complexes are consistently 
identified in the pathogenesis of viral enhancement suggesting immune mediated processes 
play a crucial role in enhanced clinical signs and disease exacerbation. 
Preexisting Antibodies - Preexisting antibodies are one of the important and necessary 
components of enhanced viral infections in multiple species.50,61,123,148 Prior sensitization or a 
priming event is required to establish the presence of preexisting antibodies. This may occur 
as a result of intrinsic priming through natural infection or due to extrinsic factors such as 
administration of non-replicating or inactivated vaccines.50 The antibodies generated from 
immunological sensitization demonstrate specific characteristics depending on how the 
antigen was administered or presented to the immune system. Antibodies associated with 
enhanced infection are commonly non-protective or non-neutralizing against secondary, 
heterologous viruses.41,49 Enhancing antibodies have also demonstrated low avidity that may 
23 
 
 
be due to a lack of affinity maturation29 and non-neutralizing antibodies may form antigen-
antibody complexes that have also contributed to enhanced viral disease.149 
 Non- or sub-neutralizing antibodies have been implicated an important component of 
the pathogenesis of VAERD in swine. Inactivated or non-replicating influenza vaccines 
induce a neutralizing response to homologous or antigenically similar viruses.161 In contrast, 
these same antibodies are limited in their ability to cross-protect against antigenic variants 
that co-circulate widely in US swine.154,161 Sub-neutralizing antibodies also contribute to 
enhanced RSV,103 MV,121 and FCoV (FIP) disease175 as well as other viruses and vaccines 
are largely responsible for the induction of sub-neutralizing antibody responses. However, 
unlike the neutralizing response generated to homologous virus with inactivated influenza 
vaccines, formalin-inactivated RSV and MV vaccines either completely lack the ability to 
induce a neutralizing response to the wild type virus (RSV) regardless of homology or the 
neutralizing antibodies are short-lived resulting in enhanced disease several years after 
protective immunity has waned (MV) leaving a population of sub-neutralizing 
antibodies.103,121 
Current VAERD studies with inactivated influenza vaccines also suggest cross-
reactive, non-neutralizing antibodies contribute to enhanced disease through mechanisms that 
need further investigation.58,160 Inactivated and adjuvanted influenza vaccines administered 
by the intramuscular route induce systemic and mucosal IgG antibodies but lack the ability to 
generate adequate IgA responses.57,115,164,160 Non-neutralizing but cross-reactive IgG 
antibodies induced by inactivated influenza vaccines have demonstrated low avidity and may 
contribute to enhanced disease through pathogenic immune complexes (Vincent; unpublished 
data). In addition, adjuvants commonly used with inactivated vaccines may contribute to 
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enhanced disease by mechanisms that are currently unknown. A previous report implicated 
the use of alum adjuvanted formalin-inactivated hMPV vaccines in macaques as the cause of 
an eosinophilic response in enhanced disease.27 However, further studies are necessary to 
discern the role of oil-in-water adjuvants commonly used in inactivated influenza vaccine 
preparations in swine and the onset of VAERD.  
Intrinsic immune sensitization and preexisting antibodies play an important role in 
enhanced DENV infections. Dengue, the cause of DF or the enhanced forms of the disease, 
DHF and DSS, is an arthropod-born Flavivirus associated with human infections in endemic 
areas as well as in travelers that have visited tropical regions.178,179 Dengue exists as four 
related but different serotypes designated 1, 2, 3 and 4. Sequential infection of DENV 
serotypes has resulted in DHF and DSS due to preexisting antibodies that fail to neutralize 
heterologous serotypes upon subsequent infection and increase viral uptake through antibody 
dependent enhancement (ADE) into macrophages facilitating viral replication.3,51 Cats with 
antibodies to FCoV from natural infection, maternal antibody or vaccine-derived humoral 
immunity may experience enhanced disease (FIP) during chronic infections where 
spontaneous mutations in the genome alters the ability of preexisting antibodies to neutralize 
the virus,157 or when passively- or vaccine-derived antibodies do not cross-protect against 
subsequent infection.156,175 Similar to DENV, preexisting FCoV antibodies promote the 
uptake of virus through ADE into macrophages enhancing virus replication or immune-
complex formation involving antibodies may activate complement and promote secondary 
vascular disturbances.175 Regardless of the outcome and the immunopathology involved, 
preexisting antibodies are a common and important feature of many enhanced viral diseases.  
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Immune Complexes (Antigen-Antibody) - The consequences of sub-neutralizing, 
preexisting antibodies go beyond the inability to prevent viral infection. When antibodies 
cross-react with non-protective viral epitopes, immune complexes (IC) may form that initiate 
a cascade of events contributing to enhanced disease and its associated immunopathology. 
Local Arthus-type or type III hypersensitivity reactions were observed when live attenuated 
vaccines were used to re-immunize individuals that previously received FI-MV.15,33,34 
Immune complexes have been implicated in ERD with RSV,123 enhanced DENV disease,149 
ADV,124 and ATM.120,121 However, ICs contribute to disease enhancement through diverse 
mechanisms that may depend on the virus involved or their tissue tropism. 
 Immune complex deposition was demonstrated in FI-RSV vaccinated mice with ERD 
primarily in peribronchiolar and perivascular regions of the lung.123 Immune complex 
deposition in dermal vessels has also been demonstrated with ATM in rhesus macaques that 
received FI-MV vaccine prior to challenge with WT virus,120 and additional viruses, such as 
DENV, have used complexes with preexisting antibodies to enhance in vitro infection.149 
 Immune complexes demonstrate similar characteristics that often include antibodies 
of low affinity. Analysis of immune complexes in enhanced disease revealed non-protective 
antibodies are common.48,103,123,121,119,148,149 In addition, these antibodies may demonstrate 
low avidity against their respective antigen30,121 or a lack of adequate affinity maturation.29,121 
Immune complexes were also associated with severe disease due to the pandemic 2009 
A/H1N1 virus in humans.100 Preexisting, non-protective antibodies in severely affected, 
middle-aged adults were associated with low avidity pulmonary IC-mediated disease. These 
same human cases demonstrated IC-mediated complement activation demonstrated by the 
presence of C4d deposition in lungs. The author hypothesized that preexisting immunity 
26 
 
 
against seasonal influenza antigen induced non-protective antibodies in the middle-aged, 
affected population that were absent in young children without prior vaccine or natural 
exposure while the elderly retained protective antibodies from H1N1 viruses circulating prior 
to 1957.100 These data are similar to what has been reported with influenza challenged, 
VAERD-affected swine where non-protective but cross-reactive antibodies may have 
contributed to severe pulmonary disease.58,160 
 Immune complexes play an important role in complement activation, infiltration of 
inflammatory cells and eventual tissue damage.17 Complement activation has been 
demonstrated with enhanced RSV and MV disease in mice and non-human primates120,123,121 
in addition to the first human cases in 1967 where retrospective staining of lung lesions 
demonstrated complement component C4d deposition in peribronchiolar areas.123 Increased 
numbers of inflammatory cells and elevated levels of proinflammatory cytokines described in 
VAERD-affected swine38 suggests a potential involvement for complement factors that may 
damage lung tissue through the cell-lytic complex, recruit inflammatory cells or promote IC-
mediated alveolitis through the action of complement anaphylotoxins such as C5a.59 
Additional studies are necessary to elucidate the characteristics of IC-associated antibodies 
and involvement of IC-mediated complement activation in VAERD-affected swine. 
Antibody-dependent Enhancement of Viral Disease - Antibody-dependent 
enhancement (ADE) or immune enhancement of disease is a mechanism utilizing preexisting 
antibodies and ICs to the advantage of the virus that may result in enhanced uptake and/or 
replication, often in antigen presenting cells, that subsequently exacerbate disease. However, 
the clinical manifestations of ADE vary depending on the virus, cells susceptible to infection 
and the isotype of preexisting antibodies. 
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 Immune complexes play a significant role in DENV enhanced disease utilizing ADE 
to increase viral uptake and replication. Polyclonal antibodies enhanced experimental in vitro 
infection of heterologous DENV serotypes suggesting ADE an important component of 
DENV enhanced disease.51,52 Additional studies recognized children with DENV-specific 
maternal antibody demonstrated more severe DF compared to children without passive 
antibody.45 A similar enhanced response to infection was demonstrated in non-human 
primates passively administered human anti-DENV maternal antibodies and challenged with 
the virus.46  
Dengue virus enhanced disease is commonly a consequence of increased viral 
replication or prolonged viremia.44,53,86,155 Increased levels of proinflammatory and 
immunomodulatory cytokines are a consequence of enhanced replication and may affect the 
degree of vascular permeability in cases of DHF and DSS.12,44 Enhancing, preexisting 
antibodies contribute to ADE increased DENV replication through Fcγ receptor (FcγR) 
mediated uptake of virus in monocytes, macrophages and dendritic cells which display FcγRs 
on the cell surface and are the target cells for DENV replication.7,67 Innate immune cells, 
such as macrophages, typically demonstrate antiviral responses upon infection. However, 
data suggests ADE may support enhanced disease by altering innate and adaptive 
intracellular anti-viral mechanisms that are typically used by the host to eliminate viral 
infection.148,149,18 
Increased uptake of influenza virus was demonstrated in murine macrophages in the 
presence of anti-HA antibody suggesting a potential role for ADE in IAV infections.109,137,144 
Additional swine viruses, such as PRRSV, have also demonstrated elevated titers in the 
presence of non-neutralizing antibodies contributing to ADE.184 In contrast to the ADE-
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supported increased viral replication demonstrated with enhanced DENV and PRRSV, 
previous reports have described a reduction in viral titers with enhanced RSV.126 Unlike 
DENV and PRRSV that use macrophages for viral replication, epitheliotropic viruses, such 
as RSV and IAV, target pulmonary epithelial cells for replication. Bronchiolar and bronchial 
epithelium lack FcγRs, which may preclude the use of immune complexes and ADE to 
increase viral replication. However, ADE or immune complexes may still play a role in RSV 
or IAV enhanced disease through increased uptake of the virus in pulmonary macrophages 
and the subsequent induction of aberrant immunomodulatory responses detrimental to the 
host.123 In addition, diminished viral titers demonstrated in enhanced RSV disease may not 
be due to a protective effect of non-neutralizing, cross-reactive antibodies induced by the 
vaccine, but rather uptake of the virus in cells that do not support replication or a hostile 
cytokine-mediated inflammatory environment in the lung that hinders viral replication. In 
addition, the substantial destruction of bronchial and bronchiolar epithelial cells by the virus 
may decrease the availability of healthy epithelium for further replication ultimately 
decreasing virus titers in the lung. 
Cell-mediated immune responses associated with enhanced viral disease -  Cell-
mediated immune responses are important for clearance of influenza viral infections and 
recovery from disease. Cytotoxic CD8+ T lymphocytes (CTL) directed against influenza 
internal proteins, specifically NP, M1 and NS1 and the polymerase proteins PB1, PB2 and 
PA, have been detected in mice and humans.11,31,42,66,130 The NP protein of IAV is targeted by 
cross-reactive CTLs in mice and humans suggesting an important component of variant 
homosubtypic and heterosubtypic immune responses critical to viral clearance and decreased 
transmission.96,146,182 In addition, CD4+ T-helper cells with a Th1 phenotype have also 
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demonstrated protection against challenge with heterosubtypic influenza virus in 
mice101,107,108 and CD4+ T cells to conserved internal influenza proteins contributed to the 
development of cross-reacting antibodies following heterosubtypic challenge.136 However, 
the role of T cells and their effect, whether protective or enhancing, in VAERD-affected 
swine requires further study.  
  Reports on the role of cell-mediated immune responses in enhanced RSV disease 
have been variable and inconsistent.  Due to prior reports describing the lung histopathology 
as primarily eosinophilic,75 investigations focused on the induction of this inflammatory cell 
and its association with T-helper 2 (Th2) cell-mediated responses.23,27,169 Previous studies 
that evaluated peripheral blood lymphocytes from FI-RSV vaccinated humans recognized 
virus-specific CD4+ lymphoproliferative responses compared to naïve subjects.76 In addition, 
passive transfer of CD4+, CD8+ or both fractions of T cells into RSV-infected mice were 
associated with clinical signs and increased lung pathology, although the most severe lung 
lesions that included pulmonary eosinophilia were correlated with the transfer of CD4+ T-
cells.5 An additional study using FI-RSV vaccinated mice demonstrated complete abrogation 
of pulmonary pathology when CD4+ T-cells were depleted prior to challenge with WT RSV 
whereas modest reductions in lung lesions were recognized in CD8+ T-cell depleted mice.23 
Additional studies have demonstrated enhanced lung pathology was the result of priming 
with specific RSV surface glycoproteins that induced excessive Th2 and CD4+ T cells.4  
These data suggest CD4+ T-cells may play a primary role in RSV enhanced disease. 
 The role of CD8+ CTLs in controlling or contributing to enhanced RSV disease is 
more ambiguous. The transfer of CD8+ T cells into RSV G-protein primed and challenged 
mice reduced lung eosinophilia caused by vaccine-induced CD4+ T cells and helped control 
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Th2-associated lung pathology.62 In contrast, cell transfer studies have demonstrated CTLs 
responsible for viral clearance but enhanced disease in RSV-infected mice.16 Similar cell-
mediated mechanisms have been suggested in ATM where Th2 responses are correlated with 
enhanced respiratory disease.99  
  Cell-mediated immune responses to IAV infection are important for viral clearance; 
however, they are also implicated as the cause of pulmonary pathology. Experimental 
influenza infections in T-cell deficient mice have demonstrated elevated viral titers and 
mortality although lung pathology was significantly reduced.102,168 Human cases have also 
correlated CD8+ T lymphocytes with diffuse alveolar damage in the lung.143 Cell-mediated 
immune responses are also important for cross-protection against infection with heterologous 
influenza viruses in swine.57 However, it is unknown how T-cell responses may contribute to 
VAERD or enhanced IAV respiratory disease. Heinen et al. 2002, demonstrated severe 
disease in swine vaccinated with a DNA construct expressing the influenza M2e and NP 
proteins. Pigs receiving the M2eNP vaccine demonstrated antibodies to the M2e protein and 
the induction of T cells correlated with severe disease.58 Although T cells appeared to 
contribute to exacerbation of the disease, other studies have shown NP DNA vaccines in 
swine did not induce severe disease without the presence of M2e antibodies.92 The author 
speculated severe disease in the M2eNP vaccinated group was enhanced by antibodies 
binding to M2e protein on the surface of infected cells that promoted destruction of the tissue 
through cell-targeted mechanisms (NK cells, ADCC, complement). However, anti-NP 
antibody may have played a role in the enhanced disease as well as CTL responses to the NP 
proteins that may have been presented by class 1 MHC molecules on the surface of infected 
cells promoting cytolytic processes and cell death. Although inactivated or non-replicating 
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vaccines are poor inducers of cellular immunity compared to live virus vaccines,71 VAERD 
models have demonstrated cell-mediated immune responses following administration of 
inactivated vaccines that included CD4+CD8+ memory T cells.118 These data suggest cell 
mediated immune responses may be involved in VAERD-affected, influenza vaccinated 
swine. In addition, non-replicating influenza vaccines are capable of inducing NP antibody 
responses, which may contribute to enhanced disease or support lung pathology through 
CTL-mediated cell death.  
Altered innate immune responses associated with enhanced viral disease - Antibody-
mediated immune mechanisms may be responsible for modifying innate antiviral responses 
following heterotypic viral infections that may affect the severity of disease.  
 Viral infections in general induce a variety of innate immune mechanisms that aid in 
viral clearance but also contribute to immunopathology if left unchecked. Interferon-γ (IFNγ) 
secreted by CD8+ T cells contributes to immunopathology in RSV infections,113 and tumor 
necrosis factor-α (TNFα) has demonstrated a more consistent role in the immunopathology 
associated with both RSV135 and influenza infections.63,116 Mice infected with the highly 
virulent 1918 influenza virus also demonstrated increased levels of macrophage-derived 
interleukin-1 (IL-1) and IL-6 that resulted in increased numbers of pulmonary inflammatory 
cells and severe hemorrhage.80 Additional viruses have demonstrated macrophage-derived 
pro-inflammatory cytokines in cases of enhanced disease as well. Severe DENV or DHF has 
been correlated with elevated IL-8, IL-6 and TNFα.19,128 Elevated pro-inflammatory 
cytokines have also been implicated in the pathogenesis of VAERD-affected swine. Studies 
have reported significantly higher concentrations of IL-8, IL-1β, IL-638 and TNFα protein in 
BALF in vaccinated swine with severe respiratory disease following challenge with 
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heterologous influenza virus compared to non-vaccinated and challenged swine (Gauger, 
Veterinary Pathology, accepted). These cytokines have been correlated with viral replication 
and clinical signs in influenza challenged swine,151 as well as pulmonary inflammation and 
lung pathology.150  
Antigen-antibody complexes or ADE-mediated uptake of virus into host cells may 
also play an important role in enhanced viral diseases, including influenza, by modifying 
innate immune responses to infection. During in vitro ADE-mediated uptake of DENV 
through Fcγ receptors, suppression pathways were stimulated that down-regulated antiviral 
responses, including the retinoic acid inducible gene 1/melanoma differentiation gene 5 
(RIG-I/MDA5) signaling pathways involved in antiviral immunity, and increased the 
expression of anti-inflammatory cytokines.18,149 Type 1 IFNs, IL-12, IFNγ and TNFα 
expression was reduced with a simultaneous increase of IL-10 which promotes Th2 biasing 
of the immune response and down-regulates antiviral mechanisms.18,149 A similar antiviral 
pathway, promoted by immune complex-mediated uptake of influenza virus into 
macrophages in the lung, may be responsible for down-regulating IFNα in VAERD-affected 
swine.38 However, unlike the diminished proinflammatory cytokine response recognized in 
DENV enhanced disease, VAERD-affected swine demonstrated elevated levels of IFNγ and 
TNFα in spite of the reduced type 1 IFN response.  
 Enhanced adaptive cytokine responses in viral diseases have attracted considerable 
attention due to their potential influence on the adaptive immune response and how this may 
affect pulmonary inflammation, such as eosinophils, in RSV infection. Formalin-inactivated 
RSV vaccines were implicated in priming Th2-mediated immune responses in vaccinated, 
naturally exposed children due to local and systemic increases in eosinophils described in the 
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initial human cases75 and in subsequent experiments with mice125,169 as well as FI-MV and 
FI-hMPV vaccinated macaques.120,28 Elevated Th2 cytokines including IL-5, IL-4 and IL-13 
have been demonstrated in FI-RSV vaccinated mice challenged with RSV125,169 and mice 
depleted of IL-4 and IL-10 demonstrated decreased pulmonary eosinophilia post-challenge 
with RSV.23 In addition, in vitro RSV infection of human dendritic cells adversely affected 
their ability to stimulate IFNγ from co-cultured naïve T cells, modulating the antiviral 
immune response.8 Atypical measles has also been associated with early suppression of IL-
12 and later production of IL-4122 and enhanced DENV infections have demonstrated 
increases in immunosuppressive cytokines such as IL-10 and attenuation of Th1 cell 
mediated responses such as IL-12 and IFNγ.18,181 Collectively, these data suggest vaccine 
associated enhanced viral infections may result from imbalanced anti-inflammatory cytokine 
responses and polarization towards a Th2 cell-mediated immune response that may promote 
hypersensitivity reactions, non-protective antibodies, diminished CD8+ T cell activation and 
dysregulation of macrophages.  
Toll-like receptors (TLR) are an important innate immune mechanism for pathogen 
recognition and stimulation of T helper and B cells as well as antibody production in viral 
infections.98 However, a consequence of inactivated vaccines are non-protective, cross-
reactive antibodies that may be produced following inadequate Toll-like receptor 
stimulation.29 One prior report described non-replicating RSV vaccines weakly stimulating a 
subset of TLRs that resulted in deficient affinity maturation of antibodies and suboptimal 
protection against subsequent infection with WT RSV.29 Low avidity antibodies to 
inactivated measles virus vaccines may also result from poor TLR stimulation although 
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further studies are necessary to elucidate the role of inactivated vaccines, TLR activation and 
its association with enhanced viral disease. 
 
Conclusion 
 Non-replicating influenza vaccines have been used in swine for over eighteen years in 
the US with less consistent protection against infection as the virus continues to undergo 
genetic divergence through antigenic drift and antigenic shift.89,163 Few reports have 
described enhanced respiratory infections associated with inactivated influenza vaccines in 
swine unlike enhanced diseases associated with formalin-inactivated vaccines and human 
RSV, MV and DENV that have been extensively studied.58,148,160 However, the increased use 
of inactivated influenza vaccines combined with the escalating diversity in contemporary 
influenza viruses circulating in US swine have increased the potential for vaccine-challenge 
virus mismatch and subsequent enhanced disease. Indeed, human seasonal influenza vaccines 
were associated with an increased risk of medically attended pH1N1 illness during the 2009 
influenza pandemic suggesting inactivated influenza vaccines may be responsible for a 
VAERD-like phenomenon in humans depending on the vaccine and challenge viruses.139 
Several models and reports describing enhanced RSV or MV in humans have similarities 
with the limited information regarding VAERD in swine. The use of inactivated vaccines, 
non-protective antibodies and immune-mediated pathology are common themes among many 
RNA viruses that have demonstrated enhanced disease in various forms of severity. 
Additionally, a diverse array of interrelated immune-mediated mechanisms is involved in the 
pathogenesis of enhanced disease. Further elucidation of the model, immunopathology and 
mechanisms of VAERD are necessary in an effort to improve influenza vaccines, reduce 
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antigenic drift due to vaccine escape, prevent reassortment and ultimately protect against 
zoonotic transmission of the virus. In addition, swine may serve as an acceptable model for 
investigating the pathogenesis of enhanced influenza disease in humans. The following 
chapters describe in further detail the model, immune response and lesions associated with 
VAERD in swine.  
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Table 1. Viruses demonstrating in vitro or in vivo immune-mediated enhancement of disease* 
Virus Genus Genus Virus Family Genome Disease Manuscript 
Influenza A virus 
(IAV) 
Influenza A Orthomyxoviridae RNA/SS Neg/Env VAERD Vincent et al. Vet Microbiol 
2008; 126(4):310-23 
Respiratory Syncytial Virus 
(RSV) 
Pneumovirus Paramyxoviridae RNA/SS Neg/Env ERD Kim et al. Am J Epidemiol  
1969; 89:422-34 
Measles virus 
(MV) 
Morbillivirus Paramyxoviridae RNA/SS Neg/Env ATM Fulginiti et al. JAMA  
1967; 202:1075-1080 
Human Metapneumovirus 
(hMPV) 
Metapneumovirus Paramyxoviridae RNA/SS Neg/Env EPD Yim et al. Vaccine  
2007;25:5034-40 
Dengue Virus 
(DENV) 
Flavivirus Flaviviridae RNA/SS Pos/Env DHF/DSS Halstead et al. J Exp Med 
1977; 146(1): 201-17 
Murray Valley Encephalitis 
Virus (MVEV) 
Flavivirus Flaviviridae RNA/SS Pos/Env - Hawkes et al.  Aust J Exp Biol Med Sci, 
1964; 42(4):465-82 
Feline Coronavirus  
(FCoV) 
Coronavirus Coronaviridae RNA/SS Pos/Env FIP Weiss et al. Comp Immunol Micro Infect 
Dis 1981; 4(2):175-89 
Ross River Virus  
(RRV) 
Alphavirus Togaviridae RNA/SS Pos/Env EPA Linn et al. J Gen Virol  
1996; 77:407-411 
Human Immunodeficiency 
Virus (HIV) 
Lentivirus Retroviridae RNA/SS Pos/Env AIDS Robinson et al. Lancet 
1988; 1(8589):790-4 
Simian Immunodeficiency 
Virus (SIV) 
Lentivirus Retroviridae RNA/SS Pos/Env SAIDS Le Grand et al. J Med Primatol 
1991; 20:172-6 
* Additional viruses associated with enhanced infection or disease:  Japanese Encephalitis Virus; West Nile Virus; Feline 
Immunodeficiency Virus; Equine Infectious Anemia Virus; Rabies virus; Simian Hemorrhagic Fever Virus; Porcine Reproductive 
and Respiratory Syndrome virus; Caprine Arthritis Virus; Aleutian Disease Virus; Lactate Dehydrogenase Virus; African Swine 
Fever Virus 
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Abstract 
Influenza is an economically important respiratory disease affecting swine world-wide with 
potential zoonotic implications.  Genetic reassortment and drift has resulted in genetically and 
antigenically distinct swine influenza viruses (SIVs). Consequently, prevention of SIV infection is 
challenging due to the increased rate of genetic change and a potential lack of cross-protection 
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between vaccine strains and circulating novel isolates.  This report describes a vaccine-heterologous 
challenge model in which pigs were administered an inactivated H1N2 vaccine with a human-like (δ-
cluster) H1 six and three weeks before challenge with H1 homosubtypic, heterologous 2009 
pandemic H1N1.  At necropsy, macroscopic and microscopic pneumonia scores were significantly 
higher in the vaccinated and challenged (Vx/Ch) group compared to non-vaccinated and challenged 
(NVx/Ch) pigs.  The Vx/Ch group also demonstrated enhanced clinical disease and a significantly 
elevated pro-inflammatory cytokine profile in bronchoalveolar lavage fluid compared to the NVx/Ch 
group.   In contrast, viral shedding and replication were significantly higher in NVx/Ch pigs although 
all challenged pigs, including Vx/Ch pigs, were shedding virus in nasal secretions.  Hemagglutination 
inhibition (HI) and serum neutralizing (SN) antibodies were detected to the priming antigen in the 
Vx/Ch pigs but no measurable cross-reacting HI or SN antibodies were detected to pandemic H1N1 
(pH1N1).  Overall, these results suggest that inactivated SIV vaccines may potentiate clinical signs, 
inflammation and pneumonia following challenge with divergent homosubtypic viruses that do not 
share cross-reacting HI or SN antibodies.  
 
Introduction 
Swine influenza is caused by influenza A virus of the Orthomyxoviridae family and the cause 
of an acute respiratory disease in swine.  Orthomyxoviruses have a negative-sense, segmented RNA 
genome that allows for genetic reassortment and generation of novel viruses.  Currently, three major 
influenza subtypes, H1N1, H3N2 and H1N2, co-circulate in the major swine producing regions of the 
United States (US) and Canada.5,34,36,40  However, two additional subtypes, H3N1 and H2N3, have 
been identified in North American swine, and drift variants of the predominant subtypes are 
increasingly more common.4,11,17,22,25,35,41,40  The increased rate of genetic change in North American 
swine influenza virus (SIV) H1 subtypes is attributed to the introduction of the human-avian-swine 
triple reassortant H3N2 subtype in 1998 and more importantly, to the acquisition of the triple 
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reassortant internal gene cassette(TRIG).21,35,41  SIV subtypes include different combinations of the 
HA and neuraminidase (NA) genes, however, the TRIG cassette, which includes the NP, M, and NS, 
genes of classical swine lineage, PB2 and PA genes of avian lineage, and PB1 of human lineage, have 
been consistently identified among contemporary isolates circulating in the North American swine 
population.34  The TRIG appears to have an enhanced ability to acquire a variety of surface 
glycoprotein gene segments generating novel isolates such as the H2N3 subtype identified in 2006, 
when the TRIG was shown to have acquired an avian H2 and N3, producing a novel triple reassortant 
SIV.18,35  Antigenic drift resulted in the evolution of three distinct H1 phylogenetic clusters (α, β, and 
γ) from the classical swine lineage. The δ-cluster emerged in 2005 in the US-and includes SIVs with 
the HA gene of human seasonal virus origin.35  The hu-like H1 (δ) influenza viruses introduced a 
fourth cluster currently endemic in US swine.35,38   
Inactivated influenza A vaccines are approved for use in US swine in pigs 3 weeks of age or 
older and have played a significant role in preventing clinical disease.2,12  However, inactivated 
vaccines have shown limited efficacy or cross-protective immunity against heterologous 
homosubtypic or heterosubtypic viruses.2,19,29,33  Consequently, use of autogenous vaccines specific to 
the farm of origin has also increased in an attempt to control disease in the face of the escalating 
diversity within North American influenza A viruses.36  In contrast, exposure to live H1N1 and H3N2 
virus has demonstrated complete protection against an SIV with an unrelated HA protein in some 
studies, suggesting live exposure results in improved cross-protection between heterologous SIVs.28  
Collectively, genetically and antigenically diverse SIVs have made prevention more challenging due 
to the increasing lack of cross-protection among heterologous viruses and the inability to update 
vaccines as rapidly as viruses change.36   
A potential problem with vaccination was demonstrated when enhanced pneumonia in a 
subset of pigs administered an inactivated H1N1 vaccine followed by challenge with a heterologous 
virus was reported.33  The viruses in that study were shown to have no cross-reactivity either as anti-
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sera or antigen in the hemagglutination inhibition (HI) assay.  The inactivated α-cluster swine H1N1 
vaccine failed to protect against challenge with a heterologous γ-cluster H1N2 SIV and resulted in 
enhanced pneumonic lesions in one-third of the pigs,33 and in all similarly treated pigs in a subsequent 
study.14 In the study described here, pigs were administered an inactivated 2008 H1N2 hu-like δ-
cluster SIV vaccine followed by challenge with 2009 pandemic H1N1 (pH1N1).  We report the 
inactivated vaccine did not protect against challenge with pH1N1 virus.  Furthermore, pigs in the 
vaccinated and challenged group (Vx/Ch) demonstrated enhanced macroscopic and microscopic 
pneumonia as well as an elevated inflammatory cytokine profile suggesting vaccination potentiated 
the clinical disease and pneumonia in the Vx/Ch group followed by heterologous challenge with 
pH1N1. 
 
Materials and Methods 
Experimental Design - Twenty-five, three-week-old cross-bred pigs were obtained from a 
herd free of SIV and porcine reproductive and respiratory syndrome virus (PRRSV) and treated with 
ceftiofur crystalline free acid (Pfizer Animal Health, New York, NY) and enrofloxacin injectable 
solution (Bayer Animal Health, Shawnee Mission, KS) according to label directions to reduce 
bacterial contaminants prior to the start of the study.  Pigs were housed in biosafety level 2 (ABSL2) 
containment during the vaccine phase of the study.  Pigs were transferred to ABSL3 containment on 
the day of challenge for the remainder of the experiment.  Pigs were cared for in compliance with the 
Institutional Animal Care and Use Committee of the National Animal Disease Center.  The 
experimental design is described in Table 1. 
SIV vaccine was prepared with A/Sw/MN/02011/08 H1N2 (MN08) at approximately 32 HA 
units and inactivated by ultraviolet irradiation with the addition of a commercial oil-in-water adjuvant 
(Emulsigen D, MVP Labs) at a v:v ratio of 4:1 virus to adjuvant.  Pigs were vaccinated with 2 ml by 
the intramuscular route at approximately 4 weeks of age and boosted at 7 weeks of age (Table 1).  
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Pigs challenged at 10 weeks of age were inoculated intratracheally with 2 ml of 1 x 105 50% tissue 
culture infectious dose (TCID50) of A/CA/04/09 pH1N1 (pH1N1) propagated in Madin-Darby Canine 
Kidney (MDCK) cells, as previously described.38  Pigs were observed daily for signs of clinical 
disease.  Rectal temperatures were taken on -1, 0, 1, 2, 3, 4, and 5 days post-infection (dpi).  Nasal 
swabs (Fisherbrand Dacron swabs, Fisher Scientific, Pittsburg, PA) were taken on 0, 3, and 5 dpi to 
evaluate nasal virus shedding by dipping the swab in minimal essential medium (MEM) and inserting 
the swab approximately 2.5 cm into each nares.  Swabs were then placed into 2 ml MEM and stored 
at -80° C until study completion.  Pigs were humanely euthanized with a lethal dose of pentobarbital 
(Sleepaway, Fort Dodge Animal Health, Fort Dodge, IA) on 5 dpi to evaluate lung lesions and viral 
load in the lungs.  Postmortem samples included serum, bronchoalveolar lavage, lung and trachea. 
Pathologic examination of lungs - At necropsy, lungs were removed and evaluated for the 
percentage of the lung affected with purple-red consolidation typical of SIV.  The percent of the 
surface affected with pneumonia was visually estimated for each lung lobe, and then a total 
percentage for the entire lung was calculated based on weighted proportions of each lobe to the total 
lung volume.7  Tissue samples from the trachea and right cardiac lung lobe were taken and fixed in 
10% buffered formalin for histopathologic examination.  Tissues were routinely processed and 
stained with hematoxylin and eosin.  Lung sections were given a score from 0 to 3 and tracheal 
sections were given a score from 0 to 2.5 to reflect the severity of bronchial and tracheal epithelial 
changes based on previously described methods.25  The lung sections were scored according to the 
following criteria: 0.0: No significant lesions; 1.0: a few airways affected with bronchiolar epithelial 
damage and light peribronchiolar lymphocytic cuffing often accompanied by mild focal interstitial 
pneumonia; 1.5: more than a few airways affected (up to 25%) often with mild focal interstitial 
pneumonia; 2.0: 26 to 50% airways affected often with moderate interstitial pneumonia; 2.5: 
approximately 51 to 75% airways affected, usually with significant interstitial pneumonia; 3.0: 
greater than 75% airways affected, usually with significant interstitial pneumonia. Trachea sections 
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were scored according to the following criteria: 0.0: Normal; 1.0: Focal squamous metaplasia of the 
epithelial layer; 2.0: Diffuse squamous metaplasia of much of the epithelial layer, cilia are focally 
evident; 2.5: Diffuse squamous metaplasia with an absence of cilia.  A single pathologist scored all 
slides and was blinded to the treatment groups. 
Diagnostic microbiology - All pigs were screened for influenza A nucleoprotein antibody by 
ELISA (MultiS ELISA, IDEXX, Westbrook, Maine) prior to the start of the study to ensure absence 
of prior immunity.  Bronchoalveolar lavage fluid BALF samples from 5 dpi were screened for aerobic 
bacterial growth on blood agar and Casmin (NAD enriched) plates.  Diagnostic PCR for PCV223 
Mycoplasma hyopneumoniae27and an in-house RT-PCR for PRRSV were conducted on nucleic acid 
extracts from BALF. 
Viral replication and shedding - Nasal swab samples were subsequently thawed and vortexed 
for 15 s, centrifuged for 10 min at 640 × g and the supernatant was passed through 0.45 µm filters to 
reduce bacterial contaminants.  Ten-fold serial dilutions in serum-free MEM supplemented with 
TPCK trypsin and antibiotics were made with each BALF sample and nasal swab filtrate sample. 
Each dilution was plated in duplicate in 100 µl volumes onto PBS-washed confluent MDCK cells in 
96-well plates. Plates were evaluated for CPE between 48–72 h post-infection. At 48 h, plates were 
fixed with 4% phosphate-buffered formalin and stained using immunocytochemistry with an anti-
influenza A nucleoprotein monoclonal antibody as previously described.12 A TCID50 titer was 
calculated for each sample using the method of Reed and Muench.24 
Antibody detection assays - For use in the HI assay, sera were heat inactivated at 56°C for 30 
min, then treated to remove nonspecific hemagglutinin inhibitors and natural serum agglutinins by 
treatment with a 20% suspension of kaolin (Sigma Aldrich, St. Louis, MO) and adsorption with 0.5% 
turkey red blood cells (RBC). The HI assays were then performed with MN08 and pH1N1 viruses as 
antigens and turkey RBCs using standard techniques.39 Reciprocal titers were divided by 10 and log2 
transformed, analyzed, and reported as the geometric mean.  Enzyme-linked immunosorbent assays 
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(ELISA) to detect total IgG and IgA antibodies against whole virus preparations of MN08 and pH1N1 
present in serum and BALF were performed as previously described16,33 with modifications.  
Concentrated MN08 or pH1N1 virus was resuspended in Tris–EDTA basic buffer, pH 7.8, and 
diluted to an HA concentration of 100 HA units/50 µl.  Immulon-2HB 96-well plates (Dynex, 
Chantilly, VA) were coated with 100 µl of antigen solution and incubated at room temperature 
overnight. Serum and BALF were diluted in PBS and MEM, respectively followed by 2-fold serial 
dilutions. The assays were performed on each sample in duplicate. The mean of duplicate wells was 
calculated and antibody titers were designated as the highest dilution with an OD greater than 2 
standard deviations above the mean of the NVx/NCh controls. Log2 transformations of IgG reciprocal 
titers were analyzed and reported as geometric means. IgA reciprocal titers were divided by 32 to 
establish a scale before log2 transformation and analysis.  IgA titers were reported as geometric 
means. 
For the serum neutralization assay, sera were heat inactivated at 56°C for 30 min, then two-
fold serially diluted from 1:10 to 1:20,480 in 96-well plates, using 50 µl serum diluted in serum-free 
MEM supplemented with TPCK trypsin and antibiotics.  Fifty microliters of SIV diluted to 103.3 
TCID50/ml was added to each dilution and incubated at 37°C for 1 hr.  Post-incubation, 100 µl of the 
serum and virus mixture was added to each well of confluent Madin-Darby canine kidney (MDCK) 
cells prepared in 96-well plates 48 hours in advance and washed twice in sterile PBS.  Plates were 
incubated for 48 hours or until the presence of cytopathic effect (CPE).  Presence of influenza virus 
was verified by immunocytochemistry for all plates, and titers were recorded as the highest dilution 
negative for virus or CPE.  Reciprocal titers were divided by 10 and log2 transformed, analyzed, and 
reported as the geometric mean.   
Cytokine assays - A 5 ml aliquot of BALF was centrifuged at 400 x g for 15 min at 4° C to 
pellet cellular debris.  The cell-free BALF was stored at -80° C until assayed for cytokine levels.  
Levels of IL-8, IL-1β and IL-6 in BALF were determined by ELISA performed according to the 
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manufacturer’s recommendations (DuoSet ELISA, R&D Systems, Minneapolis, MN).  Levels of 
IFN-α were determined by ELISA as previously described.3   
Statistical analysis - Macroscopic pneumonia scores, microscopic pneumonia scores, log10 
transformed BALF and nasal swab virus titers, and log2 transformations of HI reciprocal titers, 
ELISA reciprocal titers and cytokine data were analyzed using analysis of variance (ANOVA) with a 
P-value ≤ 0.05 considered significant (JMP, SAS Institute, Cary, NC; GraphPad Prism Version 5.00, 
San Diego, CA). Response variables shown to have a significant effect by treatment group were 
subjected to pair-wise comparisons using the Tukey–Kramer test.  Rectal temperature data were 
analyzed using a mixed linear model for repeated measures using SAS 9.1 for Windows (SAS 
Institute, Cary, NC, USA).  Linear combinations of the least squares means estimates were used in a 
priori contrasts after testing for a significant (P <0.05) treatment group effect of vaccination status.  
Comparisons were made between each group at each time-point using a 5% level of significance (P 
<0.05) to assess statistical differences. 
 
Results 
   Clinical disease - All pigs inoculated with pH1N1 developed clinical signs that included mild 
to moderate lethargy and inappetence.  Some Vx/Ch pigs demonstrated coughing with an increased 
respiration rate and elevated respiratory effort whereas NVx/Ch pigs did not.  Challenge with pH1N1 
virus induced a significant (P ≤0.05) febrile response in Vx/Ch and NVx/Ch groups at 1 dpi (Table 
2).  The initial febrile response in the NVx/Ch group began to subside by 2 dpi and was not different 
from NVx/NCh controls by 3 dpi.  However, challenged pigs that were previously vaccinated with 
MN08 virus (Vx/Ch group) exhibited a sustained febrile response that was significantly higher than 
all other treatment groups from 48 through 96 hours post infection. 
  Viral and Microbiological assays - All pigs were free of influenza A virus antibodies prior to 
the start of the experiment.  No extraneous viral or M. hyopneumoniae nucleic acids were detected in 
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BALF collected at 5 dpi from any pigs.  Routine aerobic bacterial cultures of BALF isolated 
Bordetella bronchiseptica from 3 Vx/Ch, 6 NVx/Ch and 2 NVx/NCh pigs.   
  Macroscopic and microscopic pneumonia scores - Pigs challenged with pH1N1 had purple-red 
colored cranioventral lung consolidation typical of influenza virus infection.  The extent of lung 
consolidation ranged from 10.3% to 34.5% in Vx/Ch pigs and 3.9% to 13.4% in the NVx/Ch pigs. 
NVx/NCh lung consolidation scores ranged from 0 to 2.3%.  Vx/Ch pigs that received the MN08 
inactivated vaccine had significantly (P≤0.0001) greater percentages of pneumonia in the 
cranioventral and dorsocaudal lung compared to the NVx/Ch pigs that had lesions primarily in the 
cranial and middle lung lobes (Figure 1.).  Macroscopic lung lesions also included localized 
hemorrhagic, bullous emphysema in two pigs with enhanced pneumonia (figure not shown).  Both 
challenge groups had significantly higher (P≤0.0001) pneumonia scores compared to the NVx/NCh 
pigs (Table 3).   
  Microscopic lesions of pneumonia were not observed in the NVx/NCh pigs; the scattered dark 
foci noted grossly in these pigs were atelectatic, unaffected lobules.  All pigs challenged with pH1N1 
demonstrated lung lesions consistent with SIV infection, and both inoculated groups had significantly 
greater (P≤0.0001) microscopic lesion scores compared to the NVx/NCh group.  However, Vx/Ch 
pigs had significantly (P≤0.05) higher average microscopic lesion scores compared to NVx/Ch pigs 
(Table 3).   Vx/Ch pigs also demonstrated more severe histopathological lesions than typically 
observed with uncomplicated SIV infection.  These included severe necrotizing or proliferative 
bronchiolitis, prominent peribronchiolar lymphocytic cuffing and moderate lymphohistiocytic 
interstitial pneumonia (Figure 2).  In addition, increased lymphocyte infiltration of the bronchiolar 
submucosa and suppurative bronchitis and bronchiolitis were observed in the Vx/Ch pigs (Figure 3).  
NVx/Ch pigs that did not receive prior vaccination had moderate necrotizing bronchiolitis, subtle 
peribronchiolar lymphocytic cuffing and mild interstitial pneumonia.  Microscopic tracheal lesion 
scores were also significantly (P≤0.05) higher in the Vx/Ch pigs compared to the NVx/Ch group and 
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included epithelial attenuation and necrosis, regional loss of cilia and marked submucosal 
lymphocytic inflammation. 
  Virus levels in lung and nasal secretions - Virus was not detected in NVx/NCh pigs at any time 
throughout the study.  Viral replication was detected in the lungs of all NVx/Ch pigs and in 8 of 10 
Vx/Ch pigs at 5 dpi.  Mean BALF log10 TCID50 virus titers in the lung were significantly higher 
(P≤0.05) in the NVx/Ch pigs compared to Vx/Ch pigs (Table 3).  Virus was not detected in nasal 
swabs from any group at 0 dpi.  Nasal shedding was detected in 9 of 10 Vx/Ch pigs and in 5 of 10 
NVx/Ch pigs at 3 dpi.  At 5 dpi, 10 of 10 pigs in each challenge group had virus isolated from nasal 
secretions.  No statistically significant difference was noted between the Vx/Ch and NVx/Ch pigs in 
virus titers in nasal secretions at 3 dpi although the mean log10 TCID50 nasal swab titer was slightly 
higher in the Vx/Ch pigs.  In contrast, the mean log10 TCID50 nasal swab titer at 5 dpi in the NVx/Ch 
pigs was significantly higher (P≤0.001) than the Vx/Ch pigs in spite of the same number of pigs 
shedding virus. 
  Hemagglutination-inhibition and serum neutralization tests - Pigs in the NVx/NCh group 
remained seronegative throughout the study period.  HI antibody titers in sera were observed only in 
MN08 vaccinated pigs prior to SIV challenge (0 dpi).  No MN08 HI antibodies were detected at 0 dpi 
in the NVx/Ch group and no cross-reacting HI antibody response to the pH1N1 virus was detected in 
either the Vx/Ch or NVx/Ch group at 0 dpi. In addition, there was no change in the level of MN08 HI 
antibodies in vaccinated pigs at 5 dpi compared to 0 dpi.  HI and SN antibody titers are summarized 
in Table 4.     
  Serum neutralization titers against MN08 virus were only observed in the Vx/Ch pigs (Table 4).  
The geometric mean reciprocal titer was 2743.7 in the Vx/Ch group at 0 dpi and ranged between 640 
and 10,240.  In addition, serum neutralization titers against the pH1N1 virus were not observed in 
either the Vx/Ch or NVx/Ch groups at 0 dpi. 
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  IgG and IgA antibody response to whole virus MN08 and pH1N1 - Pigs vaccinated with MN08 
and challenged with pH1N1 virus (Vx/Ch group) had anti-MN08 and cross-reacting anti-pH1N1 IgG 
in BALF.  However, NVx/Ch pigs did not develop detectable anti-MN08 or anti-pH1N1 IgG 
antibodies in BALF that were different than the NVx/NCh group. Minimal anti-MN08 IgA antibody 
was detected in BALF in the Vx/Ch pigs that were not detected in the NVx/Ch pigs.  However, the 
anti-pH1N1 IgA antibody response detected in the Vx/Ch pigs was not significantly different than the 
NVx/Ch or NVx/NCh pigs.   Geometric mean IgG and IgA antibody titers are reported in Table 5. 
  Cross-reacting anti-MN08 and anti-pH1N1 IgG antibody responses were detected in serum of 
Vx/Ch pigs at 0 dpi.  Pigs in the NVx/Ch and NVx/NCh groups did not exhibit detectable IgG 
antibodies in serum at 0 dpi to either antigen.  Geometric mean titers are reported in Table 5. 
  Cytokine analysis - Pigs in the Vx/Ch group had significantly (P ≤ 0.05) higher concentrations 
of IL-8, IL-1β, and IL-6 in the lung on dpi 5 than NVx/ Ch pigs (Figure 4).  The Vx/Ch group 
averaged 1776 pg/ml of IL-8 compared to the NVx/Ch group that averaged 376.5 pg/ml of IL-8 on 5 
dpi.  IL-1β levels averaged 100 pg/ml in the Vx/Ch group compared to the NVx/Ch group that 
averaged 12 pg/ml.  The same was observed for IL-6, with an average of 171 pg/ml versus 43 pg/ml 
in the Vx/Ch and NVx/Ch groups, respectively.  Levels of IFN-α in the lung lavage were not 
significantly different between the challenge groups and the NVx/NCh group. 
 
Discussion 
  This study demonstrates enhanced pneumonia in pigs administered an inactivated H1N2 SIV 
vaccine followed by challenge with a heterologous pH1N1 virus compared to non-vaccinated pigs 
challenged with the same virus.  A/Sw/MN/02011/08 H1N2 (MN08) was chosen as vaccine virus to 
represent the δ-cluster of hu-like SIVs identified in 2005 and currently endemic in North American 
swine.35  Presently, the δ-cluster SIVs are the most frequently isolated swine influenza virus from 
diagnostic submissions to the University of Minnesota Veterinary Diagnostic Laboratory (M. Gramer, 
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University of Minnesota Veterinary Diagnostic Laboratory, personal communication).  Pandemic 
A/CA/04/09 H1N1 (pH1N1) was chosen as the challenge virus to evaluate the risk pre-existing 
immunity against δ-cluster SIV vaccines might have on pH1N1 outbreaks in the pig population.  In 
addition, previous serologic evaluation of swine influenza virus antiserum demonstrated a lack of 
cross-reactivity between the δ-cluster SIV anti-serum and pH1N1 in HI assays, fulfilling one criteria 
for duplication of the vaccine-heterologous challenge model used in the study where enhanced 
pneumonia was first observed.32  Since the first U.S. swine outbreak of pH1N1 in October 2009, a 
number of swine cases have been reported and pH1N1 may become endemic in the U.S. swine 
population in addition to the previously circulating antigenic variants of swine-lineage H1N1 and 
H1N2. 
  Macroscopic and microscopic pneumonia typical of SIV infection was demonstrated at 5 dpi in 
both groups challenged with pH1N1.  However, the Vx/Ch pigs had a significantly greater percentage 
of lung involvement compared to the NVx/Ch pigs in spite of previous vaccination.  In addition, 
microscopic pneumonia and tracheal lesion scores were significantly higher in the Vx/Ch pigs 
compared to the NVx/Ch group.  Experimental inoculation with SIV induces necrotizing bronchiolitis 
with peribronchiolar lymphocytic cuffing and interstitial pneumonia which can vary in extent and 
severity depending on the stage of infection and virulence of the virus.6,25  However, in this study, 
marked differences in lung lesion profiles between the virus challenge groups were evident.  In 
addition to the bronchiolar epithelial necrosis, pigs with enhanced lesions (Vx/Ch) had marked 
peribronchiolar lymphocytic cuffing, subepithelial bronchiolar lymphocytic inflammation and 
moderate interstitial pneumonia to an extent not observed in the NVx/Ch pigs.  Interestingly, bronchi, 
bronchioles and alveoli also contained high numbers of neutrophils at 5 dpi atypical of an 
uncomplicated viral pneumonia.  It is unlikely a secondary bacterial infection contributed to the 
suppurative inflammation considering Bordetella bronchiseptica was isolated from a larger number of 
pigs  in the NVx/Ch and NVx/NCh control group (8 pigs total) which did not have enhanced lung 
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lesions or bronchopneumonia, compared to the Vx/Ch group with B. bronchiseptica (3 pigs).  The 
increased pro-inflammatory cytokine response in the lungs of the Vx/Ch pigs, which included 
elevated IL-8 protein levels, may have contributed to the suppurative pneumonia in the Vx/Ch pigs 
due to the potent neutrophil chemotaxis property of IL-8.1  These data suggest specific differences in 
severity and distribution of microscopic lesions may provide distinguishing features between 
enhanced pneumonia and uncomplicated infection with SIV useful to identify such issues in field 
cases.   
  The mechanism of the enhanced pneumonia phenomenon has not been elucidated although 
consistent features among studies have been described previously and in this report.13,33  These 
include 1) whole influenza virus antigen administered as a monovalent, inactivated vaccine combined 
with oil-in-water adjuvant; 2) challenge with a heterologous SIV with a homosubtypic HA three 
weeks post booster vaccination; 3) serum HI antibodies to the priming antigen that do not cross-react 
with the challenge virus; and 4) whole virus, non-HI, non-neutralizing IgG antibodies detected by 
ELISA in serum and BALF cross-reacting with the challenge virus.   
  Inactivated whole-virus influenza vaccines are commonly used in the US swine industry and 
most are multivalent with H1 and H3 subtypes included.  Inactivated SIV vaccines are efficacious 
against homologous challenge, although limited cross-protection is demonstrated against 
heterologous homosubtypic or heterosubtypic viruses.2,13,19,29,33  Previous studies by our group have 
shown that the use of live attenuated virus may enhance the efficacy of vaccines against antigenically 
heterologous viruses of the same subtype, specifically through the development of cross-reactive 
antibodies at the mucosal level.37,33  Cell-mediated immune responses, stimulated by live exposure, 
are also important for heterosubtypic immunity and recovery from infection.  One study using 
immune pigs infected with heterosubtypic SIV demonstrated elevated CD8+ T cells in the lungs 
compared to pigs challenged with homologous virus indicating the importance of T cells in 
heterosubtypic immunity.8 Collectively, these studies suggest live infection or vaccination with 
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modified live vaccines may confer more efficient cross-protection than inactivated vaccines against 
divergent influenza viruses due to activation of both humoral and cell mediated immunity.  Additional 
studies are needed to understand the differences in the immune response to inactivated vaccines 
versus live challenge and how this may affect cross-protective immune function and the aggravated 
lung pathology demonstrated in pigs in our model. 
  HI titers (1:40 – 1:320) and SN titers (1:640 – 1: 10,240) to the MN08 antigen were 
demonstrated in vaccinated pigs at 0 dpi (day of challenge); however, antibody cross-reactive with the 
pH1N1 antigen were not detected by either HI or SN test.  MN08 and pH1N1 are genetically related 
by H1 subtype, but have only 77% identity at the nucleotide level between the HA genes.  The 
identity ranged from 91-94% for the polymerase genes and 95% for NP and NS.  The NA genes are 
of different subtype and thus of low identity.  The M genes also are derived from different source 
viruses (MN08 North American swine lineage; pH1N1 human influenza A virus with Eurasian swine-
lineage) and thus of low identity as well.  The MN08 virus is a contemporary member of the δ-cluster 
or hu-like SIVs.  In the US, influenza viruses with hu-like HA were first identified in swine in 2005, 
all with triple reassortant internal genes similar to contemporary US swine influenza isolates.  The 
HA and NA genes were related to recent human seasonal influenza virus lineages.35  Influenza viruses 
related to earlier human seasonal H1N1 have been identified in pigs in China as well,42 but are 
distantly related to North American δ-cluster HA and were not shown to have reassorted with 
endemic Chinese swine viruses.  In contrast, the pH1N1 virus, which has an HA similar to the γ-
cluster H1 SIVs, contains genes from both North American and Eurasian swine influenza virus 
lineages with a constellation of the eight gene segments not known to circulate in swine prior to the 
emergence of the pandemic virus.  Serologic cross-reactivity with pH1N1 has been demonstrated in 
HI tests with sera from pigs immunized with α-, β-, and γ- clusters of H1 SIV but not with δ-cluster 
antisera.32  The lack of cross-reactive HI antibodies demonstrated in this study due to the divergent 
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H1 cluster viruses used as the vaccine antigen and challenge virus suggests that HI antibodies may 
play an important role in preventing enhanced pneumonia.   
  In contrast to the absence of HI antibodies to pH1N1 in MN08-primed anti-sera, a whole-virus 
ELISA assay detected similar levels of anti-MN08 and anti-pH1N1 IgG antibodies in serum and 
BALF at 0 and 5 dpi, respectively. These data suggest the non-HI antibodies may have contributed to 
the enhanced macroscopic and microscopic lung lesions described in this report.  Potential roles for 
vaccine-induced non-HI IgG antibody could include antibody dependent cell-mediated cytotoxicity 
(ADCC), activation of the classical complement cascade, or antibody dependent enhancement (ADE) 
through Fc-receptor mediated uptake of virus.  Low avidity antibodies were recently shown to be 
associated with antigen-antibody complexes and complement fixation in lungs of fatal human cases of 
pH1N1.20  Inactivated influenza vaccines have been shown to induce antibodies reactive in ADCC30 
or to promote cell-mediated cytotoxicity and complement fixation.10,15  Further studies are necessary 
to understand the role of non-HI antibodies and the mechanism for the development of enhanced 
pneumonia. 
  In contrast to the presence of whole virus IgG antibodies in BALF to both antigens, there were 
either minimal levels of IgA to the priming antigen or insignificant levels of IgA to the challenge 
virus in the respiratory mucosa at 5 dpi in the Vx/Ch pigs.  Our results indicate the anti-MN08 IgA 
did not cross-react with the challenge virus.  However, it is unknown if the presence of cross-reacting 
mucosal IgA, or a more robust response, would have prevented infection or the enhanced pneumonia 
in this swine study.  A previous study by our group demonstrated a relative decrease in IgA and 
increase in IgG in 3 of 9 pigs with enhanced pneumonia compared to 6 pigs without enhanced lesions 
providing support for the potential cross-protective role of IgA antibody.33  Antibody mediated 
immune reactions at the mucosal level, rather than systemic immunity, have been shown to be 
important for protecting the respiratory tract from infection with SIV.16  Therefore, the potentiation of 
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lung lesions described in this report may have been due to the insignificant levels of IgA in 
conjunction with higher levels of non-neutralizing IgG to the challenge virus. 
  The study described here suggests that cross-reactive, non-HI antibodies induced by inactivated 
vaccines may play a role in the enhanced pneumonia.  However, it remains unclear if antibodies 
against specific epitopes on the HA protein are more involved in the immunopathology than others.   
Enhanced clinical disease implicating antibody responses to minor immunogenic proteins other than 
surface glycoproteins post-challenge with influenza virus has been reported in vaccinated pigs.  A 
previous study used a DNA vaccine expressing an M2 and nucleoprotein (NP) fusion protein to 
induce anti-M2 antibodies and influenza-specific T-cell responses.9  Interestingly, clinical signs and 
mortality were more severe upon challenge with SIV in the vaccinated pigs.  The authors speculated 
that non-neutralizing antibodies to the M2 protein may have allowed increased viral uptake and 
expression of surface M2 protein, promoting cell death through ADE, ADCC or complement 
activation and T helper cells may have stimulated an exaggerated inflammatory response.  Another 
recent study also suggested an association between prior human vaccination with the 2008-2009 
trivalent inactivated influenza vaccine (TIV) and increased severity of clinical illness induced by 
infection with pandemic influenza A H1N1.26  Although cause and effect was not established between 
vaccination and illness, the authors concluded that prior vaccination with TIV may have increased the 
risk of medically attended pH1N1 illness in humans.  This study demonstrated a potential vaccine-
associated disease enhancement with human implications similar to the suggested outcome in this 
report.  Clinical signs were correlated with one specific vaccine, implying the manufacturing process 
may have played a role in the disease enhancement.  However, further studies are necessary to 
understand the role vaccine preparation may have on the clinical outcome to heterologous virus 
infection. 
  Swine with existing immunity to influenza virus through repeated exposure or vaccination with 
multiple strains may be partially protected against heterologous challenge, as was previously shown 
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in vaccinated pigs challenged with pH1N1 virus.31  However, the simultaneous increase in inactivated 
SIV vaccine use and the evolving antigenic diversity of influenza A viruses in swine creates a 
realistic potential for vaccine/challenge mismatch.  Commercial vaccines are typically multivalent to 
enable protection against exposure to multiple subtypes and antigenically diverse strains.   
Manufacturing regulations in the US limit the ability to alter fully-licensed swine influenza vaccines 
as rapidly as the virus is changing.  Future vaccines that provide adequate protection from infection 
and decrease the potential for vaccine-enhanced pneumonia will likely need to provide cross-
protection at the respiratory mucosa and activate both the humoral and cell-mediated immune 
systems.   
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Table 1. Experimental design. 
Group Vaccine Challenge N 
Weeks of age: 
Priming vaccine Booster vaccine Challenge 
Vx/Cha MN08 pH1N1 10 4 7 10 
NVx/Chb None pH1N1 10 4 7 10 
NVx/NChc None None 5 4 7 10 
aVx/Ch: vaccinated/challenged 
bNVx/Ch: non-vaccinated/challenged 
cNVx/NCh: non-vaccinated/non-challenged 
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Table 2. Mean rectal temperatures. 
Group Vaccine virus Challenge virus 
Rectal Temperature °C* 
1dpi 2 dpi 3 dpi 4 dpi 5 dpi 
Vx/Ch MN08 pH1N1 40.5a 40.1a 40.2a 39.9a 39.5a 
NVx/Ch None pH1N1 40.4a 39.6a 39.3b 39.4b 39.2a 
NVx/NCh None None 38.7b 38.4b 39.1b 39.3b 39.2a 
*Values within a column not connected by the same letter are significantly different (P ≤ 
0.05). 
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Table 3. Mean macroscopic and microscopic pneumonia scores ± standard error of the mean 
(SEM) and mean TCID50 log10 virus titers ± SEM in lung and nasal secretions.* 
Group 
Macroscopic  
Pneumonia (%) 
Microscopic  
Pneumonia (0-3) 
Log10virus titers 
BALF NS 3dpi NS 5dpi 
Vx/Ch 20.5 ± 2.8a 2.5 ± 0.3a 2.1 ± 0.5a 1.4 ± 0.2a 1.7 ± 0.1a 
NVx/Ch   8.9 ± 0.9b 1.7 ± 0.2b 3.4 ± 0.1b 1.1 ± 0.4ab 2.5 ± 0.2b 
NVx/NCh   0.5 ± 0.5c 0.0 ± 0.0c 0.0 ± 0.0c 0.0 ± 0.0b 0.0 ± 0.0c 
*Values within a column not connected by the same letter are significantly different (P ≤ 0.05). 
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Table 4.  Hemagglutination inhibition and serum neutralization geometric mean reciprocal 
titers ± standard error of the mean (SEM). 
Group 
HI Titers 0 dpi SN Titers 0 dpi 
MN08 pH1N1 MN08 pH1N1 
Vx/Ch 149.3 ± 12.7 0.0 ± 0.0 2743.7±12.7 0.0 ± 0.0 
NVx/Ch   0.0 ± 0.0 0.0 ± 0.0     0.0 ± 0.0 0.0 ± 0.0 
NVx/NCh   0.0 ± 0.0 0.0 ± 0.0     0.0 ± 0.0 0.0 ± 0.0 
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Table 5.  Isotype specific serum (0 dpi) and bronchoalveolar lavage fluid (5 dpi) geometric mean 
reciprocal antibody titers ± standard error of the mean.* 
Group Serum IgG BALF IgG BALF IgA 
 MN08 Ag pH1N1 Ag MN08 Ag pH1N1 Ag MN08 Ag pH1N1 Ag 
Vx/Ch 24,300±1,200a 18,400±1,200a 168.9±1.3a 294.1±1.2a 48.5±35.8a 39.4±35.6a 
NVx/Ch§       0.0±0.0b       0.0±0.0b      0.0±0.0b   0.0±0.0b  0.0±0.0b  0.0±0.0a 
NVx/NCh       0.0±0.0b       0.0±0.0b      0.0±0.0b 0.0±0.0b  0.0±0.0b  0.0±0.0a 
*Values within a column not connected by the same letter are significantly different (P ≤ 0.05). 
§NVx/Ch antibody responses were less than 2 standard deviations above the mean of NVx/NCh pigs. 
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Figure 1. Macroscopic lung lesions representing pigs in each challenge group.  Pigs in the 
Vx/Ch group had a greater percentage of lung involvement compared to the NVx/Ch group. 
  
Vx/Ch Pig     NVx/Ch Pig 
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Figure 2.  Microscopic lung lesions representing pigs in each challenge group.  Vx/Ch pigs with 
enhanced pneumonia demonstrated necrotizing to proliferative bronchiolitis and marked 
peribronchiolar lymphocytic cuffing compared to NVx/Ch pigs. (200X) 
  
Vx/Ch Pig     NVx/Ch Pig 
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Figure 3.  Microscopic lung lesions demonstrated in Vx/Ch pigs with enhanced pneumonia  
includes subepithelial lymphocytic inflammation (arrow) and suppurative bronchiolitis 
(arrowheads). (400X) 
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Figure 4.  Cytokine levels (pg/ml) in bronchoalveolar lavage fluid at 5 dpi.  Error bars represent 
standard error of the mean.   
 
Bars connecting columns designate significant differences at P<0.05.  
 
  
84 
 
 
Chapter 3: Kinetics of lung lesion development and pro-inflammatory 
cytokine response in pigs with vaccine-associated enhanced respiratory 
disease induced by challenge with pandemic (2009) A/H1N1 influenza virus 
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Abstract 
 The objective of this report was to characterize the enhanced clinical disease and lung 
lesions observed in pigs vaccinated with inactivated H1N2 swine δ-cluster influenza A virus 
and challenged with pandemic 2009 A/H1N1 human influenza virus.   Eighty-four, six-week-
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old, crossbred pigs were randomly allocated into 3 groups of 28 pigs to represent 
vaccinated/challenged (V/C), non-vaccinated/challenged (NV/C) and a non-vaccinated/non-
challenged (NV/NC) control groups.  Pigs were intratracheally inoculated with pH1N1and 
euthanized at 1, 2, 5 and 21 days post-inoculation (dpi).  Macroscopically, V/C pigs 
demonstrated greater percentages of pneumonia compared to NV/C pigs.  Histologically, 
V/C pigs demonstrated severe bronchointerstitial pneumonia with necrotizing bronchiolitis 
accompanied by interlobular and alveolar edema and hemorrhage at 1 and 2 dpi.  The 
magnitude of peribronchiolar lymphocytic cuffing was greater in V/C pigs by 5 dpi.  
Microscopic lung lesion scores were significantly higher in the V/C pigs at 2 and 5 dpi 
compared to NV/C and NV/NC pigs.  Elevated TNF-α, IL-1β, IL-6, and IL-8 were detected 
in bronchoalveolar lavage fluid at all-time points in V/C pigs compared to NV/C pigs.  These 
data suggest H1 inactivated vaccines followed by heterologous challenge resulted in 
potentiated clinical signs and enhanced pulmonary lesions and correlated with an elevated 
proinflammatory cytokine response in the lung.  The lung pathology and host immune 
response is consistent with the vaccine-associated enhanced respiratory disease (VAERD) 
clinical outcome observed reproducibly in our swine model.  
 
Introduction 
 Influenza A virus (IAV) is the cause of an acute respiratory disease in swine 
characterized by anorexia, fever, dyspnea, coughing and nasal discharge.30  Influenza A virus 
is a member of the Orthomyxoviridae family, with segmented, negative sense RNA genomes 
that permit the generation of novel, antigenically distinct viruses.  The swine respiratory tract 
contains receptors for both avian and human IAV’s which may increase susceptibility to 
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interspecies transmission and facilitate genetic diversity through reassortment.13  Influenza 
infection in naive swine is typically associated with high morbidity and low mortality, with 
some variation in virulence between strains. In the Northcentral United States (US), disease 
incidence peaks during the fall; however, epizootics may occur that do not follow this once 
typical seasonality.1   
The stability of classical H1N1 (cH1N1) IAV in North American swine persisted for 
over 70 years, ending in 1998 with the introduction of the triple reassortant H3N2 that 
contained genes of human-, avian-, and swine-virus lineages.47,48  Influenza A viruses that are 
currently endemic in North American swine are all triple reassortants that contain the triple 
reassortant internal gene (TRIG) cassette which consists of human-IAV lineage polymerase 
basic 1 (PB1), avian-IAV lineage polymerase basic 2 (PB2), polymerase acidic (PA) and 
swine-IAV lineage nucleoprotein (NP), matrix (M) and nonstructural (NS) genes.20,41  The 
apparent ability of the TRIG cassette to exchange gene segments for the surface 
glycoproteins hemagglutinin (HA) and neuraminidase (NA)  has further increased the 
generation of reassortant IAV’s with marked antigenic diversity.40  In addition,  drift variants 
within the three major subtypes, H1N1, H1N2 and H3N2, have also emerged.3,19,24,29,40,45 
Currently, four H1 phylogenetic clusters, α, β, γ, and δ, are endemic in US swine, 
acquired through interspecies transmission, reassortment events and antigenic drift.40,42  
Unlike IAV variants isolated before 1998 which demonstrated more consistent cross-
reactivity in the hemagglutination inhibition (HI) assay, contemporary viruses exhibit limited 
HI cross-reactivity between different clusters, in spite of the similarity in subtype.39,40 
Additionally, two sub-clusters have emerged within the H1 δ-cluster from two apparently 
independent introductions of a human seasonal HA into IAV’s in swine, and have been 
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designated δ-1 and δ-2.18 Collectively, the emergence of the pandemic 2009 H1N1 virus, the 
introduction of human seasonal influenza viruses in swine, and the generation of antigenic 
variants within a subtype with less consistent serological cross-reactivity provides substantial 
evidence of the increasing heterogeneity among IAV’s in swine.  
The use of inactivated IAV vaccines in swine is common in the US, and such 
vaccines effectively reduce clinical disease and lesion induction by homologous viruses,38 
although protection against heterologous infection has been inconsistent.2,21,36,38  However, 
inactivated influenza vaccines also have been implicated in vaccine associated enhanced 
respiratory disease (VAERD) in swine.8,12,16,38  Recently, a vaccination-heterologous-
challenge model was described in which naïve pigs vaccinated with an inactivated, 
adjuvanted H1N2 swine δ-cluster IAV and challenged with pandemic 2009 A/H1N1 human 
influenza virus demonstrated severe clinical disease, enhanced lung consolidation and 
potentiated microscopic lesions compared to non-vaccinated and challenged pigs.8  The 
vaccine did not prevent infection and hemagglutination inhibition (HI) and serum 
neutralizing (SN) antibodies did not cross-react with the challenge virus.  The inactivated 
vaccine was decidedly associated with VAERD, although the mechanism remains unclear at 
this time.  Due to the emergence of novel IAV’s in swine and a complex number of co-
circulating subtypes and variants, VAERD could occur in field situations where pigs may be 
vaccinated with farm-specific vaccines and then subsequently break with antigenically 
diverse IAV’s.  The vaccine-associated enhancement of disease phenomenon is not exclusive 
to swine and inactivated IAV vaccines.  Non-protective, low avidity antibodies elicited by 
respiratory syncytial virus and measles virus formalin-inactivated vaccines have also been 
implicated in causing Enhanced Respiratory Disease in human infants.4,26 
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 The objective of this study was to characterize the enhanced macroscopic and 
microscopic lung lesions in pigs administered an inactivated δ-cluster H1N2 IAV and 
challenged with pandemic 2009 A/H1N1 (pH1N1) as compared to non-
vaccinated/challenged pigs using a previously described model.8  Macroscopic and 
microscopic lung lesions, virus distribution in the lungs, and local inflammatory responses 
were evaluated at 1, 2, 5 and 21 dpi to elucidate the onset and development of VAERD in 
pigs challenged with pH1N1 IAV. 
 
Materials and Methods 
Experimental Design - Eighty-four, three-week-old cross-bred pigs were obtained 
from a herd free of IAV and porcine reproductive and respiratory syndrome virus (PRRSV) 
and treated with ceftiofur (Pfizer Animal Health, New York, NY) according to label 
directions to reduce respiratory bacterial pathogens prior to the start of the study.  Pigs were 
housed in biosafety level 2 (ABSL2) containment during the vaccine phase of the study.  
Fifty-six pigs were transferred to ABSL3 containment one week prior to challenge for the 
remainder of the experiment.  Pigs were cared for in compliance with the Institutional 
Animal Care and Use Committee of the National Animal Disease Center.  The experimental 
design is described in Table 1. 
Influenza A virus vaccine was prepared with a δ1 cluster A/Sw/MN/02011/2008 
H1N2 (MN08) at approximately 32 HA units or 105.7 50% tissue culture infectious dose 
(TCID50) that was inactivated by ultraviolet irradiation and mixed with an emulsified oil-in-
water adjuvant (Emulsigen®-D, MVP Technologies, Omaha, NE) at a v:v ratio of 4:1 virus to 
adjuvant.  Pigs were vaccinated with 2 ml by the intramuscular route at approximately 6 and 
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9 weeks of age, and challenged at 13 weeks of age.  For viral challenge, pigs were inoculated 
intratracheally with 2 ml of 1 x 105 TCID50 of pandemic A/CA/04/2009 H1N1 (pH1N1) 
propagated in Madin-Darby Canine Kidney (MDCK) cells, as previously described.42  Pigs 
were observed daily for signs of clinical disease and rectal temperatures were taken on -1, 0, 
1, 2, 3, 4, and 5 days post-infection (dpi).  Nasal swabs (Fisherbrand Dacron swabs, Fisher 
Scientific, Pittsburg, PA) were taken on 0, 1, 2, 3, 5 and 21 dpi to evaluate nasal virus 
shedding as previously described.39  After serum collection by venipuncture, pigs were 
humanely euthanized with a lethal dose of pentobarbital (Sleepaway, Fort Dodge Animal 
Health, Fort Dodge, IA) on 1, 2, 5 or 21 dpi to evaluate lesions, cytokine concentrations and 
virus titers in the lungs.  Postmortem samples included bronchoalveolar lavage fluid (BALF), 
lung and trachea. 
Pathologic examination of lungs - At necropsy, lungs were removed and evaluated 
for the percentage of the lung affected with purple-red consolidation typical of IAV in swine.  
The percent of the surface area affected with pneumonia was visually estimated for each lung 
lobe, and total percentage for the entire lung was calculated based on weighted proportions of 
each lobe to the total lung volume.11  Tissue samples from the trachea and right middle or 
affected lung lobe were fixed in 10% buffered formalin for histopathologic examination.  
Tissues were processed by routine histopathologic procedures and slides stained with 
hematoxylin and eosin. Microscopic lesions were evaluated by a veterinary pathologist 
blinded to treatment groups.  Individual scores were assigned to each of four parameters to 
adequately reflect the contribution of each lesion associated with VAERD: bronchial and 
bronchiolar epithelial necrosis or proliferation, suppurative bronchitis or bronchiolitis, 
peribronchiolar lymphocytic cuffing and alveolar septal thickening with inflammatory cells 
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(interstitial pneumonia).  The first two scores focused on the intrapulmonary airways: 1) 
percent of bronchi and bronchioles affected with epithelial lesions (necrotizing or 
proliferative bronchitis and bronchiolitis), 2) percent of bronchi and bronchioles that 
contained purulent exudate (suppurative bronchitis or bronchiolitis).  Two additional lung 
lesion scores were based on the following:  3) magnitude of peribronchiolar lymphocytic 
cuffing and 4) presence and severity of alveolar septal inflammation (interstitial pneumonia). 
A composite score was computed using the sum of the four individual scores.  The average 
group composite score was used for statistical analysis.  Scoring parameters for lung and 
trachea are described in Table 2.   
 Influenza virus Type A-specific antigen was detected in lung tissues using a 
previously described immunohistochemical (IHC) method with minor modification.38,43  
Modifications include treating tissue sections in 0.05% protease for 2 min. Influenza A virus-
specific monoclonal antibody (MAb) HB65 (ATCC, Manassas, VA) was applied at 1:100 
dilution.  Bound MAbs were stained with peroxidase-labeled anti-mouse IgG followed by 
chromogen using the DAKO LSAB2-HRP Detection System (DAKO, Carpinteria, CA) 
according to the manufacturer’s instructions. Antigen detection was given two scores:  1) 
airway epithelial signals and 2) alveolar septa/lumen signals.  Both scores were based only 
on affected lobules.  IHC slides were evaluated by a veterinary pathologist blinded to 
treatment groups.  Scoring parameters are described in Table 2. 
Diagnostic microbiology - All pigs were screened for antibody against influenza A 
NP by ELISA (MultiS ELISA, IDEXX, Westbrook, Maine) according to the manufacturer’s 
recommendation upon arrival to ensure absence of existing immunity from prior exposure or 
maternal derived antibody and at 0 dpi to detect vaccine-induced NP antibodies.  BALF 
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samples from 1, 2, 5 and 21 dpi were cultured for aerobic bacteria on blood agar and Casmin 
(NAD enriched) plates.  Polymerase chain reaction (PCR) assays for porcine circovirus type 
2 (PCV2),25 Mycoplasma hyopneumoniae32 and porcine reproductive and respiratory system 
virus (PRRSV) also were conducted on nucleic acid extracts from BALF collected at each  
necropsy. 
Viral replication and shedding - Nasal swabs and BALF were processed as 
previously described.39,38  MDCK-inoculated monolayers were evaluated for cytopathic 
effect (CPE) between 48–72 h post-infection and subsequently fixed with 4% phosphate-
buffered formalin and stained using immunocytochemistry with an anti-influenza A 
nucleoprotein monoclonal antibody as previously described.15 A TCID50 titer was calculated 
for each sample using the method of Reed and Muench.28 
Antibody detection assays - Hemagglutination inhibition assays were conducted as 
previously described.38  The HI assays were performed with MN08 or pH1N1 virus as 
antigen and turkey RBCs as indicators using standard techniques.44 Reciprocal titers were 
divided by 10 and log2 transformed, analyzed, and reported as the geometric mean.    
Enzyme-linked immunosorbent assays (ELISA) to detect total IgG and IgA 
antibodies against whole virus preparations of MN08 and pH1N1 present in serum were 
performed as previously described.38   Independent assays were conducted using 
concentrated MN08 or pH1N1 as ELISA antigen.  The optical density (OD) was measured at 
405 nm wavelength with an automated ELISA reader.  Antibody levels were reported as the 
mean OD and the mean OD of each treatment group were compared. 
For the SN assay, sera were heat inactivated at 56°C for 30 min, then two-fold 
serially diluted from 1:10 to 1:20,480 in 96-well plates, using 50 µl serum diluted in serum-
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free MEM supplemented with TPCK trypsin and antibiotics.  Fifty microliters of SIV diluted 
to 103.3 TCID50/ml was added to each dilution and incubated at 37°C for 1 hr.  Post-
incubation, 100 µl of the serum and virus mixture was added to each well of confluent 
MDCK cells prepared in 96-well plates 48 hours in advance and washed twice in sterile PBS.  
Plates were incubated for 48 hours or until the presence of cytopathic effect (CPE).  Presence 
of influenza virus was verified by immunocytochemistry for all plates, and titers were 
recorded as the highest dilution negative for virus or CPE.  Reciprocal titers were log2 
transformed, analyzed, and reported as the geometric mean.    
Cytokine assays - A 5 ml aliquot of BALF was centrifuged at 400 x g for 15 min at 4° 
C to pellet cellular debris.  The cell-free BALF was stored at -80° C.  Cytokine 
concentrations in BALF were determined by multiplex ELISA performed according to the 
manufacturer’s recommendations (SearchLight, Aushon Biosystems).  The average of 
duplicate wells for each sample was used for statistical analysis. 
Statistical analysis - Macroscopic pneumonia scores, microscopic pneumonia scores, 
log10 transformed BALF and nasal swab virus titers, and log2 transformations of HI and SN 
reciprocal titers, mean OD ELISA reading and cytokine data were analyzed using analysis of 
variance (ANOVA) with a P-value ≤ 0.05 considered significant (JMP, SAS Institute, Cary, 
NC; GraphPad Prism Version 5.00, San Diego, CA). Response variables shown to have a 
significant effect by treatment group were subjected to pair-wise comparisons using the 
Tukey–Kramer test.  Rectal temperature data were analyzed using a mixed linear model for 
repeated measures.  Linear combinations of the least squares means estimates were used in a 
priori contrasts after testing for a significant (P <0.05) treatment group effect of vaccination 
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status.  Comparisons were made between each group at each time-point using a 5% level of 
significance (P <0.05) to assess statistical differences. 
 
Results 
  Clinical disease - Mild lethargy was observed at 1 dpi in the NV/C pigs with activity 
returning to normal by 2 dpi.  Coughing or dyspnea was not observed in the NV/C pigs.  In 
contrast, V/C pigs were lethargic and anorexic for 48 hours, and 20% of the V/C pigs 
exhibited coughing and/or dyspnea until 3 dpi.  Challenge with pH1N1 virus induced a 
significant (P ≤0.05) febrile response in both V/C and NV/C groups at 24 and 48 hours post 
infection compared to NV/NC pigs.  This initial febrile response in the challenged pigs 
subsided by 3 dpi.  However, a significantly different febrile response was not detected 
between V/C and NV/C pigs on any sampling post-challenge.  NV/NC pigs did not 
demonstrate clinical signs or a febrile response during the trial.   
  Viral and Microbiological assays - All pigs were free of IAV antibodies prior to the 
start of the experiment.  No PCV2, PRRSV or M. hyopneumoniae nucleic acid was detected 
in BALF in any pigs.  Routine aerobic bacterial cultures of BALF isolated Bordetella 
bronchiseptica from one pig in the NV/C group.  Bacteria were not isolated from the lungs of 
any other pigs during the trial. 
  Macroscopic pneumonia - Pigs challenged with pH1N1 displayed purple-colored, 
multifocal to coalescing consolidation of the cranioventral regions of lung typical of IAV 
infection in swine.   Lung lesions were of variable extent in both challenge groups and were 
predominantly located in the left and right cranial and middle lung lobes. Lesions also were 
observed in the cranial portion of the diaphragmatic lobes in some of the V/C pigs but not in 
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the NV/C pigs.  The V/C group had a significantly greater (P≤0.001) percentage of lung 
consolidation compared to the NV/C pigs at 1, 2, 5 and 21 dpi (Table 3).  The average 
percentage of lung consolidation increased at each acute time point in V/C pigs from 
approximately 10% at 1 dpi (Fig. 1) to >20% at 5 dpi (Fig. 2).  In the NV/C pigs, only slight 
increases in percentage of lung consolidation were observed between 1 dpi (Fig. 3) and 5 dpi 
(Fig. 4) and never exceeded 7%.  Macroscopic lung lesions were absent or minimal in pigs in 
the NV/NC group.   
  Microscopic pneumonia - The average composite microscopic lung lesion score was 
significantly higher (P≤0.01) in the V/C pigs at 2 and 5 dpi compared to NV/C pigs (Table 
3).  The average composite score was also higher in the V/C pigs at 1 dpi compared to the 
NV/C group although a statistically significant difference was not observed.  Microscopic 
lesions were not evident in lung in the NV/NC pigs at any time during the study. 
NV/C pigs exhibited microscopic lung lesions consistent with uncomplicated 
influenza virus infection demonstrating mild airway epithelial attenuation with concurrent 
suppurative bronchitis and/or bronchiolitis and mild bronchointerstitial pneumonia at 1 dpi 
(Fig. 5).  Multifocal bronchi, bronchioles and alveolar lumina contained low to moderate 
numbers of neutrophils and scattered macrophages.  Necrotizing bronchiolitis became more 
pronounced by 2 dpi, although suppurative inflammation in bronchi, bronchioles, and 
particularly the alveoli, had almost completely subsided by this time. At 5 dpi, NV/C pigs 
demonstrated necrotizing or proliferative bronchitis and bronchiolitis with light, 
peribronchiolar lymphocytic cuffing (Fig. 6). Multifocally, alveolar septa were expanded by 
mild to moderate numbers of lymphocytes and macrophages.  
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In contrast to the mild microscopic lung lesions demonstrated in the NV/C pigs, lung 
lesion profiles were notably more widespread and severe in the V/C pigs with VAERD 
occurring as rapidly as 1 dpi.  Alveolar lumina were flooded by large amounts of eosinophilic 
proteinaceous material (edema) and hemorrhage (Fig. 7) that was not observed in the NV/C 
group. Marked interlobular edema was also demonstrated exclusively in the V/C pigs (Fig. 7) 
and an abundant, suppurative inflammatory infiltrate was observed in a larger percentage of 
bronchi and bronchioles in the VAERD-affected pigs compared to the NV/C group. Alveolar 
lumina bordering affected bronchioles and extending into adjacent lobules were expanded or 
occluded by large numbers of neutrophils and scattered macrophages in V/C pigs (Fig. 8) 
contrasting the mild suppurative inflammatory response in alveolar lumina of NV/C pigs 
(Fig. 5). However, VAERD-affected pigs demonstrated mild bronchi and bronchiolar 
epithelial necrosis that was similar to the NV/C group at 1 dpi. 
By 2 dpi, composite microscopic lesion scores increased in the V/C group (Table 3) 
due to a moderate elevation in alveolar septal mononuclear inflammation and abundant 
neutrophils, macrophages, edema and hemorrhage that persisted in alveolar lumina of 
affected lobules (Fig. 9). Suppurative inflammation present in the NV/C pigs at 1 dpi 
noticeably diminished by 2 dpi. Vaccinated/challenged pigs also demonstrated prominent 
peribronchiolar lymphocytic cuffing in contrast to light peribronchiolar cuffing observed in 
the NV/C group.  Both challenge groups exhibited more severe epithelial necrosis of the 
bronchioles and occasional bronchi at 2 dpi. 
Microscopic lung lesion profiles were characterized by increased lymphocytic 
inflammation in the V/C group at 5 dpi. The alveolar luminal edema and neutrophils 
decreased or were replaced by large numbers of alveolar macrophages, sloughed 
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pneumocytes and cellular debris. Alveolar lumina were often collapsed by marked, 
widespread alveolar septal thickening by lymphocytes, macrophages and type II pneumocyte 
hypertrophy and hyperplasia that were mildly observed in the NV/C pigs at 5 dpi. Only the 
VAERD-affected pigs demonstrated broad peribronchiolar cuffs of densely-packed 
lymphocytes (Fig. 10). Large numbers of lymphocytes expanded the bronchiolar lamina 
propria, displacing the affected epithelium and occasionally narrowing the bronchiolar lumen 
(Fig. 10).  Neutrophils persisted in the lumen of a larger percentage of bronchi and 
bronchioles in the V/C pigs (Fig. 10) compared to the NV/C group, with occasional 
neutrophil exocytosis within bronchiolar epithelium. Both challenge group’s demonstrated 
similar levels of bronchi and bronchiolar epithelial necrosis which was often replaced by 
proliferative, columnar epithelium by 5 dpi. 
Microscopic Trachea Lesions - Average trachea lesion scores in the V/C group were 
significantly higher (P≤0.001) at 1, 2, and 5 dpi compared to NV/C pigs.  Average trachea 
lesion scores for NV/C pigs were 0.16, 0.13 and 0.63 at 1, 2 and 5 dpi, respectively. NV/C 
pigs had minimal to mild attenuation of the tracheal epithelium with mild to moderate, 
multifocal, lymphocytic tracheitis at 1 and 2 dpi that became more pronounced at 5 dpi. In 
contrast, average trachea lesion scores for V/C pigs were 1.41, 1.88 and 1.84 at 1, 2 and 5 
dpi, respectively. Vaccinated/challenged pigs demonstrated multifocal regions of trachea 
epithelial attenuation with moderate lymphocytic and suppurative infiltrates at 1 dpi.  At 2 
and 5 dpi, tracheal lesions became more severe and widespread to include locally extensive, 
lymphoplasmacytic and necrosuppurative tracheitis with regional loss of cilia and severe 
lymphoplasmacytic infiltration of tracheal submucosa (Fig. 11).  Occasionally, aggregates of 
neutrophils were apparent in trachea epithelium in the V/C pigs.  Lesions were similarly 
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minimal in both challenge groups at 21 dpi.  Microscopic lesions were not evident in trachea 
in the NV/NC pigs at any time during the study. 
Lung immunohistochemistry - Influenza A virus antigen was detected by IHC as 
brown, granular, nuclear and cytoplasmic signals in all pigs challenged with pH1N1 at 1 dpi 
(Fig. 12).  At 2 dpi, IAV signals were detected in 8 of 8 V/C pigs and in 6 of 8 NV/C pigs.  In 
contrast, at 5 dpi, IAV antigen was detected in 6 of 8 V/C pigs and in 8 of 8 NV/C pigs.   
Influenza A virus signals in bronchioles of affected lung tissue from both challenge groups 
consisted of aggregates of immunoreactive epithelial cells that were attenuated, necrotic or 
occasionally morphologically unaffected.  In addition, rare individual immunoreactive cells 
were identified in the epithelium of bronchi.  Scores for airway epithelial IAV signals did not 
differ significantly between the challenge groups at 1 dpi (data not shown).  However, the 
average score for airway epithelial signals in the V/C group was significantly higher 
(P≤0.01) than the score for the NV/C pigs at 2 dpi.  Conversely, the average score was 
significantly higher (P≤0.05) in the NV/C pigs at 5 dpi compared to the V/C group. 
IAV signals in the alveolar septa or lumen, although present in both challenge groups, 
were more widely distributed in the V/C pigs at 1 and 2 dpi (Fig. 13), in which average IHC 
scores specifically for alveolar signals were significantly higher (P≤0.05) (data not shown).  
Similar levels of alveolar septa and lumen signals were observed in both challenge groups by 
5 dpi.  No influenza antigen was detected in either challenge group at 21 dpi or in the NV/NC 
pigs at any time during the trial. Influenza A virus antigen was identified as cytoplasmic or 
nuclear signals in hypertrophic and hyperplastic type II pneumocytes in the alveolar septum 
(Fig. 14) or within individual cells confined to the alveolar lumen and interpreted as alveolar 
macrophages or sloughed pneumocytes (Fig. 15). 
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Trachea immunohistochemistry - Moderately abundant immunoreactive trachea 
epithelial cells contained brown cytoplasmic or nuclear signals observed in necrotic (Fig. 16) 
or histopathologically unaffected epithelium.  IAV antigen was not detected in the 
submucosa.  Scores for IAV signals in trachea were significantly higher in the V/C pigs at 2 
dpi but similar to the NV/C pigs at both 1 and 5 dpi (data not shown). 
  Virus levels in lung and nasal secretions - No IAV was detected in nasal secretions 
from challenged pigs in either group at 0 or 1 dpi.  At 2 dpi, 7 of 8 V/C pigs and 3 of 8 NV/C 
pigs were shedding virus.  At 3 and 5 dpi, all remaining pigs challenged with pH1N1 were 
shedding virus in nasal secretions.  Virus titers from nasal swabs at 2 and 3 dpi were not 
significantly different between the V/C and NV/C pigs.  In contrast, at 5 dpi, titers in swabs 
from the NV/C pigs were significantly higher (P≤0.01) than from V/C pigs (Table 4).  Virus 
was not being shed in nasal secretions from any challenged pig remaining at 21 dpi. 
   Influenza A virus was isolated from the BALF of all challenged pigs at 1 and 2 dpi and 
from 8 of 8 NV/C pigs and 4 of 8 V/C pigs at 5 dpi.  Virus was not detected in any pigs 
remaining from either group at 21 dpi.  Mean virus titers in the BALF were significantly 
higher (P≤0.05) in the NV/C pigs than in V/C pigs at 1 and 5 dpi.  In contrast, mean BALF 
virus titers were significantly higher (P≤0.0001) in the V/C pigs compared to NV/C pigs at 2 
dpi (Table 4).  Virus was not detected at any time in BALF or nasal swabs in the NV/NC 
pigs. 
  Nucleoprotein ELISA, Hemagglutination-inhibition and Serum neutralization tests - 
Pigs in the NV/NC group remained seronegative throughout the study.  Anti-nucleoprotein 
ELISA (data not shown) and anti-MN08 HI antibody titers were detected in serum 
exclusively in the V/C pigs on the day of challenge (0 dpi).  The geometric mean reciprocal 
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HI titer was 37.5 (range 10 - 160).  Unvaccinated pigs did not demonstrate detectable anti-
MN08 HI antibodies.  None of the pigs demonstrated detectable anti-pH1N1 HI antibodies at 
0 dpi.  Serum neutralization titers against MN08 virus were only observed in the V/C pigs.  
The geometric mean reciprocal titer was 951.0 at 0 dpi (range 80 - 5,120).  Serum 
neutralization titers were not observed against the pH1N1 virus in the V/C, NV/C or NV/NC 
groups at 0 dpi. 
IgG antibody response to whole virus MN08 and pH1N1 -  Serum anti-MN08 and 
cross-reacting anti-pH1N1 IgG antibodies were detected in V/C pigs at 0 dpi, the day of 
challenge (data not shown).  Vaccinated pig serum anti-MN08 and –pH1N1 IgG OD levels 
were significantly higher (P≤0.0001) than the NV/C and NV/NC IgG OD levels.  Serum IgG 
OD levels to either antigen were not significantly different between NV/C and NV/NC pigs.   
  Local anti-viral and pro-inflammatory cytokine response - Cytokine concentrations in 
BALF were evaluated on days 1, 2, 5 and 21 post-challenge.  At 1 dpi, concentrations of IL-
1β, IL-8 and TNF-α were significantly higher in the V/C pigs compared to the NV/C pigs 
(Fig. 17 & 18). This trend continued on dpi 2, although not all concentrations in V/C pigs 
were significantly greater than NV/C or NV/NC pigs.  Pigs in the V/C group had 
significantly (P<0.05) higher concentrations of all cytokines at 5 dpi compared to NV/C and 
NV/NC pigs (Fig. 17 & 18).   At 21 dpi, concentrations of proinflammatory cytokines were 
considerably lower in all groups compared to dpi 5 and were comparable to dpi 1 
concentrations.    
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Discussion 
Vaccine associated enhanced respiratory disease (VAERD) was demonstrated in pigs 
administered a δ-cluster inactivated adjuvanted IAV vaccine followed by challenge with 
pH1N1, a strain in which the HA is genetically related to the γ-cluster H1 swine viruses.6,37  
Vaccine associated enhanced respiratory disease is a reproducible phenomenon characterized 
by an acute onset of severe respiratory disease reported previously in studies with vaccinated 
and challenged cross-bred pigs.8,12,16,38  However, to further understand the pathogenesis and 
elucidate potential mechanisms associated with VAERD, it was necessary to evaluate the 
development of macroscopic and microscopic lung lesions at multiple times during the acute, 
post-challenge phase of the inflammatory response. 
Microscopically, uncomplicated influenza infection in swine affects the 
intrapulmonary epithelium causing a necrotizing bronchiolitis.9,10 During the acute phase of 
infection, a transient neutrophil response to the epithelial necrosis is replaced by 
peribronchiolar and interstitial lymphocytes similar to what we describe in the NV/C pigs in 
this report.23,29,34,46 However, V/C pigs demonstrated more severe microscopic lesions in 
sharp contrast to the NV/C group that we interpret as features exclusive to VAERD. 
Widespread interlobular and alveolar edema with marked hemorrhage were observed as early 
as 1 dpi suggesting VAERD is an acute inflammatory reaction associated with the immune 
response to the vaccine (Fig. 7 and 8). Interlobular edema and hemorrhage have been 
previously described for other porcine respiratory viruses such as porcine circovirus type 27 
and PRRSV.11 To our knowledge, the enhanced pulmonary lesions we observed in VAERD-
affected pigs are unique compared to lesions associated with acute influenza virus infection 
described previously in naïve pigs34 and may be a component of the pathogenesis of 
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VAERD. In addition, a marked suppurative inflammatory response in the V/C pigs extended 
beyond affected bronchi and bronchioles to include widespread regions of the alveoli in 
affected lobules at 1 dpi (Fig. 7). The hemorrhage and edema persisted at 2 dpi in the V/C 
group with a persistent neutrophil response that had subsided as expected in the NV/C pigs 
suggesting another difference between VAERD-affected and non-vaccinated/challenged pigs 
(Fig. 9). It is unknown whether the elevated lung consolidation in the V/C pigs may have 
been elicited by the abundant neutrophil response in both intrapulmonary airways and 
alveoli, although they have been implicated as contributors to the clinicopathologic effects of 
influenza virus infection.17,33  
At 2 and 5 dpi, microscopic lung lesions continued to increase in severity in the V/C 
pigs and correlated with the elevated macroscopic lung consolidation (Fig 2).  Widespread 
alveolar septal thickening was characterized by intense lymphocyte and macrophage 
infiltration of alveolar septa and lumina, prominent type II pneumocyte hypertrophy and 
hyperplasia and variable numbers of neutrophils (Fig. 9). Additional lesions characteristic of 
VAERD included thick peribronchiolar lymphocytic cuffs and marked infiltration of 
lymphocytes in the bronchiolar lamina propria (Fig. 10).  The pronounced lymphocyte 
inflammatory response in the lung appears to be a consistent lesion associated with VAERD 
in swine. Our data also suggests the trachea undergoes an enhanced lymphocytic 
inflammatory response similar to the lungs representing another component of VAERD. 
Interestingly, V/C and NV/C pigs demonstrated similar levels of necrotizing bronchitis and 
bronchiolitis throughout the study reflecting the effects of influenza virus replication in 
respiratory epithelium. This is consistent with the lack of cross-protective vaccine immunity 
observed in the V/C pigs. However, viral titers in BALF or nasal swabs were not correlated 
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with enhanced lesions demonstrated in the V/C pigs as the acute, post-inoculation period 
progressed and elevated viral replication does not explain the pathogenesis of VAERD. 
Proinflammatory cytokines play an important role in the pathogenesis of influenza 
infection in swine and have been correlated with viral replication and clinical signs35 as well 
as increased lung lesions and neutrophil infiltration.34 In this report, TNF-α, IL-1β, IL-6 and 
IL-8 BALF concentrations were elevated in the V/C pigs compared to the NV/C pigs. A 
similar proinflammatory cytokine response was previously described by our group8 
suggesting elevated proinflammatory cytokines may be characteristic of VAERD and 
contribute to the development of acute lesions observed in the V/C pigs. Elevated IL-8, a 
neutrophil chemotactic cytokine, may have contributed to the prominent and prolonged 
suppurative response in alveoli, bronchi and bronchioles in V/C pigs.  In addition, previous 
reports have shown a positive correlation between elevated TNF-α and IL-1β with neutrophil 
recruitment to the lungs suggesting both cytokines may have been involved in the neutrophil 
response described in this report.34 A specific mechanism, such as Fc-receptor or compliment 
mediated activation, may have contributed to the exaggerated cytokine response detected in 
the V/C pigs. Mechanisms associated with VAERD remain unknown but under investigation 
at this time. 
VAERD in swine has been reproduced under experimental conditions although it may 
remain undiagnosed in field situations where mixed viral and bacterial respiratory infections 
are common.  However, an antigenically diverse population of IAV’s combined with 
increased IAV vaccine usage in swine creates optimal conditions for vaccine-virus mismatch 
and potential VAERD.  Seronegative children or mice administered an inactivated RSV 
vaccine followed by exposure to wild type RSV demonstrated enhanced respiratory disease 
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similar to what we describe for VAERD in swine.4,14,27 Preexisting vaccine antibodies may 
enhance other viral infections in humans. Atypical measles resulted from the use of formalin-
inactivated vaccines administered to infants and children who later developed severe forms 
of the disease when exposed to wild type virus suggesting a similar mechanism to enhanced 
disease associated with vaccine immunity to RSV.5 
Our data suggests VAERD results from a multifactorial mechanism that includes 
cross-reactive antibodies (IgG isotype) to conserved or non-neutralizing epitopes elicited by 
inactivated vaccines in the absence of HI or neutralizing antibodies.  Non-neutralizing 
antibodies induced by the vaccine may play a role in antibody dependent cell-mediated 
cytotoxicity or antibody dependent enhancement. Antibodies involved in antigen-antibody 
complexes or complement fixation may have also contributed to the clinical disease and lung 
lesions we observed in this study. A previous study in vaccinated swine described an 
association between non-neutralizing M2 antibodies and an NP-specific lymphoproliferative 
response with enhanced clinical disease.12  The data suggested the cellular immune response 
(lymphocytes), in addition to antibodies, may have contributed to disease enhancement.  The 
V/C pigs in the current study also demonstrated an NP antibody response to the inactivated 
vaccine, although the role for NP-induced antibodies or cellular responses in VAERD 
requires further characterization. 
A recent epidemiological report from Canada described an association between prior 
immunization with the 2008-09 trivalent inactivated seasonal influenza vaccine and an 
increased risk of medically attended pH1N1 illness in humans.31  Although differences exist 
between human and swine VAERD, data from human subjects suggest mechanisms that may 
overlap with VAERD in swine.22  A recent report described a correlation between severe 
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pandemic 2009 H1N1 respiratory disease in middle-aged adults and the presence of 
preexisting serum antibodies that cross-reacted with the virus but did not confer protection.22  
The report described the presence of pulmonary immune complexes consisting of low avidity 
antibodies to the 2009 pH1N1 antigen in association with high levels of activated 
complement in people with severe respiratory disease.  A detailed description of potential 
VAERD mechanisms is beyond the scope of this report; however, studies are in progress to 
determine the pathogenesis of VAERD in swine. 
In summary, this report demonstrates an enhanced disease process in vaccinated pigs 
challenged with a heterologous influenza A virus resulting in more severe macroscopic and 
microscopic lung lesions compared to pigs that did not receive prior vaccination but 
challenged with the same virus.  Cross-reactive antibodies that lack neutralizing capabilities 
but have the ability to activate complement may play an initiating role in the process since 
features of the phenomenon occur very rapidly, as early as 1 dpi.  However, multiple 
contributing factors, including dysregulation of proinflammatory cytokines and the various 
immune cell types identified in the cellular infiltrates in VAERD affected lungs, need further 
investigating to determine the cause of the immunopathology associated with VAERD in 
swine.   
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Table 1. Experimental design. 
    Necropsy N 
Group* Vaccine Challenge N 1 dpi† 2 dpi 5 dpi 21 dpi 
V/C MN08 pH1N1 28 8 8 8 4 
NV/C None pH1N1 28 8 8 8 4 
NV/NC None None 28 8 8 8 4 
*Groups include vaccinated/challenged (V/C), non-vaccinated/challenged (NV/C), non-
vaccinated/non-challenged (NV/NC). 
†Days post inoculation (dpi). 
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Table 2.  Scoring parameters used for evaluation of hematoxylin/eosin (H&E) 
microscopic lesions and immunohistochemistry (IHC) signals in lung and trachea. 
Scores range from 0-3. 
  Numerical score 
Tissue Lesion 0 1 1.5 2 2.5 3 
Lung 
H & E 
Necrotizing 
bronchitis/bronchiolitis None 
< 5%*  5 - 25%  26 - 50%  51 - 75%  > 75%  
Suppurative 
bronchitis/bronchiolitis None 
< 5%†  5 - 25%  26 - 50%  51 - 75%  > 75%  
Peribronchiolar 
lymphocytic cuffing None 
Mild  
light inflammation‡ 
Moderate  
prominent  
Severe 
marked 
Alveolar septal 
inflammation None 
Mild  
focal inflammation‡ 
Moderate  
local extensive  
Severe  
diffuse  
Trachea 
H & E 
Epithelial  
attenuation/necrosis 
None 
Focal 
cilia present   
Diffuse 
focal loss of cilia  
Diffuse 
cilia absent  
Lung  
IHC 
Airway epithelium signal  None 
Minimal 
occasional signals‡ 
Moderate 
scattered signals 
Abundant  
scattered signals 
Alveoli lumen/septum 
signal  
None 
Minimal 
focal signals‡ 
Moderate 
multifocal signals 
Abundant 
diffuse signals 
Trachea 
IHC 
Epithelial signals None 
Minimal 
focal signals‡ 
Moderate 
multifocal signals 
Abundant 
diffuse signals 
*Percent of bronchi and bronchioles with epithelial necrosis in sections examined.  
†Percent of bronchi and bronchioles with suppurative inflammation in sections examined. 
‡Scores based on mild, moderate, severe inflammation in H&E sections or minimal, 
moderate, abundant signals in IHC sections. 
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Table 3. Comparison of the mean percent lung lesions (purple-red consolidation) and 
mean microscopic lesion score (necrotizing bronchiolitis, suppurative 
bronchiolitis/bronchitis, peribronchiolar lymphocytic cuffing, alveolar septal thickening 
with mononuclear inflammation) in vaccinated/challenged (V/C), non-
vaccinated/challenged (NV/C) and non-vaccinated/non-challenged (NV/NC) pigs at 1, 2, 
5 and 21 days after pH1N1 inoculation. Data presented as the mean percent 
consolidation or mean composite lesion score ± standard error of the mean. 
Group 
Lung consolidation *  Microscopic Pneumonia Score† 
1 dpi 2 dpi 5 dpi 21 dpi  1 dpi 2 dpi 5 dpi 21 dpi 
V/C 10.7 ± 1.5a‡ 13.4 ± 2.3a 21.4 ± 3.1a 1.3 ± 0.4a  7.5 ± 0.4a 9.8 ± 0.5a 10.3 ± 0.9a 0.7 ± 0.3a 
NV/C  3.6 ± 0.6b   4.1 ± 0.7b   6.8 ± 1.6b 0.1 ± 0.1b  5.9 ± 1.0a 5.3 ± 1.1b 7.2 ± 0.4b 0.7 ± 0.2a 
NV/NC 0.1 ± 0.1c   0.1 ± 0.1b   0.1 ± 0.0b 0.1 ± 0.1b  0.0 ± 0.0b 0.0 ± 0.0c 0.0 ± 0.0c 0.0 ± 0.0a 
*Percent consolidation calculated on a weighted average of each lung lobe. 
†Composite scores range from 0 to 12 based on parameters described in Table 2. 
‡Different superscripts (a, b, c) indicate significantly different (P ≤ 0.05) mean percent 
consolidation or microscopic pneumonia scores within a column for each dpi. 
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Table 4. Comparison of pH1N1 virus titers in bronchoalveolar lavage fluid (BALF) and 
nasal swabs in vaccinated/challenged (V/C), non-vaccinated/challenged (NV/C) and 
non-vaccinated/non-challenged (NV/NC) pigs at 1, 2 and 5 days after pH1N1 
inoculation. Data presented as the mean virus titer ± standard error of the mean. 
Group 
Virus titers* (BALF)  Virus titers* (nasal swabs) 
1 dpi 2 dpi 5 dpi  2 dpi 3 dpi 5 dpi 
V/C 4.5 ± 0.3a† 4.8 ± 0.2a 1.4 ± 0.6a  2.5 ± 0.5a 3.4 ± 0.2a 2.4 ± 0.2a 
NV/C 6.1 ± 0.3b 3.7 ± 0.1b 4.2 ± 0.3b  1.6 ± 0.7a 3.5 ± 0.4a 3.2 ± 0.1b 
NV/NC 0.0 ± 0.0c 0.0 ± 0.0c 0.0 ± 0.0c  0.0 ± 0.0b 0.0 ± 0.0b 0.0 ± 0.0c 
*Virus titers represented as log10/ml of BALF or nasal swab solution. 
†Different superscripts (a, b, c) indicate significantly different (P ≤ 0.05) mean virus titers 
(log10/ml) within a column for each dpi. 
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Figure 1.  Lung, Pig 112, V/C group. Note the multifocal, purple-colored cranioventral and 
diaphragmatic pulmonary consolidation at 1 dpi in a pig with vaccine-associated enhanced 
respiratory disease (VAERD). 
Figure 2.  Lung, Pig 127, V/C group. Cranioventral and diaphragmatic consolidation was 
more widespread affecting an average of 21% of the lung at 5 dpi in pigs with VAERD. 
Figure 3.  Lung, Pig 139, NV/C group. Non-vaccinated pigs challenged with pH1N1 
demonstrated significantly less pulmonary consolidation compared to Figure 1 at 1 dpi 
affecting only the cranioventral lung lobes. 
Figure 4.  Lung, Pig 151, NV/C group. Note the significantly lower magnitude of pulmonary 
consolidation affecting only the cranioventral lung lobes in non-vaccinated pigs challenged 
with pH1N1 demonstrated at 5 dpi compared to the VAERD-affected lung in Figure 2. 
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Figure 5.  Lung, Pig 135, NV/C group. Mild bronchiolar epithelial attenuation and 
suppurative bronchiolitis (arrow) were observed at 1 dpi with mild alveolar septal thickening 
and light peribronchiolar cuffing (arrowhead). Hematoxylin and eosin, 400X. 
Figure 6.  Lung, Pig 150, NV/C group. A large bronchiole with epithelial necrosis (arrow). 
Note the mild alveolar septal thickening (arrowhead) and light peribronchiolar lymphocytic 
cuffing at 5 dpi.  Hematoxylin and eosin, 400X. 
Figure 7.  Lung, Pig 110, V/C group. Note the acute interlobular and peribronchiolar edema 
(arrows) and dilated lymphatics observed in pigs with VAERD at 1 dpi. Hematoxylin and 
eosin, 100X. Insert: Lung; Pig 110, V/C group. Marked edema, hemorrhage and neutrophils 
(arrow) in alveolar lumina with interlobular edema (asterisk). Hematoxylin and eosin, 200X. 
Figure 8.  Lung, Pig 110, V/C group. Marked suppurative and hemorrhagic bronchiolitis and 
alveolitis (arrows) were demonstrated by VAERD-affected pigs at 1dpi compared to the 
NV/C lung displayed in Figure 5. Note the widespread hemorrhage (arrowheads) and edema 
(asterisk). Hematoxylin and eosin, 400X. 
Figure 9. Lung, Pig 115, V/C group. Note the persistent suppurative alveolitis (arrows), 
hemorrhage and congestion with type II pneumocyte hypertrophy (arrowhead) demonstrated 
at 2 dpi. Hematoxylin and eosin, 400X. Insert: Lung; Pig 115, V/C group. Alveoli are dilated 
with large amounts of edema (asterisk) at 2 dpi. Hematoxylin and eosin, 400X. 
Figure 10.  Lung, Pig 123, V/C group. Note the broad, dense, peribronchiolar lymphocytic 
cuffing (double arrow) with marked lymphocyte infiltration of the lamina propria (arrow) and 
suppurative bronchiolitis (arrowhead) in pigs with VAERD at 5 dpi compared to a NV/C pig 
displayed in Figure 6.  Hematoxylin and eosin, 400X. 
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Figure 11.  Trachea, Pig 117, V/C group. Pigs with VAERD demonstrated diffuse 
necrotizing and lymphocytic tracheitis (arrows). Note the marked, subepithelial lymphocytic 
infiltration and epithelial sloughing (asterisk).  Hematoxylin and eosin, 400X. 
Figure 12.  Lung, Pig 110, V/C group. A bronchiole demonstrating dark brown nuclear and 
cytoplasmic signals for influenza A viral antigen in attenuated epithelial cells at 1 dpi.  
Peroxidase labeled avidin-biotin complex with hematoxylin counterstain, 200X.  
Figure 13.  Lung, Pig 115, V/C group. Diffusely scattered interstitial influenza A signals 
were detected in alveolar septa or lumina at elevated levels in pigs with VAERD at 1 and 2 
dpi. A necrotic bronchiole exhibits influenza A signals in epithelium (arrowhead).  
Peroxidase labeled avidin-biotin complex with hematoxylin counterstain, 200X.  
Figure 14.  Lung, Pig 106, V/C group. Note the nuclear and cytoplasmic influenza A viral 
antigen signals in alveolar type II hypertrophic and hyperplastic pneumocytes (arrows) in 
pigs with VAERD at 1 dpi. Peroxidase labeled avidin-biotin complex with hematoxylin 
counterstain, 400X.  
Figure 15.  Lung, Pig 115, V/C group. Nuclear influenza A viral antigen signals were 
detected in cells interpreted as macrophages or sloughed pneumocytes (arrows) located in 
alveolar lumina among neutrophils and cellular debris in V/C pigs at 2 dpi.  Peroxidase 
labeled avidin-biotin complex with hematoxylin counterstain, 600X.  
Figure 16.  Trachea, Pig 113, V/C group. A trachea with influenza A viral antigen signals 
within attenuated or necrotic epithelium (arrows). Peroxidase labeled avidin-biotin complex 
with hematoxylin counterstain, 100X.  Insert: Trachea; Pig 113, V/C group. Note the nuclear 
influenza A viral antigen signals in necrotic epithelium (arrowhead). Peroxidase labeled 
avidin-biotin complex with hematoxylin counterstain, 400X.  
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Figure 17.  Cytokine IL-1β and IL-8 protein concentration in bronchoalveolar lavage fluid 
(BALF) from vaccinated/challenged (V/C), non-vaccinated/challenged (NV/C) and non-
vaccinated/non-challenged (NV/NC) pigs at 1, 2, 5 and 21 days after pH1N1 inoculation. 
Data presented as box plots demonstrating the median cytokine concentration (pg/ml), 5th and 
95th percentile and standard deviation per group. Connecting horizontal lines are significantly 
different (P<0.05).   
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Figure 18. Cytokine IL-6 and TNF-α protein concentration in bronchoalveolar lavage fluid 
(BALF) of vaccinated/challenged (V/C), non-vaccinated/challenged (NV/C) and non-
vaccinated/non-challenged (NV/NC) pigs at 1, 2, 5 and 21 days after pH1N1 inoculation. 
Data presented as box plots demonstrating the median cytokine concentration (pg/ml) per 
group with the 5th and 95th percentile and standard deviation. Connecting horizontal lines are 
significantly different (P<0.05).   
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Abstract 
 The objective of this study was to evaluate the ability of vaccine associated enhanced 
respiratory disease (VAERD) affected pigs to mount an adaptive immune response against 
the heterologous challenge virus inciting the VAERD.  Pigs were vaccinated with an 
inactivated swine δ-cluster MN08 virus with an HA of the human seasonal lineage and 
challenged with heterologous 2009 pandemic A/H1N1 (pH1N1). Vaccinated pigs 
demonstrated significantly higher post-challenge anti-pH1N1 serum neutralizing (SN) 
antibodies at 14 and 21 dpi compared to pigs that were challenged alone, indicating a priming 
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effect of the vaccine. Systemic and mucosal anti-MN08 and -pH1N1 IgG ELISA antibodies 
in the vaccine primed group were also significantly higher than the challenge only and naïve 
pigs at 0, 7, 14 and 21 dpi. Systemic anti-pH1N1 IgG antibodies were not detected until 14 
dpi in NV/C pigs, as expected in a primary immune response. Systemic anti-MN08 and -
pH1N1 IgA ELISA antibodies in the vaccine primed pigs were also significantly higher than 
the challenge only pigs at 0, 7, 14 and 21 dpi. Lung IgA ELISA antibodies to either antigen 
were not detected until 21 dpi in the vaccine primed pigs. In contrast, challenge only pigs did 
not develop anti-MN08 and -pH1N1 serum IgA or mucosal IgG and IgA ELISA antibody 
responses at any time measured post inoculation. Interleukin-2, IL-4, IL-12p70, IL-10 and 
IFNγ protein concentrations in the lung were significantly elevated in vaccine primed pigs at 
5 dpi. Collectively, vaccine primed pigs demonstrated a robust humoral immune response 
and elevated local adaptive cytokine concentrations in response to challenge with pH1N1.  
This indicates that VAERD does not adversely affect the induction of an immune response to 
challenge with heterologous, homosubtypic virus despite the severe underlying lung 
pathology.  
 
Introduction 
 Contemporary influenza A viruses (IAV) in North American swine are characterized 
by marked genetic and antigenic diversity. Since the introduction of the triple reassortant 
H3N2 IAV in 1998, emerging viruses have retained the triple reassortant internal gene 
cassette (TRIG) which includes the NP, M and NS genes of classical swine lineage, PB2 and 
PA genes of avian lineage and PB1 of human lineage.56 Current endemic, triple reassortant 
IAV’s identified in United States (US) swine contain a similar TRIG56 and have 
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demonstrated antigenic drift and antigenic shift in the hemagglutinin (HA) gene resulting in 
multiple, antigenically distinct H1 phylogenetic clusters designated α, β, γ and δ.54,55 Unlike 
the α, β and γ cluster viruses that evolved from the classical H1N1 (cH1N1) lineage, the δ-
cluster IAV’s are the most genetically diverse from the cH1N1 HA as they contain HA genes 
similar to human seasonal H1 viruses that were first identified in Canada in 200317 and later 
in the US.55  Furthermore, the TRIG cassette was identified in a novel H2N3 swine virus with 
avian H2 and N3 genes26 and a transient reassortant swine lineage H3N1 virus contained the 
TRIG emphasizing its enduring presence in triple reassortant swine viruses.23 Collectively, 
the TRIG cassette may represent an adaptive mechanism that allows IAV’s to tolerate  less 
discriminate combinations of HA and neuraminidase (NA) surface glycoproteins imparting a 
selective advantage to those particular viruses in the swine host. 
 Prevention and control of IAV’s in swine becomes more complex as the virus 
continues to evolve. The antigenic diversity within an IAV subtype has resulted in more 
variable cross-reactivity in the hemagglutination inhibition (HI) assay between H1 
phylogenetic clusters. Viruses that evolved from the cH1N1 swine-lineage have retained 
moderate to strong cross-reactivity within a cluster.22,54 In contrast, limited cross-reactivity 
has been demonstrated between cH1N1 derivatives and the more recent δ-cluster viruses.22,52 
Furthermore, the δ-cluster viruses with human seasonal influenza HA glycoproteins 
demonstrate a higher degree of antigenic diversity among members of this phylogenetic 
cluster.22,55  
The lack of serological cross-reactivity among contemporary IAV’s is correlated with 
decreased cross-protective immune responses following vaccination. Commercially available 
IAV vaccines for swine are inactivated, whole-virus preparations that contain various 
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combinations of H1N1, H1N2 and H3N2 subtypes that currently circulate in North American 
swine. Inactivated vaccines have demonstrated partial to adequate protection against 
homologous challenge.3,19,20,27,49,54,53,51 However, inactivated vaccines have limited cross-
protective ability against heterologous homosubtypic, or heterosubtypic influenza 
viruses.19,50,49,54,53,51 In contrast, vaccines that imitate natural infection, such as live attenuated 
influenza vaccines (LAIV), have demonstrated superior protection against heterologous 
challenge through reduced viral shedding and prevention of clinical disease compared to the 
inactivated preparations.1,28,35,57 
 Only recently have commercial IAV vaccines for swine included the δ-cluster viruses 
in their multivalent vaccine preparations in response to the increasing prevalence of these 
viruses circulating in swine.51 We recently reported a disease phenomenon, termed vaccine 
associated enhanced respiratory disease (VAERD), in swine vaccinated with monovalent 
inactivated δ-cluster H1N2 virus and exposed to pH1N1.7  The mechanism responsible for 
VAERD is unknown at this time, although the pre-challenge antibody response elicited by 
inactivated vaccines has been implicated.7,12,53  Although the δ-cluster vaccine did not induce 
cross-reactive HI or serum neutralizing (SN) antibodies to the pH1N1 virus prior to 
challenge, cross-reacting whole virus IgG antibodies are induced against pH1N1 by the 
mismatched vaccine. Currently, few studies have evaluated the post-challenge immune 
response following pH1N1 heterologous infection in pigs with prior immunity to a 
monovalent δ-cluster vaccine. 
 Pigs with VAERD demonstrate severe, prolonged clinical signs and increased 
macroscopic and microscopic lung lesions; however, VAERD-affected pigs recover from 
disease in spite of the negative health impact.7 As reassortment and antigenic drift continues 
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among IAV’s in swine, it becomes increasingly important to understand how the immune 
response to heterologous challenge may contribute to VAERD in pigs with prior vaccine 
immunity. In addition, it is equally important to evaluate the ability of VAERD-affected pigs 
to mount an adaptive immune response against the heterologous challenge virus that incited 
the VAERD.  The objectives of this study were to evaluate the pre- and post-challenge 
humoral immune response and local adaptive cytokine concentrations in the lungs of 
VAERD-affected pigs.  
 
Materials and Methods 
Experimental Design, vaccine and virus inoculum -  Eighty-four, three-week-old 
cross-bred pigs of mixed sex were obtained from a herd free of IAV and porcine reproductive 
and respiratory syndrome virus (PRRSV). Pigs were housed in biosafety level 2 containment 
during the vaccine phase of the study before transferring fifty-six pigs to ABSL3 
containment one week prior to challenge, recommended at the time for pH1N1 challenge 
studies. Upon arrival, pigs were treated prophylactically with ceftiofur (Pfizer Animal 
Health, New York, NY) according to label directions to reduce respiratory bacterial flora 
prior to the start of the study.  Pigs were cared for in compliance with the Institutional 
Animal Care and Use Committee of the National Animal Disease Center.  The experimental 
design is described in Table 1. 
Influenza A virus vaccine was prepared with A/Sw/MN/02011/2008 (MN08) δ1 
cluster H1N2 at approximately 32 HA units or 105.7 50% tissue culture infectious dose 
(TCID50) per ml that was inactivated by ultraviolet irradiation and mixed with an emulsified 
oil-in-water adjuvant (Emulsigen®-D, MVP Technologies, Omaha, NE) at a v:v ratio of 4:1 
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virus to adjuvant.  Pigs were vaccinated with 2 ml by the intramuscular route at 
approximately 6 and 9 weeks of age, and challenged at 13 weeks of age.  For viral challenge, 
pigs were inoculated intratracheally with 2 ml of 1 x 105 TCID50 of pandemic A/CA/04/2009 
H1N1 (pH1N1) propagated in Madin-Darby Canine Kidney (MDCK) cells, as previously 
described.58  Pigs were humanely euthanized with a lethal dose of pentobarbital (Sleepaway, 
Fort Dodge Animal Health, Fort Dodge, IA) on 1, 2, 5 or 21 dpi to evaluate lung lesions, 
viral replication, cytokine concentrations and antibody responses in the lungs.  Serum was 
collected from pigs at necropsy and additionally at 7 and 14 dpi.  Postmortem samples 
included serum and bronchoalveolar lavage fluid (BALF). 
Diagnostic microbiology - All pigs were screened for antibody against influenza A 
NP by ELISA (MultiS ELISA, IDEXX, Westbrook, Maine) upon arrival to ensure absence of 
preexisting immunity from prior exposure or maternal derived antibody and at 0 dpi to detect 
vaccine-induced NP antibodies.  BALF samples from 1, 2, 5 and 21 dpi were cultured for 
aerobic bacteria on blood agar and Casmin (NAD enriched) plates.  Polymerase chain 
reaction (PCR) assays for PCV2,34 Mycoplasma hyopneumoniae43 and RT-PCR for PRRSV 
were conducted on nucleic acid extracts from BALF collected at each  necropsy. 
Antibody detection assays - Hemagglutination inhibition assays were conducted as 
previously described.53  Briefly, sera were heat inactivated at 56°C for 30 min, then treated to 
remove nonspecific hemagglutination inhibitors and natural serum agglutinins by treatment 
with a 20% suspension of kaolin (Sigma Aldrich, St. Louis, MO) and adsorption with 0.5% 
turkey red blood cells (RBC). The HI assays were then performed with MN08 or pH1N1 
virus as antigen and turkey RBCs as indicators using standard techniques as previously 
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described.53 Reciprocal titers were divided by 10 and log2 transformed, analyzed, and 
reported as the geometric mean.    
Enzyme-linked immunosorbent assays (ELISA) to detect total IgG and IgA 
antibodies against whole virus preparations of MN08 and pH1N1 present in serum and 
BALF were performed as previously described.7,54 Independent assays were conducted using 
concentrated MN08 or pH1N1 as ELISA antigen.  Each sample was analyzed in duplicate. 
The optical density (OD) was measured at 405 nm wavelength with an automated ELISA 
reader.  Antibody levels were reported as the mean OD and the mean OD of each treatment 
group were compared. 
Serum neutralization (SN) assays were conducted as previously described.7,54 Briefly, 
sera were heat inactivated at 56°C for 30 min, then two-fold serially diluted using 50 µl in 
serum-free MEM supplemented with TPCK trypsin and antibiotics.  Fifty microliters of 
MN/08 or pH1N1, diluted to 103.3 TCID50/ml, was added to each serum dilution and 
incubated at 37°C for 1 hr.  Post-incubation, 100 µl of the serum and virus mixture was 
added to each well of confluent MDCK cells prepared in 96-well plates that had been washed 
twice with sterile PBS.  Plates were incubated for 48 hours, fixed with formalin and stained 
using immunocytochemistry to detect virus as previously described.18  Titers were recorded 
as the highest dilution negative for virus staining or CPE after the presence of virus was 
verified by immunocytochemistry for all plates.  Reciprocal titers were divided by 10, log2 
transformed, analyzed, and reported as the geometric mean.    
Cytokine assays - A 5 ml aliquot of BALF was centrifuged at 400 x g for 15 min at 4° 
C to pellet cellular debris.  The cell-free BALF was stored at -80° C.  Cytokine 
concentrations in BALF, which included IL-2, IL-4, IL-12p70, IL-10 and IFN-γ, were 
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determined by multiplex ELISA performed according to the manufacturer’s 
recommendations (SearchLight, Aushon Biosystems).  The average of duplicate samples for 
each sample was used for statistical analysis. 
Statistical analysis - Log2 transformed HI and SN reciprocal titers, mean OD ELISA 
IgG and IgA antibody levels and cytokine concentrations were analyzed using analysis of 
variance (ANOVA) with a P-value ≤ 0.05 considered significant (JMP, SAS Institute, Cary, 
NC; GraphPad Prism Version 5.00, San Diego, CA). Response variables shown to have a 
significant effect by treatment group were subjected to pair-wise comparisons using the 
Tukey–Kramer test. 
 
Results 
Viral and microbiological assays - Influenza A NP specific antibodies were not 
detected in any pig prior to vaccination as expected. All pigs were free of PRRSV, PCV2 or 
M. hyopneumoniae nucleic acids in BALF collected at 5 dpi. Routine aerobic bacterial 
cultures isolated Bordetella bronchiseptica in the BALF of one NV/C pig.  Macroscopic and 
microscopic lung lesions indicative of VAERD were present in all pigs in the V/C (VAERD 
group) and were reported previously with nasal shedding and lung virus titers (Gauger, Vet 
Pathology, accepted for publication). 
VAERD did not prevent the induction of an HI antibody response to heterologous 
challenge - Anti-MN08 or -pH1N1 HI antibodies were not detected in pigs that did not 
receive vaccine or challenge virus during the pre- and/or post-challenge phase of the study. 
Group geometric mean anti-MN08 HI antibody titers in VAERD-affected pigs were 
significantly higher (P≤0.05) than the NV/C and NV/NC group titers at 7, 14 and 21 days 
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post infection (dpi). Challenge with pH1N1 boosted the mean anti-MN08 HI antibody titers 
in the V/C pigs, peaking at 14 dpi. 
Importantly, the vaccine primed, VAERD-affected group mounted a humoral immune 
response to the pH1N1 challenge virus in spite of the severe underlying pathology induced 
by VAERD.  Moreover, the geometric mean anti-pH1N1 HI antibody titers were 
significantly higher (P≤0.05) than the NV/C and NV/NC group at 7 dpi. Significant 
differences between V/C and NV/C pigs were not detected at 14 and 21 dpi, although V/C 
pigs demonstrated a trend of higher anti-pH1N1 HI titers compared to the naïve challenged 
pigs. Anti-pH1N1 HI antibodies were first detected in the V/C and NV/C pigs at 7 dpi and 
peaked at 14 dpi in both challenge groups. Anti-MN08 and anti-pH1N1 geometric mean HI 
antibody titers are summarized in Table 2. 
VAERD did not prevent the induction of an SN antibody response to heterologous 
challenge - Anti-MN08 or -pH1N1 SN antibodies were not detected in pigs that did not 
receive vaccine or challenge virus during the pre- and/or post-challenge phase of the study. 
Similar to the HI results, the VAERD-affected group geometric mean anti-MN08 SN 
antibody titers were significantly higher (P≤0.001) than the NV/C and NV/NC titers at all 
dpi. Anti-MN08 SN antibody titers in the VAERD-affected pigs were boosted post-challenge 
with pH1N1, peaked at 7 dpi and rapidly declined at 14 and 21 dpi. Anti-MN08 geometric 
mean reciprocal SN antibody titers are summarized in Table 3. 
Pigs in the VAERD-affected group responded to heterologous challenge with 
geometric mean anti-pH1N1 SN antibody titers similar to the NV/C group at 7 dpi but 
significantly higher (P≤0.001) than the NV/C and NV/NC groups at 14 and 21 dpi. Anti-
pH1N1 geometric mean reciprocal SN antibody titers are summarized in Table 3. 
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Serum and BALF whole virus anti-MN08 and cross-reactive anti-pH1N1 IgG 
antibody in VAERD-affected pigs - Anti-MN08 and cross-reactive anti-pH1N1 IgG 
antibodies were detected in serum exclusively in the V/C group prior to challenge. Group 
mean pre- and post-challenge anti-MN08 and post-challenge anti-pH1N1 OD levels were 
significantly higher (P≤0.0001) in vaccine-primed pigs compared to NV/C and NV/NC pigs 
at all dpi measured and remained consistently high at all dpi tested. Of note, non-
vaccinated/challenged pigs did not demonstrate cross-reactive anti-MN08 post-challenge 
antibody levels that were significantly different than the NV/NC pigs in contrast to the cross-
reacting pH1N1 serum IgG primed by the MN08 UV-inactivated vaccine administered 
parenterally, suggesting a difference in antibody response depending on the route and type of 
priming event. However, non-primed pigs responded to challenge with serum anti-pH1N1 
IgG antibody levels detected at 14 dpi and peaking at 21 dpi, indicating a primary immune 
response to the challenge virus.  
 IgG antibodies in the lung against MN08 and pH1N1 were detected in the BALF 
from vaccine-primed pigs at 1, 2, 5 and 21 dpi. Group mean anti-MN08 and anti-pH1N1 IgG 
antibodies in the V/C pigs were significantly higher (P≤0.01) than NV/C and NV/NC mean 
antibody levels at all dpi measured post-challenge. Anti-MN08 and anti-pH1N1 IgG V/C 
group mean antibody levels peaked at 21 dpi and demonstrated an increase between 2 and 21 
dpi to either antigen in response to the heterologous challenge. However, in non-primed 
pH1N1 challenged pigs, anti-MN08 and anti-pH1N1 BALF IgG antibody levels were not 
different from non-challenged negative controls. It is unclear if this was due to the difference 
between a primary and secondary immune response, difference in the type of priming event, 
or if the peak antibody levels occurred between 5 and 21 dpi or beyond 21 dpi and was not 
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detected due to timing of sample collection.  Serum and BALF IgG OD levels are described 
in Table 4. 
Serum and BALF whole virus anti-MN08 and cross-reactive anti-pH1N1 IgA 
antibody in VAERD-affected pigs - Anti-MN08 and cross-reactive anti-pH1N1 IgA 
antibodies were detected in serum exclusively in the V/C group prior to challenge. Serum 
anti-MN08 and anti-pH1N1 IgA levels in the V/C pigs did not change at 7, 14 and 21 dpi 
after challenge with pH1N1. Group mean anti-MN08 and anti-pH1N1 IgA serum antibodies 
in vaccine-primed pigs were significantly higher (P≤0.001) at all dpi compared to NV/C and 
NV/NC pigs. Challenge with pH1N1 did not induce an IgA serum antibody response to 
either antigen in non-primed pigs, similar to the IgG response to pH1N1 in the lung. 
 Anti-MN08 and anti-pH1N1 IgA mucosal antibodies in the lower respiratory tract 
were not significantly different in the V/C or the NV/C group at 1 and 2 dpi compared to the 
NV/NC pigs. However, at 21 dpi, anti-MN08 group mean antibody levels in the lungs of 
vaccine-primed pigs were significantly higher (P≤0.0001) than the NV/C and NV/NC group 
mean IgA levels. Likewise, group mean anti-pH1N1 IgA antibody levels in the lungs of 
vaccine-primed pigs were also significantly higher (P≤0.001) than NV/C and NV/NC pigs at 
5 and 21 dpi. Non-primed, challenged group mean IgA antibody levels were similar to the 
NV/NC group post-challenge although there was a trend for slightly elevated anti-pH1N1 
levels at 21 dpi compared to 1, 2 and 5 dpi and may indicate that the IgA response was not 
detected due to timing of sampling.  Serum and BALF IgA levels are described in Table 5. 
Local adaptive cytokine response peaked on 5 dpi in VAERD affected pigs- Cytokine 
protein concentrations in BALF for IL-2, IL-4, IL-12p70, IFN-γ and IL-10 were significantly 
higher (P<0.05) in the vaccine-primed pigs that demonstrated VAERD upon necropsy at 5 
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dpi. Additionally, V/C pigs demonstrated significantly higher (P<0.05) IFN-γ levels 
compared to the other two groups at 1 and 2 dpi. A similar elevated trend in IL-2, IL-4, IL-
12p70 and IL-10 protein concentrations were demonstrated at 1 and 2 dpi although not all 
V/C cytokine concentrations were statistically different than NV/C and NV/NC pigs. 
Concentrations of adaptive cytokines in the V/C pigs had returned to baseline levels by 21 
dpi and no significant differences were observed between the groups. Cytokine 
concentrations are depicted in Figure 1. 
 
Discussion 
 Continual genetic mutation and reassortment supports the evolution of antigenically 
diverse IAV’s in swine.22,25,24,55 Genetic diversity has been demonstrated in all currently 
identified H1 phylogenetic clusters (α-, β-, γ-, δ1 and δ2); however, the δ-cluster viruses 
exhibit greater genetic divergence compared to the other three clusters.22 Therefore, vaccine-
challenge mismatch is potentially more likely between influenza viruses derived from the 
cH1N1 and δ-cluster viruses. We have previously demonstrated VAERD using a model 
where pigs were vaccinated with an inactivated δ1-cluster (human-like) IAV and challenged 
with pH1N1.7 The objective of the current study was to evaluate if pigs with VAERD would 
mount an adaptive immune response specific to the heterologous challenge virus, pH1N1. 
Although prior studies have highlighted the lack of serological cross-reactivity between δ- 
and γ-cluster IAV’s,52,22 previous studies have not evaluated the immune response generated 
by heterologous, homosubtypic virus challenge in pigs previously vaccinated with a 
monovalent δ-cluster IAV, particularly in swine demonstrating enhanced clinical disease and 
pneumonia (VAERD) due to vaccine-challenge mismatch.7 
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 The macroscopic and microscopic lung lesions and description of the acute features 
of VAERD have been previously described for the treatment groups evaluated for post-
challenge immune responses in this manuscript (Gauger, Veterinary Pathology, accepted for 
publication). Surviving cohort pigs in the vaccine-primed VAERD group developed anti-
pH1N1 HI and SN antibodies in a similar pattern as the naïve NV/C pigs, suggesting neither 
antecedent vaccine immunity nor VAERD affected the induction of a primary post-challenge 
immune response to heterologous pH1N1 virus. Cross-reactive anti-pH1N1 HI or SN 
antibodies were not detected in any group prior to challenge; however, vaccine-primed pigs 
challenged with the heterologous pH1N1 responded with modestly elevated HI or 
dramatically elevated SN titers against pH1N1. These data suggest the vaccine may prime for 
more broadly cross-reacting SN antibodies in comparison to HI-specific antibodies after 
challenge with the heterologous virus. Additionally, the SN assay is likely more sensitive 
than HI and may also be more appropriate for assessing functional anti-influenza antibody 
responses in swine. Serum neutralization titers have reportedly been higher compared to HI 
titers in assays using homologous swine anti-sera and antigen.46 Previous reports have also 
demonstrated anti-influenza SN antibody in humans seronegative by the HI test8 and SN 
assays were able to detect elevations in titers not evident by HI further indicating a 
heightened sensitivity of SN tests.10 
Anti-MN08 HI and SN antibodies in the V/C group were boosted post pH1N1 
challenge compared to pre-challenge levels demonstrated at 0 dpi. These data suggest 
priming naïve pigs with inactivated IAV results in a more robust post-challenge humoral 
immune response to both the priming antigen and challenge virus in spite of the lack of 
HI/SN cross-reactivity between vaccine and inoculum strains prior to secondary exposure 
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and in spite of the dramatic lung pathology associated with VAERD. Similar results were 
reported in pigs where preexisting HI and SN immune responses to primary inoculation 
increased following challenge with an antigenically different influenza virus of the same 
subtype.46 In that same study, administration of an inactivated influenza vaccine to pigs 
previously inoculated with heterologous virus also boosted preexisting antibody suggesting 
this phenomenon may occur regardless of how the immune system is initially primed.46 In 
the current study, simultaneously detecting post-challenge anti-pH1N1 HI and SN antibodies 
in the MN08 vaccine-primed pigs with boosted antibody levels to the priming MN08 vaccine 
antigen does not fit the concept of original antigenic sin where antibodies exclusive to the 
priming antigen are augmented at the expense of a response to unique epitopes presented by 
the challenge virus.5,6,9 As the two viruses evaluated in this study are both of the H1 subtype 
and demonstrate non-neutralizing antibody cross-reactivity, they may be too similar to induce 
original antigenic sin.  The elevated anti-pH1N1 HI and SN titers in the MN08 vaccine-
primed pigs after challenge suggests pigs would be protected from a subsequent re-exposure 
to pH1N1. However, further in-vivo protection studies would be necessary to determine if 
V/C and NV/C groups would be equally protected during subsequent re-exposure to the 
pH1N1 virus. 
 In contrast to the absent cross-reactive anti-pH1N1 HI or SN antibodies in the MN08 
vaccine-primed pigs prior to challenge, whole virus cross-reacting anti-pH1N1 systemic IgG 
and IgA ELISA antibodies were detected in serum before and after challenge. Anti-pH1N1 
IgG antibodies in BALF were also detected as early as 1 and 2 dpi in the V/C pigs, 
suggesting cross-reactive mucosal IgG antibodies were likely present at low levels at the time 
of challenge.  However, these levels were rapidly elevated by 5 dpi due to a predicted post-
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challenge transudation across pulmonary capillaries from systemic IgG.  Future studies 
evaluating BALF IgG immune responses following vaccination but prior to challenge are 
needed to determine the presence and source of IgG in the BALF. Regardless, the vaccine-
induced anti-pH1N1 systemic or mucosal ELISA IgG antibodies were not cross-protective as 
confirmed by the presence of infectious virus in the lungs and nasal swabs of V/C pigs from 
this study (Gauger, Veterinary Pathology, accepted for publication) and in previous studies.51 
The MN08 and pH1N1 viruses used as antigen and challenge in this study are genetically 
related by H1 subtype, but their respective HA genes share only 77.7% amino acid 
homology. This suggests that non-neutralizing epitopes shared between the HA proteins may 
be responsible for the cross-reactive ELISA antibodies since the NA genes are of a different 
subtype. However, it remains unknown if these ELISA antibodies contributed to the 
enhanced pneumonia that has been previously described for VAERD.7  
 Unlike the anti-MN08 and -pH1N1 IgG antibodies detected in the lungs of V/C pigs, 
the inactivated vaccine or single exposure by live challenge did not result in a measureable 
IgA antibody response to either antigen by our methods until 21 dpi. The lack of anti-MN08 
IgA mucosal antibodies to the inactivated vaccine was not unexpected in the V/C pigs prior 
to challenge. Consistent with previous reports, inactivated vaccines administered 
intramuscularly to swine induce lower levels of mucosal IgA compared to live inoculation or 
intranasal vaccination with LAIV.13,35,57,53 A limited mucosal IgA antibody response to IAV 
inactivated vaccines has also been demonstrated in other species.32 In contrast, experimental 
H1N1 intranasal infection in swine demonstrated a predominant IgA response in nasal wash 
and BALF compared to IgG levels; although in the same experiment, the converse was 
demonstrated in serum.21 This previous report and what we describe in the inactivated 
137 
 
 
vaccine-primed pigs in this report suggests the route of vaccine administration stimulates 
specific compartments of the immune system. Unlike systemic IgG that transfers across the 
pulmonary epithelium to protect the lower respiratory tract post infection in pigs, the cross-
reactive anti-pH1N1 IgA detected in the serum in V/C pigs did not appear to influence the 
level of mucosal IgA to either antigen in the acute phase after challenge. Serum IgA 
antibodies transferred to the upper and lower respiratory tract have been demonstrated to 
contribute only a small proportion of total IgA in this compartment,31 suggesting mucosal 
immunization is required for adequate production of IgA antibody secreting cells to protect 
the upper respiratory tract.14,13,21,35,57 
Intratracheal challenge with pH1N1 did not induce a measureable systemic IgA, 
mucosal IgA or mucosal IgG antibody response in the naïve NV/C pigs at the time points 
evaluated in this study. Anti-pH1N1 HI and SN antibodies detected in the serum of NV/C 
pigs demonstrated a robust humoral response to the viral challenge in this group. Indeed, the 
HI and SN assays detected anti-pH1N1 antibodies one week earlier at 7 dpi compared to the 
whole virus ELISA IgG assay used in this study suggesting the HI and SN tests may have 
been more sensitive than the ELISA method or the route of exposure preferentially induced 
HI or SN antibodies that may have been IgM rather than IgG or IgA. A single primary 
exposure of virus to naïve pigs may not be sufficient to induce a detectable IgA or IgG 
mucosal immune response during the study period by our methods, i.e. single intratracheal 
inoculation, or a secondary stimulation may be required.  However, it is possible the mucosal 
IgG and IgA levels in the non-primed challenge group peaked between 5 and 21 dpi or after 
21 dpi when BALF samples were not evaluated. The elevated anti-MN08 and -pH1N1 IgA 
antibodies detected at 21 dpi in the vaccine-primed pigs may be the result of B-cell isotype 
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switching from IgG to IgA antibody secreting cells that localized to the lung or local lymph 
node after infection. Cytokines known to induce B-cell isotype switching from IgG to IgA, 
such as IL-5 and TGFβ, were not evaluated in V/C BALF in this study.41,42 The lack of a 
systemic anti-pH1N1 IgA response in the non-primed challenged pigs supports the 
possibility that a detectable serum IgA immune response may depend on the specific 
compartment where initial exposure or vaccination occurred.   A secondary stimulation may 
also be required for isotype switching from IgM to IgG or IgA. In any case, the non-
detectable mucosal IgA immune response in the NV/C pigs does not suggest pigs would be 
unprotected if subsequently re-exposed to homologous virus considering HI and SN antibody 
responses detected in the NV/C pigs may confer adequate protection. 
Influenza A virus induced pro-inflammatory cytokine responses in swine have been 
extensively studied and shown to be correlated with viral replication, disease and lung 
pathology.2,7,15,16,47,45,44,48 In contrast, adaptive cytokine responses to influenza infection in 
swine have been less frequently reported. The adaptive cytokines are important in the 
activation of lymphocytes and cells of the innate immune system, proliferation of T and B 
cells, cell differentiation and immune regulation.39 The V/C pigs in the current study 
demonstrated significantly elevated levels of IL-2, IL-4, IL-12p70, IFN-γ and IL-10 protein 
in the lung at 5 dpi compared to the NV/C and NV/NC groups. A similar trend was apparent 
at 1 and 2 dpi. Most notable is the increased IL-2 and significantly elevated IFN-γ 
concentrations at 24 and 48 hours post infection in the MN08 vaccine-primed pigs. This 
cytokine profile appears consistent with IL-2 and IFN-γ secreting CD4+CD8+ memory T 
cells in swine.4 An influenza specific, cross-reactive CD4+CD8+ memory T cell population 
was detected only in the MN08-primed pigs prior to challenge and reported previously by our 
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group.36 In the same study, a significant increase in cross-reactive CD8+ T-cells were 
detected by flow cytometry in the V/C pigs post stimulation with pH1N1 suggesting CD8 T-
cells were primed by the inactivated vaccine.36 These cytotoxic T-cells may have contributed 
to the elevated IFN-γ concentrations detected in the V/C post-challenge BALF.4 However, 
the previous study evaluated pre-challenge T-cell responses in the peripheral blood that may 
demonstrate a much different phenotype than post-challenge T-lymphocytes or central 
memory CD4+CD8+ T cells that preferentially traffic in lymphoid tissues or pulmonary 
lymph nodes. 
The cell-mediated arm of the immune response is reported to be partially responsible 
for heterosubtypic immunity specific for conserved internal influenza viral proteins, which 
may explain why the vaccinated pigs in the current study responded with a greater magnitude 
in cytokine production as well as in antibody response to the heterologous pH1N1 
challenge.11,37,60 Pigs in the NV/C group may have developed a cell-mediated response by 21 
dpi suggested by the increased concentrations of both IL-2 and IFN-γ compared to levels 
detected at 1 and 2 dpi; however, this would require further investigation. The role in which 
the primed CMI arm of the immune system played in the lung lesions observed in VAERD 
(Gauger, Veterinary Pathology, accepted for publication) needs to be further refined, but a 
role for CTLs in the immunopathology is supported by the cytokine profile reported here as 
well as the evidence for low level CMI activation by the inactivated vaccine.36 
Interleukin-10 is a regulatory cytokine that maintains a homeostatic immune response 
in the lung and decreases macrophage activation.30 Naïve and memory T cells differentiate 
toward a TH2 phenotype under the influence of IL-438 whereas IL-12 influences the 
development of a TH1 response and directs host defenses against intracellular pathogens.59 
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The TH1/TH2 dichotomy has not been characterized in pigs and relative ratios of these three 
particular cytokines that were simultaneously elevated in the V/C pigs at 5 dpi (IL-4, IL-12, 
IL-10) may be important to the post-challenge immune response. Prior vaccination with the 
killed adjuvanted vaccine, challenge with heterologous virus and the incurring 
immunopathology may be related to the induction of these particular cytokines as well. The 
over-production of this array of cytokines may be a specific phenomenon of VAERD 
affected pigs and a physiological attempt by the immune system to control the exuberant 
inflammation demonstrated in the V/C pigs.7 Previous studies have reported concentrations 
of IL-4 and IL-10 in pigs that were naïve influenza-challenged or non-challenged15,59that are 
similar to the IL-4 and IL-10 concentrations in NV/C and NV/NC pigs in this report, 
suggesting again the role prior vaccine immunity, or challenge with heterologous virus, may 
play in the magnitude of post-challenge cytokine responses. Collectively, additional studies 
are necessary to understand the role of IAV induced adaptive cytokines in swine and how 
they may contribute to VAERD.    
Prevention of IAV infection in swine will continue to rely on the use of vaccines; 
however, vaccine efficacy depends on the ability to cross-protect against antigenically 
diverse influenza viruses. Therefore, it is critical to understand the effectiveness of vaccine 
immune responses to heterologous infection and how this response may be improved. In 
addition, there is a risk of VAERD in swine when vaccine immunity cross-reacts but does not 
cross-protect against antigenically distinct IAV’s. This concern is increasingly more 
important as reassortant and drifted IAV’s become more prevalent in the swine population 
with an increasing number of antigenically distinct H1 viruses in US22 and Canadian swine,33 
while the global picture is perhaps similar with regional diversity as well.  
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A phenomenon similar to VAERD may have been expressed in the human population 
during the 2009 influenza pandemic.29,40 Therefore, swine could serve as a model for 
enhanced respiratory disease in vaccinated humans. The V/C pigs experiencing VAERD in 
the current study appeared to develop an HI and SN immune response to pH1N1 similar to 
what was shown for naïve exposed pigs. However, it remains unknown whether the immune 
response to pH1N1 in the MN08 vaccine-primed pigs would have been fully protective 
against subsequent re-exposure to the virus, but it is likely with the HI and SN response 
demonstrated in this study. Collectively, many aspects of the immune response in VAERD 
affected pigs require further investigation to understand the mechanisms that may be 
associated with vaccine-induced exacerbation of disease or the effects of VAERD on future 
infections.  
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Table 1. Experimental Design. 
 
Group Vaccine Challenge 
Serum N/BALF N 
1 dpi 2 dpi 5 dpi 7 dpi 14 dpi 21 dpi 
V/C MN08 pH1N1 8/8 8/8 8/8 4/0 4/0 4/4 
NV/C None pH1N1 8/8 8/8 8/8 4/0 4/0 4/4 
NV/NC None None 8/8 8/8 8/8 4/0 4/0 4/4 
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Table 2. Hemagglutination inhibition geometric mean reciprocal titers.a 
Group 
MN08 pH1N1 
0 dpi 7 dpi 14 dpi 21 dpi 0 dpi 7 dpi 14 dpi 21 dpi 
V/C 20.0±14.9a 95.1±13.9a 134.5±13.9a 56.6±15.6a 0.0±0.0a 40.0±10.0a 95.1±13.9a 47.6±18.1a 
NV/C 0.0±0.0a 0.0±0.0b   0.0±0.0b 0.0±0.0b 0.0±0.0a 20.0±13.3b 67.3±11.9a  23.8±13.9ab 
NV/NC 0.0±0.0a 0.0±0.0b   0.0±0.0b 0.0±0.0b 0.0±0.0a 0.0±0.0c 0.0±0.0b 0.0±0.0b 
aGeometric mean ± standard error of the mean.  Group geometric mean reciprocal HI
 
titers with different letters within a column 
are significantly different (P≤0.05).  Each group is indicated as vaccinated/challenged (V/C); non-vaccinated/challenged (NV/C); 
non-vaccinated/non-challenged (NV/NC). 
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Table 3. Serum neutralization geometric mean reciprocal titers.a 
Group 
Anti-MN08 SN titers Anti-pH1N1 SN titers 
0 dpi 7 dpi 14 dpi 21 dpi 0 dpi 7 dpi 14 dpi 21 dpi 
V/C 452.5±18.2a 1280.0±13.3a 761.1±19.3a 640.0±16.3a 0.0±0.0a 380.5±13.9a 2152.7±15.5a 1280.0±13.3a 
NV/C   0.0±0.0b      0.0±0.0b    0.0±0.0b    0.0±0.0b 0.0±0.0a 113.1±15.6a    380.5±11.9b   538.2±11.9b 
NV/NC   0.0±0.0b      0.0±0.0b    0.0±0.0b    0.0±0.0b 0.0±0.0a   0.0±0.0b      0.0±0.0c     0.0±0.0c 
aGeometric mean ± standard error of the mean.  Geometric mean reciprocal SN
 
titers with different letters within a column are 
significantly different (P ≤ 0.05).  Each group is indicated as vaccinated/challenged (V/C); non-vaccinated/challenged (NV/C); 
non-vaccinated/non-challenged (NV/NC). 
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Table 4. Isolate specific IgG levels in serum and BALF post-challenge with pH1N1.a 
  Serum (Days Post Challenge) BALF (Days Post Challenge) 
Antigen Group 0 7 14 21 1 2 5 21 
MN08 
V/C 1.69±0.03 a 1.79±0.06 a 1.82±0.05 a 1.67±0.04 a 0.67±0.15 a 0.64±0.15 a 1.00±0.12 a 1.12±0.06 a 
NV/C 0.07±0.01 b 0.21±0.03 b 0.55±0.12 b 0.31±0.12 b 0.25±0.04 b 0.13±0.02 b 0.19±0.03 b 0.22±0.02 b 
NV/NC  0.11±0.01 b 0.17±0.06 b 0.26±0.04 b 0.04±0.00 b 0.21±0.02 b 0.11±0.02 b 0.23±0.06 b 0.12±0.04 b 
pH1N1 
V/C 1.71±0.04 a 1.62±0.07 a 1.68±0.04 a 1.79±0.13 a 0.48±0.13 a 0.31±0.08 a 0.70±0.07 a 1.17±0.11 a 
NV/C 0.29±0.01 b 0.40±0.04 b 0.89±0.09 b 1.32±0.07 b 0.05±0.02 b 0.04±0.01 b 0.09±0.02 b 0.16±0.02 b 
NV/NC 0.35±0.03 b 0.33±0.03 b 0.44±0.05 c 0.24±0.03 c 0.09±0.01 b 0.05±0.02 b 0.07±0.02 b 0.10±0.03 b 
a
 Mean OD ± standard error of the mean in the whole virus ELISA. Different letters within the same column for each antigen are 
significantly different (P ≤ 0.05).   
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Table 5. Isolate specific IgA levels in serum and BALF post-challenge with pH1N1.a 
  Serum (Days Post Challenge) BALF (Days Post Challenge) 
Antigen Group 0 7 14 21 1 2 5 21 
MN08 
V/C 0.88±0.12 a 1.01±0.08 a 1.00±0.07 a 1.04±0.04 a 0.24±0.08 a 0.22±0.08 a 0.44±0.09 a 1.29±0.11 a 
NV/C 0.13±0.01 b 0.20±0.01 b 0.26±0.02 b 0.22±0.03 b 0.26±0.09 a 0.18±0.04 a 0.27±0.07 a 0.31±0.07 b 
NV/NC 0.15±0.01 b 0.13±0.01 b 0.21±0.03 b 0.15±0.03 b 0.26±0.08 a 0.10±0.04 a 0.20±0.06 a 0.05±0.06 b 
pH1N1 
V/C 0.84±0.12 a 0.96±0.05 a 0.93±0.07 a 0.88±0.08 a 0.08±0.01 a 0.09±0.03 a 0.25±0.04 a 1.33±0.11 a 
NV/C 0.16±0.01 b 0.21±0.02 b 0.29±0.05 b 0.18±0.03 b 0.06±0.01 a 0.04±0.01 a 0.07±0.02 b 0.27±0.04 b 
NV/NC 0.16±0.01 b 0.12±0.01 b 0.16±0.01 b 0.10±0.01 b 0.08±0.01 a 0.04±0.02 a 0.07±0.01 b 0.05±0.02 b 
a
 Mean OD ± standard error of the mean in the whole virus ELISA. Different letters within the same column for each antigen are 
significantly different (P ≤ 0.05).   
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Figure 1. Cytokine protein levels (pg/ml) in bronchoalveolar lavage fluid of vaccinated 
and challenged, non-vaccinated and challenged and non-vaccinated and non-challenged 
pigs measured at 1, 2, 5 and 21 days post inoculation.  Connecting horizontal lines are 
significantly different (P<0.05).  Error bars represent standard error of the mean. 
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CHAPTER 5: GENERAL CONCLUSIONS 
 
General Discussion 
 Multiple viruses are associated with enhanced disease in mammals, affecting different 
systems with diverse clinical manifestations and exacerbated lesions.10,29 Several of these 
viruses are single-stranded, enveloped RNA viruses that may induce non-protective 
antibodies when administered as inactivated vaccine preparations, naturally occur as 
heterotypic viruses of the same genera or rapidly evolve into genetic and antigenic 
variants.6,29 Influenza viruses have recently been implicated as the cause of enhanced disease 
in experimentally vaccinated and challenged swine referred to as vaccine-associated 
enhanced respiratory disease (VAERD).5,13,37 Two factors inherent to influenza viruses may 
influence the manifestation of VAERD. Influenza A viruses are continually evolving due to 
antigenic drift and antigenic shift and inactivated influenza vaccines demonstrate variable 
protection against heterologous viruses. A surge in the use of inactivated vaccines combined 
with the increasing heterogeneity of influenza viruses circulating in US swine may increase 
potential vaccine-challenge virus mismatch in field situations. Clinically, previous natural 
infection, preexisting antibodies, or secondary bacterial infections in the field may influence 
VAERD. However, this does not diminish the potential adverse effects non-protective 
antibodies induced by inactivated influenza vaccines may have on both the health and 
productivity of swine exposed to a diverse array of influenza viruses under natural 
conditions. 
Inactivated, adjuvanted δ-cluster influenza vaccines followed by challenge with 
pandemic H1N1 (γ-like cluster) induces VAERD in swine. 
155 
 
 
 Enhanced disease, or VAERD, has been previously reported in swine administered 
inactivated influenza vaccines followed by heterologous challenge.8,13,37 We hypothesized 
two heterologous, homosubtypic H1 influenza viruses that did not demonstrate serological 
cross-reactivity in vitro would be effective in inducing VAERD in a vaccination/challenge 
study. In Chapter 2, we demonstrate a reproducible VAERD model using a δ1 cluster 
influenza virus as a UV-inactivated, adjuvanted vaccine followed by challenge with the γ-
like cluster pH1N1 virus.5  The VAERD model was reproduced in the study presented in 
Chapter 3 (Veterinary Pathology; accepted for publication).  The δ- and γ-cluster viruses 
used in this model share 76% nucleotide similarity between the HA protein genes. However, 
the extent of nucleotide diversity between vaccine and challenge antigen necessary to induce 
VAERD is currently unknown and it is likely more relevant to assess the antigenic diversity 
for predicting VAERD. The NA protein of the two influenza viruses used in our VAERD 
model were of different subtypes and immunity induced by one NA may not contribute to the 
enhanced disease demonstrated in the V/C pigs due to the lack of cross-reacting antibodies, 
although this requires further investigation. Vaccine associated enhanced respiratory disease-
affected pigs also demonstrated a more severe clinical presentation compared to naïve, 
challenged pigs that included prolonged respiratory distress and coughing in addition to the 
typical anorexia and lethargy observed with uncomplicated IAV infection. Clinical signs 
characteristic of experimentally induced VAERD in swine are similar to influenza field 
infections where secondary bacterial infections contribute to the coughing and dyspnea;21 
however, bacterial co-infection is not a component of our experimental VAERD model. 
These results suggest that VAERD may be a valuable model for future investigations in the 
pathogenesis of enhanced influenza disease in swine and the development of efficacious 
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vaccines that prevent similar clinical manifestations. In addition, this model may help 
investigate the mechanisms associated with enhanced disease induced by other mammalian 
viruses that demonstrate similar characteristics with VAERD.  
Inactivated, adjuvanted δ-cluster influenza vaccines induce cross-reactive, non-
protective antibodies against heterologous pandemic A/H1N1 that correlate with 
VAERD. 
 Neutralizing antibodies that specifically target the HA and NA surface glycoproteins 
are an important component of the immune response against influenza infection.16,38 
Inactivated influenza vaccines reduce clinical disease and lesions against homologous 
viruses37 although evidence to demonstrate protection against heterologous infections is 
inconsistent.2,17,35,36,37 The lack of protection demonstrated by inactivated influenza vaccines 
may be due to poor cross-neutralization of contemporary, heterologous viruses circulating in 
US swine influenced by continual antigenic drift and antigenic shift15 or due to deficient 
cross-protective cell-mediated immune (CMI) responses typical of inactivated influenza 
vaccines.9 In Chapters 2 and 3 we demonstrate a correlation between cross-reactive, non-
protective antibodies induced by UV-inactivated influenza vaccines in VAERD-affected 
pigs. Using serum neutralization assays, pigs vaccinated with δ1 cluster inactivated influenza 
virus did not induce serum neutralizing antibodies against heterologous pH1N1. However, 
ELISA assays using whole virus antigen demonstrated robust cross-reactive IgG antibody 
responses to pH1N1 in serum and BALF. These data suggest the cross-reactive, non-
neutralizing antibody response may have played an important role in the pathogenesis of 
VAERD. Potential mechanisms include pathogenic immune complex formation between 
antigen and antibody and the activation of complement, induction of proinflammatory 
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cytokines, ADE and ADCC. Although pH1N1 virus titers in the lung of VAERD-affected 
pigs were consistently lower than NV/C pigs, virus levels in BALF of V/C pigs suggested a 
lack of protection induced by the inactivated vaccine. In addition, pH1N1 viral titers in 
BALF did not correlate with clinical signs and lung pathology suggesting VAERD is 
independent of viral replication. This is unlike some enhanced viral diseases such as DENV 
where viral replication is increased due to ADE, which ultimately exacerbates clinical 
disease.6 However, reduced RSV titers in the lung of cotton rats administered inactivated 
RSV vaccines correlated with severe clinical disease and lung pathology similar to what we 
describe for VAERD, demonstrating the dissociation between viral replication and 
immunopathology in some enhanced viral disease processes.26 
 Chapter 2 and 3 also demonstrated that inactivated influenza vaccines induce minimal 
mucosal IgA immune responses to homologous or heterologous virus. Whole virus ELISA 
IgA antibodies were not detected in the lung of V/C pigs prior to challenge, or were detected 
inconsistently at low quantities only against vaccine antigen. Prior reports have demonstrated 
parenterally delivered influenza vaccines induce poor quality mucosal immune responses in 
humans and mice7,28 and systemic IgA induced by parenteral vaccines does not contribute to 
mucosal protective immune responses.28 These data suggest the lack of IgA in the respiratory 
tract concurrent with a cross-reactive, non-protective IgG mucosal immune response may 
have contributed to VAERD in V/C pigs due to inactivated, parenterally administered, 
adjuvanted influenza vaccines. 
 Collectively, our VAERD model consists of four components: 1) naïve, conventional 
pigs between three and ten-weeks-old; 2) inactivated, adjuvanted influenza vaccines 
administered twice approximately three weeks apart; 3) challenge with heterologous virus of 
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the same subtype approximately three to four weeks post boost vaccination; 4) presence of 
cross-reactive, non-neutralizing, non-HI antibodies and absence of vaccine-induced IgA in 
the lung at the time of challenge. A schematic of our model is represented in Figure 1. 
VAERD-affected swine demonstrate increased macroscopic lung lesions and distinct 
lung pathology compared to non-vaccinated/challenged pigs. 
 Influenza infection in swine may result in cranioventral consolidation that varies in 
extent of lung involvement depending on the virulence of the virus, quantity of virus 
administered and route of inoculation.27 In chapter 2 and 3 we describe significantly greater 
percentages of lung consolidation in pigs that received prior influenza vaccination followed 
by challenge compared to non-vaccinated/challenged swine suggesting the immune response 
to the vaccine contributed to the macroscopic lesions. In addition, marked differences in 
microscopic lung lesion profiles were demonstrated in V/C pigs characterized by lung 
pathology novel to acute and subacute influenza infection in swine. Previous reports 
describing non-enhanced IAV induced microscopic lung lesions are similar to what is 
demonstrated in NV/C pigs in Chapter 3.20,27,33,40 Characteristic microscopic lung lesions in 
VAERD-affected swine during the acute phase of influenza infection include alveolar and 
interlobular edema, hemorrhage and congestion with a prolonged and severe suppurative 
bronchitis, bronchiolitis and alveolitis. The suppurative inflammatory response may be 
secondary to the elevated IL-8, TNFα and IL-1β cytokines detected in the lung of V/C pigs. 
However, neutrophils that typically infiltrate and dissipate in approximately twenty-four 
hours post-influenza infection33 are present in elevated numbers at 5 dpi in VAERD-affected 
pigs. Prior reports have described suppurative alveolitis the histologic marker of vaccine-
enhanced disease associated with RSV infection which is consistent with our pathological 
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assessment of VAERD.25 In addition, widespread interstitial pneumonia, marked 
peribronchiolar lymphocytic cuffing, subepithelial infiltration of the bronchiolar lamina 
propria as well as type II pneumocyte hypertrophy and hyperplasia are consistent 
microscopic features characteristic of VAERD during the subacute phase of the disease 
process. Enhanced trachea lesions that include suppurative and lymphocytic tracheitis with 
tracheal necrosis are also noted in VAERD-affected pigs. Collectively, microscopic lung 
lesions correlate with elevated lung consolidation in V/C pigs, further suggesting immune 
mediated mechanisms are involved in the exaggerated lung pathology we describe in Chapter 
2 and 3. 
Elevated pulmonary pro-inflammatory cytokines are correlated with VAERD in 
influenza vaccinated and challenged swine. 
Proinflammatory cytokines play an important role in the pathogenesis of influenza 
infection in swine and have been correlated with viral replication and clinical signs34 as well 
as increased lung lesions and neutrophil infiltration.33 We report in Chapter 2 and Chapter 3 
an enhanced proinflammatory cytokine response that correlated with VAERD-affected swine 
and is reproducible by our experimental methods. TNFα, IL-1β, IL-6 and IL8 are 
significantly elevated at 5 dpi in V/C pigs compared to NV/C pigs that did not demonstrate 
significant differences compared to NV/NC pigs. Cytokine storms have been described with 
pandemic influenza viruses in previous reports,14 suggesting their impact in severe influenza 
respiratory disease. Cytokines may also contribute to the prolonged neutrophil response we 
describe in the VAERD-affected pigs, which contrasts against the typical transient 
suppurative response that subsides by 5 dpi in uncomplicated influenza infections.33 More 
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importantly, cytokine responses in VAERD-affected pigs may provide clues to the 
mechanisms associated with the exaggerated inflammatory response. 
Innate immune responses, such as type 1 interferons, are an important first line of 
defense against viral infections. Type 1 IFNs, such as IFNα/β, are typically upregulated after 
influenza virus enters host cells and activates intracellular receptors.4 An important 
characteristic of VAERD-affected swine demonstrated in Chapter 2 is the abrogated IFNα 
response in lungs of V/C pigs compared to the naïve-challenged group. This was an 
unexpected result that suggests a potential immune mediated modification of the host 
antiviral response. Influenza is recognized in the cytoplasm of infected cells through NOD-
like receptors that includes retinoic acid inducible gene I (RIG-I) and melanoma 
differentiation-associated gene 5 (MDA5) that trigger transcription factors and increased 
production of IFNα/β.12,22 Previous studies have shown that when immune complexes bind to 
FcγRs (in particular FcγRI and FcγRIIa), suppression pathways are induced that down-
regulate antiviral innate immune responses.30 These include the deoxyadenosine kinase 
(DAK), antigen 5 autophagy-related gene complex (Atg5-Atg12) and the IL-10 pathway. The 
DAK and Atg5-Atg12 weaken the RIG-I/MDA5 expression pathway by decreasing down-
stream signaling molecules that ultimately decrease type I IFN. Increased IL-10 may 
suppress the nitric oxide synthase pathway, decreasing another antiviral component of the 
innate immune response. Although these suppressive pathways have not been described in 
VAERD-affected pigs, they may serve as a potential mechanism for the abrogated IFNα 
response we describe in Chapter 2. Although further mechanistic investigations are 
necessary, a potential VAERD-associated innate immune suppression model, adapted from 
Ubol et. al. 2010, is presented in Figure 2.29 
161 
 
 
VAERD-affected pigs develop a robust post-challenge immune response to heterologous 
virus when primed with inactivated influenza vaccine. 
 Hemagglutination inhibition and SN antibody responses were detected against the 
challenge virus at 5 dpi in V/C pigs in spite of VAERD. Severe disease, pulmonary lesions 
and excess inflammation did not appear to affect the induction of an immune response to 
mucosally administered heterologous pH1N1; suggesting pigs with VAERD would be 
protected from further subsequent infections with antigenically similar viruses. Children with 
severe RSV or ATM did not experience an enhanced form of either disease when re-exposed 
to WT virus later in life suggesting a protective immune response was established with 
concurrent enhanced disease.24 VAERD-affected pigs also demonstrated a more robust HI 
and SN antibody response to the challenge virus more similar to a secondary response as 
compared to the primary response seen in the non-vaccinated and challenged pigs.  This 
suggests prior inactivated vaccine antigen primes the immune system for a heightened post-
challenge antibody response despite the limited homology between vaccine antigen and 
challenge virus, even if the vaccine is non-protective. This may be due to T-helper cells 
primed with conserved epitopes in the HA2 domain of the HA or in other viral proteins.  
Consecutive experimental influenza infections in swine have demonstrated a similar 
phenomenon where vaccination of immune pigs with preexisting antibody from previous 
exposure demonstrated an increase in HI and SN titers to the priming and vaccine antigens 
although naive vaccinated pigs seroconverted near the lower detectable limits.32 In Chapter 4, 
VAERD-affected pigs also demonstrated a post-challenge boost to the vaccine antigen. 
Although technically not considered antigenic sin due to the simultaneous detection of 
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antibodies to the challenge virus, the immune system appears to demonstrate a propensity to 
boost antibodies directed against the antigen present at initial exposure. 
Adaptive cytokines are elevated at 5 dpi in VAERD-affected pigs and may contribute to 
enhanced disease by unknown mechanisms. 
 Adaptive cytokines are necessary to help induce a balanced and effective immune 
response. Adaptive cytokines may bias immune reactions towards a Th1 or Th2 cell-
mediated immune response.19 In addition, adaptive cytokines, such as IL-10, may provide the 
necessary feedback to down-regulate immune responses that promote inflammation.18 
Chapter 4 describes an exacerbated post-challenge adaptive cytokine response in VAERD-
affected pigs compared to the NV/C group. However, it is unknown if the elevated levels of 
IL-12, IL-4, IL-10 and IFNγ contribute to enhanced disease or are a consequence of VAERD. 
The presence of both IL-12 and IL-4 may suggest a balance between Th1 and Th2 responses. 
The elevated IL-10 may be an attempt by the pig to diminish the excessive inflammatory 
response we describe in Chapters 2 and 3. Or, IL-10 levels may be an aberrant response to 
immune-mediated disease. Regardless, the exacerbated cytokine response at 5 dpi correlates 
with the severe clinical disease and pneumonia in V/C pigs suggesting additional immune-
mediated mechanisms may be involved in VAERD that require further study. 
 
Recommendations for Future Research 
 Vaccine-associated enhanced respiratory disease is a reproducible phenomenon in 
swine administered inactivated influenza vaccines followed by challenge with heterologous 
virus. These studies have revealed that VAERD is an effective model for studying the 
pathogenesis of enhanced respiratory disease and similar enhanced diseases in mammals. We 
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have identified two H1 influenza viruses used as vaccine antigen (δ1 cluster H1N2) and 
challenge virus (γ-like cluster H1N1) that share 76% HA homology at the nucleotide level 
that induce VAERD in a vaccine/challenge mismatch model.5 Future studies should evaluate 
the degree of divergence between vaccine and challenge virus HA that would be predictive of 
VAERD in an effort prevent this phenomenon in future vaccines. The current level of 
divergence recognized in contemporary H1 viruses circulating in swine suggests the risk of 
VAERD may continue in the future. Our model may help evaluate novel vaccine platforms 
that avoid VAERD and provide more effective, cross-protective immune responses against 
heterologous influenza viruses. 
 Chapter 3 describes in detail the microscopic lesions associated with VAERD-
affected pigs. Marked inflammation, vascular permeability and elevated cytokine responses 
in the lung suggest multifactorial mechanisms contributed to VAERD and extensive studies 
are warranted that investigate different mechanisms responsible for the pulmonary lesions. 
Immune-mediated mechanisms that may be involved and require further analysis include 
peribronchiolar and perivascular immune complex deposition, complement fixing antibodies 
and complement activation, antibody dependent cell mediated cytotoxicity, antibody 
dependent enhancement, NOD-like receptor activation and low avidity antibodies. 
Discerning their presence and how these immune-mediated mechanisms may contribute to 
enhanced disease will be important features for future vaccine research.  
In addition, research is needed to evaluate the effect vaccine adjuvants may have on 
VAERD and if multivalent vaccines may manifest a similar disease phenomenon. The use of 
alum adjuvants in humans was implicated as the cause of the eosinophilic inflammatory 
response in some models that used formalin-inactivated vaccines.3 Adjuvants are used with 
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inactivated vaccines to enhance the immunogenicity of the antigen by prolonging antigen 
deposition in tissue and increasing its uptake by antigen presenting cells such as 
macrophages. However, it is unknown if oil-in-water adjuvants augment antibody responses 
against non-protective epitopes that may contribute to immune-mediated enhanced disease. 
In addition, novel adjuvants used in experimental influenza vaccine and challenge studies 
may be more appropriate for use with inactivated vaccines that may prevent VAERD in 
swine.11,31  
Inactivated vaccines are the only approved preparations for influenza in swine. 
Disadvantages of killed vaccines include poor cross-protection against variant viruses and 
inadequate cell-mediated immune responses in addition to VAERD. Additional research is 
needed that evaluates different vaccine platforms and methods of delivery that may enhance 
cross-protection, induce mucosal immune responses and prevent vaccine-associated 
enhanced disease. Live-attenuated influenza vaccine products have demonstrated superior 
efficacy compared to inactivated preparations and may be appropriate for eliminating 
undesirable vaccine-associated adverse immune responses and enhanced disease in 
swine.1,23,39 
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Figure 1. Components of the vaccine-associated enhanced respiratory disease swine model. 
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Figure 2. Subneutralizing-antibody/influenza A virus complexes may induce suppression of innate immune responses. 
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APPENDIX B: ABBREVIATIONS 
ADE antibody dependent enhancement 
ADV Aleutian disease virus 
AIDS Acquired immunodeficiency syndrome 
ASFV African swine fever virus 
ATM atypical measles 
BALF bronchoalveolar lavage fluid 
cH1N1 classical H1N1 
CMI cell-mediated immunity 
CTL cytotoxic T lymphocytes 
DENV Dengue virus 
DF Dengue fever 
DHF Dengue hemorrhagic fever 
DSS Dengue shock syndrome 
EIAV Equine infectious anemia virus 
EPA epidemic polyarthritis 
EPD enhanced pulmonary disease 
ERD enhanced respiratory disease 
FCoV Feline Coronavirus  
FcγR Fc gamma receptor 
FI-hMPV formalin  inactivated human metapneumovirus 
FI-MV formalin-inactivated measles vaccine 
FIP Feline infectious peritonitis 
FI-RSV formalin-inactivated respiratory syncytial virus 
FIV Feline immunodeficiency virus 
HA hemagglutinin 
HI hemagglutination inhibition 
HIV Human immunodeficiency virus 
hMPV human metapneumovirus 
IAV influenza A virus 
IC immune complexes 
IFNγ interferon gamma 
IL-1 interleukin 1 
IL-10 interleukin 10 
IL-12 interleukin 12 
IL-12p70 interleukin 12 
IL-13 interleukin 13 
IL-2 interleukin 2 
IL-4 interleukin 4 
IL-5 interleukin 5 
IL-6 interleukin 6 
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IL-8 interleukin 8 
JEV Japanese encephalitis virus 
LDEV Lactate dehydrogenase elevating virus 
M matrix 
M2e matrix 2 extracellular protein domain 
MDA5 melanoma differentiation gene 5 
MV measles virus 
MVEV Murray valley encephalitis virus 
NA  neuraminidase 
NAHMS National animal health monitoring system 
NP nucleoprotein 
NS nonstructural 
PA polymerase acidic 
PB1 polymerase basic 1 
PB2 polymerase basic 2 
pH1N1 pandemic 2009 A/H1N1 
PKR protein kinase R 
PRDC porcine respiratory disease complex 
PRRSV Porcine reproductive and respiratory disease virus 
rH1N1 reassortant H1N1 
RIG-I retinoic acidic inducible gene 1 
RRV Ross river virus 
RSV Respiratory syncytial virus 
RV Rabies virus 
SAIDS Simian acquired immunodeficiency syndrome 
SHFV Simian hemorrhagic fever virus 
SIV Simian immunodeficiency virus 
SN serum neutralization 
Th T helper 
Th2 T helper 2 
TLR toll-like receptor 
TNFα tumor necrosis factor alpha 
TRIG triple reassortant internal gene 
VAERD vaccine-associated enhanced respiratory disease 
WHO World health organization 
WNV West nile virus 
WT wild type 
US United States 
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